



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> C12N 7/01, 15/34, 15/35, C07K 16/08, 14/015, C12N 15/85	<b>A3</b>	<b>(11) International Publication Number:</b> WO 99/61601 <b>(43) International Publication Date:</b> 2 December 1999 (02.12.99)								
<b>(21) International Application Number:</b> PCT/US99/11958 <b>(22) International Filing Date:</b> 28 May 1999 (28.05.99)  <b>(30) Priority Data:</b> 60/087,029 28 May 1998 (28.05.98) US  <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 60/087,029 (CIP) Filed on 28 May 1998 (28.05.98)  <b>(71) Applicant (for all designated States except US):</b> THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20854-3804 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> CHIORINI, John, A. [US/US]; 2604 Loma Street, Silver Spring, MD 20902 (US). KOTIN, Robert, M. [US/US]; 6510 Broxburn Drive, Bethesda, MD 20817 (US).	<b>(74) Agents:</b> SPRATT, Gwendolyn, D. et al.; Needle & Rosenberg, P.C., Suite 1200, The Candler Building, 127 Peachtree Street, N.E., Atlanta, GA 30303-1811 (US).  <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 17 February 2000 (17.02.00)									
<b>(54) Title:</b> AAV5 VECTOR AND USES THEREOF  <p style="text-align: center;">Apical transduction of human airway epithelia with rAAV2 and rAAV5</p> <table border="1"><caption>Apical transduction of human airway epithelia with rAAV2 and rAAV5</caption><thead><tr><th>Condition</th><th>bgal light units</th></tr></thead><tbody><tr><td>aav5</td><td>~3.5e+6</td></tr><tr><td>aav2</td><td>~0.1e+6</td></tr><tr><td>cells alone</td><td>~0.1e+6</td></tr></tbody></table> <b>(57) Abstract</b> <p>The present invention provides an adeno-associated virus 5 (AAV5) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV5 vectors and particles.</p>			Condition	bgal light units	aav5	~3.5e+6	aav2	~0.1e+6	cells alone	~0.1e+6
Condition	bgal light units									
aav5	~3.5e+6									
aav2	~0.1e+6									
cells alone	~0.1e+6									

BEST AVAILABLE COPY

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

Inter. .nal Application No  
PCT/US 99/11958

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N7/01 C12N15/34 C12N15/35 C07K16/08 C07K14/015  
C12N15/85

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	B. GEORG-FRIES ET AL.: "Analysis of proteins, helper dependence and seroepidemiology of a new human parvovirus" VIROLOGY, vol. 134, 1984, pages 64-71, XP002027460	1-45
X	the whole document	34, 35
Y	R.J. SAMULSKI ET AL.: "Helper-free stocks of recombinant AAV: normal integration does not require viral gene expression" JOURNAL OF VIROLOGY, vol. 63, no. 9, 1989, pages 3822-3828, XP000283071 the whole document	1-45

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 December 1999

Date of mailing of the international search report

28/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Marie, A

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/11958

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Y. MAEDA ET AL.: "Gene transfer into vascular cells using AAV vectors" CARDIOVASCULAR RESEARCH, vol. 35, 1997, pages 514-522, XP002125030 the whole document ---	1-45
Y	WO 93 24641 A (THE UNITED STATES OF AMERICA ET AL.) 9 December 1993 (1993-12-09) the whole document ---	1-45
Y	WO 96 15777 A (THE GOVERNMENT OF THE USA ) 30 May 1996 (1996-05-30) the whole document ---	1-45
X	D.S. IM ET AL.: "Partial purification of AAV Rep 78, Rep52 and Rep40 and their biochemical characterization" JOURNAL OF VIROLOGY, vol. 66, no. 2, 1992, pages 1119-1128, XP002125031 the whole document ---	18
Y	the whole document	19,20
X	S.R.M. KYOSTIO ET AL.: "Analysis of AAV wild-type and mutant rep proteins for their ability to negatively regulate AAV p5 and p19 mRNA levels" JOURNAL OF VIROLOGY, vol. 68, no. 5, 1994, pages 2947-2957, XP002125032 the whole document ---	18
Y	the whole document	19,20
Y	DE 44 36 664 A (MAX PLANCK GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.) 4 July 1996 (1996-07-04) the whole document ---	18
X	K. PRASAD ET AL.: "Characterization of the Rep78/AAV complex" VIROLOGY, vol. 229, 1997, pages 183-192, XP002125033 the whole document ---	21
Y	WO 95 11997 A (DEUTSCHES KREBSFORSCHUNGSZENTRUM) 4 May 1995 (1995-05-04) the whole document ---	18
X	WO 96 00587 A (UNIVERSITY OF PITTSBURGH) 11 January 1996 (1996-01-11) the whole document ---	22
Y	the whole document	23-34
	--- -/--	



# INTERNATIONAL SEARCH REPORT

Intern. Application No  
PCT/US 99/11958

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	M.J. DURING ET AL.: "AAV vectors for gene therapy of neurodegenerative disorders" CLINICAL NEUROSCIENCE, vol. 3, no. 5, 1995, pages 292-300, XP002125034	22
Y	the whole document	23-34
Y	WO 98 11244 A (THE GOVERNEMENT OF THE USA) 19 March 1998 (1998-03-19) the whole document	1-45
P,X	WO 98 41240 A (THE CHILDREN'S HOSPITAL OF PHILADELPHIA) 24 September 1998 (1998-09-24) the whole document	1-45
P,X	WO 98 45462 A (ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A.) 15 October 1998 (1998-10-15) the whole document	1-45
P,X	J.A. CHIORINI ET AL.: "Cloning and characterization of AAV5" JOURNAL OF VIROLOGY, vol. 73, no. 2, 1999, pages 1309-1319, XP002125035 the whole document	1-45
X	Database EMBL, Entry GGACTAA, Accession number M61166, 27/3/91 XP002125220 the whole document	44

# INTERNATIONAL SEARCH REPORT

Information on patent family members


International Application No

PCT/US 99/11958

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9324641 A	09-12-1993	US 5587308 A	24-12-1996
		AU 673367 B	07-11-1996
		AU 4598193 A	30-12-1993
		CA 2136441 A	09-12-1993
		EP 0644944 A	29-03-1995
		US 5866696 A	02-02-1999
WO 9615777 A	30-05-1996	CA 2205874 A	30-05-1996
		EP 0786989 A	06-08-1997
		JP 10509046 T	08-09-1998
DE 4436664 A	04-07-1996	CA 2202664 A	25-04-1996
		WO 9612010 A	25-04-1996
		EP 0785991 A	30-07-1997
		JP 10507352 T	21-07-1998
WO 9511997 A	04-05-1995	CA 2175256 A	04-05-1995
		EP 0725837 A	14-08-1996
		JP 9504173 T	28-04-1997
WO 9600587 A	11-01-1996	AU 705564 B	27-05-1999
		AU 2913895 A	25-01-1996
		CA 2193802 A	11-01-1996
		EP 0766569 A	09-04-1997
		JP 10502526 T	10-03-1998
		US 5863541 A	26-01-1999
WO 9811244 A	19-03-1998	AU 4645697 A	02-04-1998
		EP 0932694 A	04-08-1999
WO 9841240 A	24-09-1998	AU 6458698 A	12-10-1998
WO 9845462 A	15-10-1998	IT RM970200 A	08-10-1998
		AU 7077898 A	30-10-1998



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12N 7/01, 15/34, 15/35, C07K 16/08, 14/015, C12N 15/85	A3	(11) International Publication Number: <b>WO 99/61601</b> (43) International Publication Date: 2 December 1999 (02.12.99)								
<p>(21) International Application Number: PCT/US99/11958</p> <p>(22) International Filing Date: 28 May 1999 (28.05.99)</p> <p>(30) Priority Data: 60/087,029 28 May 1998 (28.05.98) US</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/087,029 (CIP) Filed on 28 May 1998 (28.05.98)</p> <p>(71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20854-3804 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): CHIORINI, John, A. [US/US]; 2604 Loma Street, Silver Spring, MD 20902 (US). KOTIN, Robert, M. [US/US]; 6510 Broxburn Drive, Bethesda, MD 20817 (US).</p>		<p>(74) Agents: SPRATT, Gwendolyn, D. et al.; Needle &amp; Rosenberg, P.C., Suite 1200, The Candler Building, 127 Peachtree Street, N.E., Atlanta, GA 30303-1811 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p> <p>(88) Date of publication of the international search report: 17 February 2000 (17.02.00)</p>								
<p>(54) Title: AAV5 VECTOR AND USES THEREOF</p> <p>Apical transduction of human airway epithelia with rAAV2 and rAAV5</p>  <table border="1"><caption>Apical transduction of human airway epithelia with rAAV2 and rAAV5</caption><thead><tr><th>Condition</th><th>bgal light units</th></tr></thead><tbody><tr><td>aav5</td><td>~3.5e+6</td></tr><tr><td>aav2</td><td>~0.1e+6</td></tr><tr><td>cells alone</td><td>~0.1e+6</td></tr></tbody></table> <p>(57) Abstract</p> <p>The present invention provides an adeno-associated virus 5 (AAV5) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV5 vectors and particles.</p>			Condition	bgal light units	aav5	~3.5e+6	aav2	~0.1e+6	cells alone	~0.1e+6
Condition	bgal light units									
aav5	~3.5e+6									
aav2	~0.1e+6									
cells alone	~0.1e+6									

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## AAV5 VECTOR AND USES THEREOF

This application claims priority to U.S. provisional application Serial No. 60/087029 filed on May 28, 1998. The 60/087029 provisional patent application is  
5 herein incorporated by this reference in its entirety.

## BACKGROUND OF THE INVENTION

### Field of the Invention

10 The present invention provides adeno-associated virus 5 (AAV5) and vectors derived therefrom. Thus, the present invention relates to AAV5 vectors for and methods of delivering nucleic acids to cells of subjects.

### Background Art

15 Adeno associated virus (AAV) is a small nonpathogenic virus of the parvoviridae family (for review see 28). AAV is distinct from the other members of this family by its dependence upon a helper virus for replication. In the absence of a helper virus, AAV has been shown to integrate in a locus specific manner into the q arm of chromosome 19 (21). The approximately 5 kb genome of AAV consists of one  
20 segment of single stranded DNA of either plus or minus polarity. Physically, the parvovirus virion is non-enveloped and its icosohedral capsid is approximately 20-25 nm in diameter.

To date 8 serologically distinct AAVs have been identified and 6 have been  
25 isolated from humans or primates and are referred to as AAV types 1-6 (1). The most extensively studied of these isolates is AAV type 2 (AAV2). The genome of AAV2 is 4680 nucleotides in length and contains two open reading frames (ORFs), the right ORF and the left ORF. The left ORF encodes the non-structural Rep proteins, Rep40, Rep52, Rep68 and Rep78, which are involved in regulation of replication and  
30 transcription in addition to the production of single-stranded progeny genomes (5-8, 11, 12, 15, 17, 19, 21-23, 25, 34, 37-40). Furthermore, two of the Rep proteins have been associated with the preferential integration of AAV genomes into a region of the q arm

of human chromosome 19. Rep68/78 have also been shown to possess NTP binding activity as well as DNA and RNA helicase activities. The Rep proteins possess a nuclear localization signal as well as several potential phosphorylation sites. Mutation of one of these kinase sites resulted in a loss of replication activity.

5

The ends of the genome are short inverted terminal repeats which have the potential to fold into T-shaped hairpin structures that serve as the origin of viral DNA replication. Within the ITR region two elements have been described which are central to the function of the ITR, a GAGC repeat motif and the terminal resolution site (TRS).

10 The repeat motif has been shown to bind Rep when the ITR is in either a linear or hairpin conformation (7, 8, 26).

This binding serves to position Rep68/78 for cleavage at the TRS which occurs in a site- and strand-specific manner. In addition to their role in replication, these two  
15 elements appear to be central to viral integration. Contained within the chromosome 19 integration locus is a Rep binding site with an adjacent TRS. These elements have been shown to be functional and necessary for locus specific integration.

The AAV2 virion is a non-enveloped, icosohedral particle approximately 20-25  
20 nm in diameter. The capsid is composed of three related proteins referred to as VP1,2 and 3 which are encoded by the right ORF. These proteins are found in a ratio of 1:1:10 respectively. The capsid proteins differ from each other by the use of alternative splicing and an unusual start codon. Deletion analysis of has shown that removal or alteration of AAV2 VP1 which is translated from an alternatively spliced message  
25 results in a reduced yield of infections particles (15, 16, 38). Mutations within the VP3 coding region result in the failure to produce any single-stranded progeny DNA or infectious particles (15, 16, 38).

The following features of the characterized AAVs have made them attractive  
30 vectors for gene transfer (16). AAV vectors have been shown *in vitro* to stably integrate into the cellular genome; possess a broad host range; transduce both dividing and non dividing cells *in vitro* and *in vivo* (13, 20, 30, 32) and maintain high levels of

expression of the transduced genes (41). Viral particles are heat stable, resistant to solvents, detergents, changes in pH, temperature, and can be concentrated on CsCl gradients (1,2). Integration of AAV provirus is not associated with any long term negative effects on cell growth or differentiation (3,42). The ITRs have been shown to  
5 be the only cis elements required for replication, packaging and integration (35) and may contain some promoter activities (14).

AAV2 was originally thought to infect primate and non-primate cell types provided the appropriate helper virus was present. However, the inability of AAV2 to  
10 infect certain cell types is now known to be due to the particular cellular tropism exhibited by the AAV2 virus. Recent work has shown that some cell lines are transduced very poorly by AAV2 (30). Binding studies have indicated that heparin sulfate proteoglycans are necessary for high efficiency transduction with AAV2. AAV5 is a unique member of the parvovirus family. The present DNA hybridization  
15 data indicate a low level of homology with the published AAV1-4 sequences (31). The present invention shows that, unlike AAV2, AAV5 transduction is not effected by heparin as AAV2 is and therefore will not be restricted to the same cell types as AAV2.

The present invention provides a vector comprising the AAV5 virus or a vector  
20 comprising subparts of the virus, as well as AAV5 viral particles. While AAV5 is similar to AAV2, the two viruses are found herein to be physically and genetically distinct. These differences endow AAV5 with some unique properties and advantages which better suit it as a vector for gene therapy. For example, one of the limiting features of using AAV2 as a vector for gene therapy is production of large amounts of  
25 virus. Using standard production techniques, AAV5 is produced at a 10-50 fold higher level compared to AAV2. Because of its unique TRS site and rep proteins, AAV5 should also have a distinct integration locus compared to AAV2.

Furthermore, as shown herein, AAV5 capsid protein, again surprisingly, is  
30 distinct from AAV2 capsid protein and exhibits different tissue tropism, thus making AAV5 capsid-containing particles suitable for transducing cell types for which AAV2 is unsuited or less well-suited. AAV2 and AAV5 have been shown to be serologically



distinct and thus, in a gene therapy application, AAV5, and AAV5-derived vectors, would allow for transduction of a patient who already possess neutralizing antibodies to AAV2 either as a result of natural immunological defense or from prior exposure to AAV2 vectors. Another advantage of AAV5 is that AAV5 cannot be rescued by other serotypes. Only AAV5 can rescue the integrated AAV5 genome and effect replication, thus avoiding unintended replication of AAV5 caused by other AAV serotypes. Thus, the present invention, by providing these new recombinant vectors and particles based on AAV5 provides a new and highly useful series of vectors.

## 10 SUMMARY OF THE INVENTION

The present invention provides a nucleic acid vector comprising a pair of adeno-associated virus 5 (AAV5) inverted terminal repeats and a promoter between the inverted terminal repeats.

15

The present invention further provides an AAV5 particle containing a vector comprising a pair of AAV2 inverted terminal repeats.

Additionally, the instant invention provides an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:1 (AAV5 genome). Furthermore, the present invention provides an isolated nucleic acid consisting essentially of the nucleotide sequence set forth in SEQ ID NO:1 (AAV5 genome).

The present invention provides an isolated nucleic acid encoding an AAV5 Rep protein, for example, the nucleic acid as set forth in SEQ ID NO:10. Additionally provided is an isolated full-length AAV5 Rep protein or a unique fragment thereof. Additionally provided is an isolated AAV5 Rep 40 protein having the amino acid sequence set forth in SEQ ID NO:12, or a unique fragment thereof. Additionally provided is an isolated AAV5 Rep 52 protein having the amino acid sequence set forth in SEQ ID NO:2, or a unique fragment thereof. Additionally provided is an isolated AAV5 Rep 68 protein, having the amino acid sequence set forth in SEQ ID NO:14 or a unique fragment thereof. Additionally provided is an isolated AAV5 Rep 78 protein

having the amino acid sequence set forth in SEQ ID NO:3, or a unique fragment thereof. The sequences for these proteins are provided below in the Sequence Listing and elsewhere in the application where the proteins are described.

5           The present invention further provides an isolated AAV5 capsid protein, VP1, having the amino acid sequence set forth in SEQ ID NO:4, or a unique fragment thereof. Additionally provided is an isolated AAV5 capsid protein, VP2, having the amino acid sequence set forth in SEQ ID NO:5, or a unique fragment thereof. Also provided is an isolated AAV5 capsid protein, VP3, having the amino acid sequence set  
10   forth in SEQ ID NO:6, or a unique fragment thereof.

          The present invention additionally provides an isolated nucleic acid encoding AAV5 capsid protein, for example, the nucleic acid set forth in SEQ ID NO:7, or a unique fragment thereof.

15

          The present invention further provides an AAV5 particle comprising a capsid protein consisting essentially of the amino acid sequence set forth in SEQ ID NO:4, or a unique fragment thereof.

20           Additionally provided by the present invention is an isolated nucleic acid comprising an AAV5 p5 promoter having the nucleic acid sequence set forth in SEQ ID NO:18, or a unique fragment thereof.

          The instant invention provides a method of screening a cell for infectivity by  
25   AAV5 comprising contacting the cell with AAV5 and detecting the presence of AAV5 in the cells.

          The present invention further provides a method of delivering a nucleic acid to a cell comprising administering to the cell an AAV5 particle containing a vector  
30   comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

The present invention also provides a method of delivering a nucleic acid to a subject comprising administering to a cell from the subject an AAV5 particle comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, and returning the cell to the subject, thereby delivering the nucleic acid to the subject.

5

The present invention also provides a method of delivering a nucleic acid to a cell in a subject comprising administering to the subject an AAV5 particle comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to a cell in the subject.

10

The instant invention further provides a method of delivering a nucleic acid to a cell in a subject having antibodies to AAV2 comprising administering to the subject an AAV5 particle comprising the nucleic acid, thereby delivering the nucleic acid to a cell in the subject.

15

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows Heparin inhibition results. Cos cells were plated in 12 well dishes at  $5 \times 10^4$  cells per well. Serial dilutions of AAV2 or AAV5 produced and purified as previously described and supplemented with  $5 \times 10^5$  particles of wt adenovirus were incubated for 1 hr at Rt in the presence of 20  $\mu\text{g/ml}$  heparin (sigma). Following this incubation the virus was added to the cells in 400  $\mu\text{l}$  of media for 1 hr after which the media was removed, the cells rinsed and fresh media added. After 24 hrs the plates were stained for Bgal activity.

25

Figure 2 shows AAV2 and AAV5 vector and helper complementation. Recombinant AAV particles were produced as previously described using a variety of vector and helper plasmids as indicated the bottom of the graph. The vector plasmids contained the Bgal gene with and RSV promoter and flanked by either AAV2 ITRs (2ITR) or AAV5 ITRs (5ITR). The helper plasmids tested contained either AAV2 Rep and cap genes (2repcap) AAV5 rep and cap genes with or without an SV40 promoter (5repcapA and 5repcapb respectively) only the AAV2 rep gene (2rep) in varying

30

amounts (1) or (.5) or an empty vector (pUC). The resulting AAV particles were then titrated on cos cells. AAV particles were only produced when the same serotype of ITR and Rep were present.

5           Figure 3 shows AAV2 and AAV5 tissue tropism. Transduction of a variety of cell types indicated that AAV2 and AAV5 transduce cells with different efficiencies. Equal number of either AAV2 or AAV5 particles were used to transduce a variety of cell types and the number of bgal positive cells is reported.

10           Figure 4 is a sequence comparison of the AAV2 genome and the AAV5 genome.

            Figure 5 is a sequence comparison of the AAV2 VP1 capsid protein and the AAV5 VP1 capsid protein.

15

            Figure 6 is a sequence comparison of the AAV2 rep 78 protein and the AAV5 rep 78 protein.

            Figure 7 shows the transduction of airway epithelial cells by AAV5. Primary  
20   airway epithelial cells were cultured and plated. Cells were transduced with an equivalent number of rAAV2 or rAAV5 particles containing a nuclear localized  $\beta$ -gal transgene with 50 particles of virus/cell (MOI 50) and continued in culture for 10 days.  $\beta$ -gal activity was determined and the relative transduction efficiency compared. AAV5 transduced these cells 50- fold more efficiently than AAV2. This is the first  
25   time apical cells or cells exposed to the air have been shown to be infected by a gene therapy agent.

            Figure 8 shows transduction of striated muscle by AAV5. Chicken myoblasts were cultured and plated. Cells were allowed to fuse and then transduced with a similar  
30   number of particles of rAAV2 or rAAV5 containing a nuclear localized  $\beta$ -gal transgene after 5 days in culture. The cells were stained for  $\beta$ -gal activity and the relative

transduction efficiency compared. AAV5 transduced these cells approximately 16 fold more efficiently than AAV2.

Figure 9 shows transduction of rat brain explants by AAV5. Primary neonatal  
5 rat brain explants were prepared. After 7 days in culture, cells were transduced with a similar number of particles of rAAV5 containing a nuclear localized  $\beta$ -gal transgene. After 5 days in culture, the cells were stained for  $\beta$ -gal activity. Transduction was detected in a variety of cell types including astrocytes, neuronal cells and glial cells.

10 Figure 10 shows transduction of human umbilical vein endothelial cells by AAV5. Human umbilical vein endothelial cells were cultured and plated. Cells were transduced with rAAV2 or rAAV5 containing a nuclear localized  $\beta$ -gal transgene with 10 particles of virus/ cell (MOI 5) in minimal media then returned to complete media. After 24 hrs in culture, the cells were stained for  $\beta$ -gal activity and the relative  
15 transduction efficiency compared. As shown in AAV5 transduced these cell 5-10 fold more efficiently than AAV2.

### DETAILED DESCRIPTION OF THE INVENTION

20 As used in the specification and in the claims, "a" can mean one or more, depending upon the context in which it is used. The terms "having" and "comprising" are used interchangeably herein, and signify open ended meaning.

The present application provides a recombinant adeno-associated virus 5  
25 (AAV5). This virus has one or more of the characteristics described below. The compositions of the present invention do not include wild-type AAV5. The methods of the present invention can use either wild-type AAV5 or recombinant AAV5-based delivery.

30 The present invention provides novel AAV5 particles, recombinant AAV5 vectors, recombinant AAV5 virions and novel AAV5 nucleic acids and polypeptides. An AAV5 particle is a viral particle comprising an AAV5 capsid protein. A

recombinant AAV5 vector is a nucleic acid construct that comprises at least one unique nucleic acid of AAV5. A recombinant AAV5 virion is a particle containing a recombinant AAV5 vector, wherein the particle can be either an AAV5 particle as described herein or a non-AAV5 particle. Alternatively, the recombinant AAV5 virion is an AAV5 particle containing a recombinant vector, wherein the vector can be either an AAV5 vector as described herein or a non-AAV5 vector. These vectors, particles, virions, nucleic acids and polypeptides are described below.

The present invention provides the nucleotide sequence of the AAV5 genome and vectors and particles derived therefrom. Specifically, the present invention provides a nucleic acid vector comprising a pair of AAV5 inverted terminal repeats (ITRs) and a promoter between the inverted terminal repeats. While the rep proteins of AAV2 and AAV5 will bind to either a type 2 ITR or a type 5 ITR, efficient genome replication only occurs when type 2 Rep replicates a type 2 ITR and a type 5 Rep replicates a type 5 ITR. This specificity is the result of a difference in DNA cleavage specificity of the two Reps which is necessary for replication. AAV5 Rep cleaves at CGGT<sup>^</sup>GTGA (SEQ ID NO: 21) and AAV2 Rep cleaves at CGGT<sup>^</sup>TGAG (SEQ ID NO: 22) (Chiorini et al., 1999. J. Virol. 73 (5) 4293-4298). Mapping of the AAV5 ITR terminal resolution site (TRS) identified this distinct cleavage site, CGGT<sup>^</sup>GTGA, which is absent from the ITRs of other AAV serotypes. Therefore, the minimum sequence necessary to distinguish AAV5 from AAV2 is the TRS site where Rep cleaves in order to replicate the virus. Examples of the type 5 ITRs are shown in SEQ ID NO: 19 and SEQ ID NO: 20, AAV5 ITR "flip" and AAV5 "flop", respectively. Minor modifications in an ITR of either orientation are contemplated and are those that will not interfere with the hairpin structure formed by the AAV5 ITR as described herein and known in the art. Furthermore, to be considered within the term "AAV5 ITR" the nucleotide sequence must retain one or more features described herein that distinguish the AAV5 ITR from the ITRs of other serotypes, e.g. it must retain the Rep binding site described herein.

30

The D- region of the AAV5 ITR (SEQ ID NO: 23), a single stranded region of the ITR, inboard of the TRS site, has been shown to bind a factor which depending on



its phosphorylation state correlates with the conversion of the AAV from a single stranded genome to a transcriptionally active form that allows for expression of the viral DNA. This region is conserved between AAV2, 3, 4, and 6 but is divergent in AAV5. The D+ region is the reverse complement of the D- region.

5

The promoter can be any desired promoter, selected by known considerations, such as the level of expression of a nucleic acid functionally linked to the promoter and the cell type in which the vector is to be used. That is, the promoter can be tissue/cell-specific. Promoters can be prokaryotic, eukaryotic, fungal, nuclear, mitochondrial, viral or plant promoters. Promoters can be exogenous or endogenous to the cell type being transduced by the vector. Promoters can include, for example, bacterial promoters, known strong promoters such as SV40 or the inducible metallothionein promoter, or an AAV promoter, such as an AAV p5 promoter. Additionally, chimeric regulatory promoters for targeted gene expression can be utilized. Examples of these regulatory systems, which are known in the art, include the tetracycline based regulatory system which utilizes the tet transactivator protein (tTA), a chimeric protein containing the VP16 activation domain fused to the tet repressor of *Escherichia coli*, the IPTG based regulatory system, the CID based regulatory system, and the Ecdysone based regulatory system (44). Other promoters include promoters derived from actin genes, immunoglobulin genes, cytomegalovirus (CMV), adenovirus, bovine papilloma virus, adenoviral promoters, such as the adenoviral major late promoter, an inducible heat shock promoter, respiratory syncytial virus, Rous sarcoma virus (RSV), etc., specifically, the promoter can be AAV2 p5 promoter or AAV5 p5 promoter. More specifically, the AAV5 p5 promoter can be about same location in SEQ ID NO: 1 as the AAV2 p5 promoter, in the corresponding AAV2 published sequence. Additionally, the p5 promoter may be enhanced by nucleotides 1-130 of SEQ ID NO: 1.

Furthermore, smaller fragments of p5 promoter that retain promoter activity can readily be determined by standard procedures including, for example, constructing a series of deletions in the p5 promoter, linking the deletion to a reporter gene, and determining whether the reporter gene is expressed, *i.e.*, transcribed and/or translated. The promoter can be the promoter of any of the AAV serotypes, and can be the p19 promoter (SEQ ID NO: 16) or the p40 promoter set forth in the sequence listing as SEQ ID NO: 17.



It should be recognized that any errors in any of the nucleotide sequences disclosed herein can be corrected, for example, by using the hybridization procedure described below with various probes derived from the described sequences such that the coding sequence can be reisolated and resequenced. Rapid screening for point mutations can also be achieved with the use of polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) (43). The corresponding amino acid sequence can then be corrected accordingly.

The AAV5-derived vector of the invention can further comprise a heterologous nucleic acid functionally linked to the promoter. By "heterologous nucleic acid" is meant that any heterologous or exogenous nucleic acid, i.e. not normally found in wild-type AAV5 can be inserted into the vector for transfer into a cell, tissue or organism. By "functionally linked" is meant that the promoter can promote expression of the heterologous nucleic acid, as is known in the art, and can include the appropriate orientation of the promoter relative to the heterologous nucleic acid. Furthermore, the heterologous nucleic acid preferably has all appropriate sequences for expression of the nucleic acid. The nucleic acid can include, for example, expression control sequences, such as an enhancer, and necessary information processing sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences.

The heterologous nucleic acid can encode beneficial proteins or polypeptides that replace missing or defective proteins required by the cell or subject into which the vector is transferred or can encode a cytotoxic polypeptide that can be directed, *e.g.*, to cancer cells or other cells whose death would be beneficial to the subject. The heterologous nucleic acid can also encode antisense RNAs that can bind to, and thereby inactivate, mRNAs made by the subject that encode harmful proteins. The heterologous nucleic acid can also encode ribozymes that can effect the sequence-specific inhibition of gene expression by the cleavage of mRNAs. In one embodiment, antisense polynucleotides can be produced from a heterologous expression cassette in an AAV5 vector construct where the expression cassette contains a sequence that promotes cell-type specific expression (Wirak *et al.*, *EMBO* 10:289

(1991)). For general methods relating to antisense polynucleotides, see *Antisense RNA and DNA*, D. A. Melton, Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1988).

5           Examples of heterologous nucleic acids which can be administered to a cell or subject as part of the present AAV5 vector can include, but are not limited to the following: nucleic acids encoding secretory and nonsecretory proteins, nucleic acids encoding therapeutic agents, such as tumor necrosis factors (TNF), such as TNF- $\alpha$ ; interferons, such as interferon- $\alpha$ , interferon- $\beta$ , and interferon- $\gamma$ ; interleukins, such as  
10 IL-1, IL-1 $\beta$ , and ILs -2 through -14; GM-CSF; adenosine deaminase; cellular growth factors, such as lymphokines; soluble CD4; Factor VIII; Factor IX; T-cell receptors; LDL receptor; ApoE; ApoC; alpha-1 antitrypsin; ornithine transcarbamylase (OTC); cystic fibrosis transmembrane receptor (CFTR); insulin; Fc receptors for antigen  
15 binding domains of antibodies, such as immunoglobulins; anti-HIV decoy tar elements; and antisense sequences which inhibit viral replication, such as antisense sequences which inhibit replication of hepatitis B or hepatitis non-A, non-B virus. The nucleic acid is chosen considering several factors, including the cell to be transfected. Where the target cell is a blood cell, for example, particularly useful nucleic acids to use are those which allow the blood cells to exert a therapeutic effect, such as a gene encoding  
20 a clotting factor for use in treatment of hemophilia. Another target cell is the lung airway cell, which can be used to administer nucleic acids, such as those coding for the cystic fibrosis transmembrane receptor, which could provide a gene therapeutic treatment for cystic fibrosis. Other target cells include muscle cells where useful nucleic acids, such as those encoding cytokines and growth factors, can be transduced  
25 and the protein the nucleic acid encodes can be expressed and secreted to exert its effects on other cells, tissues and organs, such as the liver. Furthermore, the nucleic acid can encode more than one gene product, limited only, if the nucleic acid is to be packaged in a capsid, by the size of nucleic acid that can be packaged.

30           Furthermore, suitable nucleic acids can include those that, when transferred into a primary cell, such as a blood cell, cause the transferred cell to target a site in the body where that cell's presence would be beneficial. For example, blood cells such as TIL

cells can be modified, such as by transfer into the cell of a Fab portion of a monoclonal antibody, to recognize a selected antigen. Another example would be to introduce a nucleic acid that would target a therapeutic blood cell to tumor cells. Nucleic acids useful in treating cancer cells include those encoding chemotactic factors which cause  
5 an inflammatory response at a specific site, thereby having a therapeutic effect.

Cells, particularly blood cells, muscle cells, airway epithelial cells, brain cells and endothelial cells having such nucleic acids transferred into them can be useful in a variety of diseases, syndromes and conditions. For example, suitable nucleic acids  
10 include nucleic acids encoding soluble CD4, used in the treatment of AIDS and  $\alpha$ -antitrypsin, used in the treatment of emphysema caused by  $\alpha$ -antitrypsin deficiency. Other diseases, syndromes and conditions in which such cells can be useful include, for example, adenosine deaminase deficiency, sickle cell deficiency, brain disorders such as Alzheimer's disease, thalassemia, hemophilia, diabetes, phenylketonuria, growth  
15 disorders and heart diseases, such as those caused by alterations in cholesterol metabolism, and defects of the immune system.

As another example, hepatocytes can be transfected with the present vectors having useful nucleic acids to treat liver disease. For example, a nucleic acid encoding  
20 OTC can be used to transfect hepatocytes (*ex vivo* and returned to the liver or *in vivo*) to treat congenital hyperammonemia, caused by an inherited deficiency in OTC. Another example is to use a nucleic acid encoding LDL to target hepatocytes *ex vivo* or *in vivo* to treat inherited LDL receptor deficiency. Such transfected hepatocytes can also be used to treat acquired infectious diseases, such as diseases resulting from a viral  
25 infection. For example, transduced hepatocyte precursors can be used to treat viral hepatitis, such as hepatitis B and non-A, non-B hepatitis, for example by transducing the hepatocyte precursor with a nucleic acid encoding an antisense RNA that inhibits viral replication. Another example includes transferring a vector of the present invention having a nucleic acid encoding a protein, such as  $\alpha$ -interferon, which can  
30 confer resistance to the hepatitis virus.

For a procedure using transfected hepatocytes or hepatocyte precursors, hepatocyte precursors having a vector of the present invention transferred in can be grown in tissue culture, removed from the tissue culture vessel, and introduced to the body, such as by a surgical method. In this example, the tissue would be placed  
5 directly into the liver, or into the body cavity in proximity to the liver, as in a transplant or graft. Alternatively, the cells can simply be directly injected into the liver, into the portal circulatory system, or into the spleen, from which the cells can be transported to the liver via the circulatory system. Furthermore, the cells can be attached to a support, such as microcarrier beads, which can then be introduced, such as by injection, into the  
10 peritoneal cavity. Once the cells are in the liver, by whatever means, the cells can then express the nucleic acid and/or differentiate into mature hepatocytes which can express the nucleic acid.

The AAV5-derived vector can include any normally occurring AAV5 sequences  
15 in addition to an ITR and promoter. Examples of vector constructs are provided below.

The present vector or AAV5 particle or recombinant AAV5 virion can utilize any unique fragment of these present AAV5 nucleic acids, including the AAV5 nucleic acids set forth in SEQ ID NOS: 1 and 7-11, 13, 15, 16, 17, and 18. To be unique, the  
20 fragment must be of sufficient size to distinguish it from other known sequences, most readily determined by comparing any nucleic acid fragment to the nucleotide sequences of nucleic acids in computer databases, such as GenBank. Such comparative searches are standard in the art. Typically, a unique fragment useful as a primer or probe will be at least about 8 or 10, preferable at least 20 or 25 nucleotides in length, depending upon  
25 the specific nucleotide content of the sequence. Additionally, fragments can be, for example, at least about 30, 40, 50, 75, 100, 200 or 500 nucleotides in length and can encode polypeptides or be probes. The nucleic acid can be single or double stranded, depending upon the purpose for which it is intended. Where desired, the nucleic acid can be RNA.

30

The present invention further provides an AAV5 capsid protein to contain the vector. In particular, the present invention provides not only a polypeptide comprising

all three AAV5 coat proteins, *i.e.*, VP1, VP2 and VP3, but also a polypeptide comprising each AAV5 coat protein individually, SEQ ID NOS: 4, 5, and 6, respectively. Thus an AAV5 particle comprising an AAV5 capsid protein comprises at least one AAV5 coat protein VP1, VP2 or VP3. An AAV5 particle comprising an AAV5 capsid protein can be utilized to deliver a nucleic acid vector to a cell, tissue or subject. For example, the herein described AAV5 vectors can be encapsidated in an AAV5 capsid-derived particle and utilized in a gene delivery method. Furthermore, other viral nucleic acids can be encapsidated in the AAV5 particle and utilized in such delivery methods. For example, an AAV1, 2,3,4, or 6 vector (e.g. AAV1,2,3,4, or 6 ITR and nucleic acid of interest) can be encapsidated in an AAV5 particle and administered. Furthermore, an AAV5 chimeric capsid incorporating both AAV2 capsid and AAV5 capsid sequences can be generated, by standard cloning methods, selecting regions from the known sequences of each protein as desired. For example, particularly antigenic regions of the AAV2 capsid protein can be replaced with the corresponding region of the AAV5 capsid protein. In addition to chimeric capsids incorporating AAV2 capsid sequences, chimeric capsids incorporating AAV1, 3, 4, or 6 and AAV5 capsid sequences can be generated, by standard cloning methods, selecting regions from the known sequences of each protein as desired.

20           The capsids can also be modified to alter their specific tropism by genetically altering the capsid to encode a specific ligand to a cell surface receptor. Alternatively, the capsid can be chemically modified by conjugating a ligand to a cell surface receptor. By genetically or chemically altering the capsids, the tropism can be modified to direct AAV5 to a particular cell or population of cells. The capsids can also be altered immunologically by conjugating the capsid to an antibody that recognizes a specific protein on the target cell or population of cells.

30           The capsids can also be assembled into empty particles by expression in mammalian, bacterial, fungal or insect cells. For example, AAV2 particles are known to be made from VP3 and VP2 capsid proteins in baculovirus. The same basic protocol can produce an empty AAV5 particle comprising an AAV5 capsid protein.



The herein described recombinant AAV5 nucleic acid derived vector can be encapsidated in an AAV particle. In particular, it can be encapsidated in an AAV1 particle, an AAV2 particle, an AAV3 particle, an AAV4 particle, an AAV5 particle or an AAV6 particle, a portion of any of these capsids, or a chimeric capsid particle as described above, by standard methods using the appropriate capsid proteins in the encapsidation process, as long as the nucleic acid vector fits within the size limitation of the particle utilized. The encapsidation process itself is standard in the art. The AAV5 replication machinery, i.e. the rep initiator proteins and other functions required for replication, can be utilized to produce the AAV5 genome that can be packaged in an AAV1, 2, 3, 4, 5 or 6 capsid.

The recombinant AAV5 virion containing a vector can also be produced by recombinant methods utilizing multiple plasmids. In one example, the AAV5 rep nucleic acid would be cloned into one plasmid, the AAV5 ITR nucleic acid would be cloned into another plasmid and the AAV1, 2, 3, 4, 5 or 6 capsid nucleic acid would be cloned on another plasmid. These plasmids would then be introduced into cells. The cells that were efficiently transduced by all three plasmids, would exhibit specific integration as well as the ability to produce AAV5 recombinant virus. Additionally, two plasmids could be used where the AAV5 rep nucleic acid would be cloned into one plasmid and the AAV5 ITR and AAV5 capsid would be cloned into another plasmid. These plasmids would then be introduced into cells. The cells that were efficiently transduced by both plasmids, would exhibit specific integration as well as the ability to produce AAV5 recombinant virus.

An AAV5 capsid polypeptide encoding the entire VP1, VP2, and VP3 polypeptide can overall has greater than 56% homology to the polypeptide having the amino acid sequence encoded by nucleotides in SEQ ID NOS:7,8 and 9, as shown in figures 4 and 5. The capsid protein can have about 70% homology, about 75% homology, 80% homology, 85% homology, 90% homology, 95% homology, 98% homology, 99% homology, or even 100% homology to the protein having the amino acid sequence encoded by the nucleotides set forth in SEQ ID NOS:7, 8 or 9. The percent homology used to identify proteins herein, can be based on a nucleotide-by-

nucleotide comparison or more preferable is based on a computerized algorithm as described herein. Variations in the amino acid sequence of the AAV5 capsid protein are contemplated herein, as long as the resulting particle comprising an AAV5 capsid protein remains antigenically or immunologically distinct from AAV1, AAV2, AAV3, AAV4 or AAV6 capsid, as can be routinely determined by standard methods. Specifically, for example, ELISA and Western blots can be used to determine whether a viral particle is antigenically or immunologically distinct from AAV2 or the other serotypes. Furthermore, the AAV5 particle preferably retains tissue tropism distinction from AAV2, such as that exemplified in the examples herein. An AAV5 chimeric particle comprising at least one AAV5 coat protein may have a different tissue tropism from that of an AAV5 particle consisting only of AAV5 coat proteins, but is still distinct from the tropism of an AAV2 particle.

The invention further provides a recombinant AAV5 virion, comprising an AAV5 particle containing, *i.e.*, encapsidating, a vector comprising a pair of AAV5 inverted terminal repeats. The recombinant vector can further comprise an AAV5 Rep-encoding nucleic acid. The vector encapsidated in the particle can further comprise an exogenous nucleic acid inserted between the inverted terminal repeats. AAV5 Rep confers targeted integration and efficient replication, thus production of recombinant AAV5, comprising AAV5 Rep, yields more particles than production of recombinant AAV2. Since AAV5 is more efficient at replicating and packaging its genome, the exogenous nucleic acid inserted, or in the AAV5 capsids of the present invention, between the inverted terminal repeats can be packaged in the AAV1, 2, 3, 4, or 6 capsids to achieve the specific tissue tropism conferred by the capsid proteins.

25

The invention further contemplates chimeric recombinant ITRs that contains a rep binding site and a TRS site recognized by that Rep protein. By "Rep protein" is meant all four of the Rep proteins, Rep 40, Rep 78, Rep 52, Rep 68. Alternatively, "Rep protein" could be one or more of the Rep proteins described herein. One example of a chimeric ITR would consist of an AAV5 D region (SEQ ID NO: 23), an AAV5 TRS site (SEQ ID NO: 21), an AAV2 hairpin and an AAV2 binding site. Another example would be an AAV5 D region, an AAV5 TRS site, an AAV3 hairpin and an

30



AAV3 binding site. In these chimeric ITRs, the D region can be from AAV1, 2, 3, 4, 5 or 6. The hairpin can be derived from AAV 1,2 3, 4, 5, 6. The binding site can be derived from any of AAV1, 2, 3, 4, 5 or 6. Preferably, the D region and the TRS are from the same serotype.

5

The chimeric ITRs can be combined with AAV5 Rep protein and any of the AAV serotype capsids to obtain recombinant virion. For example, recombinant virion can be produced by an AAV5 D region, an AAV5 TRS site, an AAV2 hairpin, an AAV2 binding site, AAV5 Rep protein and AAV1 capsid. This recombinant virion would possess the cellular tropism conferred by the AAV1 capsid protein and would possess the efficient replication conferred by the AAV5 Rep.

10

Other examples of the ITR, Rep protein and Capsids that will produce recombinant virus are provided in the list below:

15

- 5ITR + 5Rep + 5Cap=virus
- 5ITR + 5Rep + 1Cap=virus
- 5ITR + 5Rep + 2Cap=virus
- 5ITR + 5Rep + 3Cap=virus
- 20 5ITR + 5Rep + 4Cap=virus
- 5ITR + 5Rep + 6Cap=virus
- 1ITR + 1Rep + 5Cap=virus
- 2ITR + 2Rep + 5Cap=virus
- 3ITR + 3Rep + 5Cap=virus
- 25 4ITR + 4Rep + 5Cap=virus
- 6ITR + 6Rep + 5Cap=virus

In any of the constructs described herein, inclusion of a promoter is preferred. As used in the constructs herein, unless otherwise specified, Cap (capsid) refers to any of AAV5 VP1, AAV5 VP2, AAV5 VP3, combinations thereof, functional fragments of any of VP1, VP2 or VP3, or chimeric capsids as described herein. The ITRs of the

30

constructs described herein, can be chimeric recombinant ITRs as described elsewhere in the application.

Conjugates of recombinant or wild-type AAV5 virions and nucleic acids or  
5 proteins can be used to deliver those molecules to a cell. For example, the purified AAV5 can be used as a vehicle for delivering DNA bound to the exterior of the virus. Examples of this are to conjugate the DNA to the virion by a bridge using poly-L-lysine or other charged molecule. Also contemplated are virosomes that contain AAV5 structural proteins (AAV5 capsid proteins), lipids such as DOTAP, and nucleic  
10 acids that are complexed via charge interaction to introduce DNA into cells.

Also provided by this invention are conjugates that utilize the AAV5 capsid or a unique region of the AAV5 capsid protein (e.g. VP1, VP2 or VP3 or combinations thereof) to introduce DNA into cells. For example, the type 5 VP3 protein or fragment  
15 thereof, can be conjugated to a DNA on a plasmid that is conjugated to a lipid. Cells can be infected using the targeting ability of the VP3 capsid protein to achieve the desired tissue tropism, specific to AAV5. Type 5 VP1 and VP2 proteins can also be utilized to introduce DNA or other molecules into cells. By further incorporating the Rep protein and the AAV TRS into the DNA-containing conjugate, cells can be  
20 transduced and targeted integration can be achieved. For example, if AAV5 specific targeted integration is desired, a conjugate composed of the AAV5 VP3 capsid, AAV5 rep or a fragment of AAV5 rep, AAV5 TRS, the rep binding site, the heterologous DNA of interest, and a lipid, can be utilized to achieve AAV5 specific tropism and AAV5 specific targeted integration in the genome.

25

Further provided by this invention are chimeric viruses where AAV5 can be combined with herpes virus, baculovirus or other viruses to achieve a desired tropism associated with another virus. For example, the AAV5 ITRs could be inserted in the herpes virus and cells could be infected. Post-infection, the ITRs of AAV5 could be  
30 acted on by AAV5 rep provided in the system or in a separate vehicle to rescue AAV5 from the genome. Therefore, the cellular tropism of the herpes simplex virus can be combined with AAV5 rep mediated targeted integration. Other viruses that could be

utilized to construct chimeric viruses include, lentivirus, retrovirus, pseudotyped retroviral vectors, and adenoviral vectors.

The present invention further provides isolated nucleic acids of AAV5. For example, provided is an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:1 (AAV5 genome). This nucleic acid, or portions thereof, can be inserted into vectors, such as plasmids, yeast artificial chromosomes, or other viral vector (particle), if desired, by standard cloning methods. The present invention also provides an isolated nucleic acid consisting essentially of the nucleotide sequence set forth in SEQ ID NO:1. The nucleotides of SEQ ID NO:1 can have minor modifications and still be contemplated by the present invention. For example, modifications that do not alter the amino acid encoded by any given codon (such as by modification of the third, "wobble," position in a codon) can readily be made, and such alterations are known in the art. Furthermore, modifications that cause a resulting neutral (conserved) amino acid substitution of a similar amino acid can be made in a coding region of the genome. Additionally, modifications as described herein for the AAV5 components, such as the ITRs, the p5 promoter, etc. are contemplated in this invention. Furthermore, modifications to regions of SEQ ID NO:1 other than in the ITR, TRS Rep binding site and hairpin are likely to be tolerated without serious impact on the function of the nucleic acid as a recombinant vector.

As used herein, the term "isolated" refers to a nucleic acid separated or significantly free from at least some of the other components of the naturally occurring organism, for example, the cell structural components or viral components commonly found associated with nucleic acids in the environment of the virus and/or other nucleic acids. The isolation of the native nucleic acids can be accomplished, for example, by techniques such as cell lysis followed by phenol plus chloroform extraction, followed by ethanol precipitation of the nucleic acids. The nucleic acids of this invention can be isolated from cells according to any of many methods well known in the art.

As used herein, the term "nucleic acid" refers to single-or multiple stranded molecules which may be DNA or RNA, or any combination thereof, including

modifications to those nucleic acids. The nucleic acid may represent a coding strand or its complement, or any combination thereof. Nucleic acids may be identical in sequence to the sequences which are naturally occurring for any of the novel genes discussed herein or may include alternative codons which encode the same amino acid as those provided herein, including that which is found in the naturally occurring sequence. These nucleic acids can also be modified from their typical structure. Such modifications include, but are not limited to, methylated nucleic acids, the substitution of a non-bridging oxygen on the phosphate residue with either a sulfur (yielding phosphorothioate deoxynucleotides), selenium (yielding phosphorselenoate deoxynucleotides), or methyl groups (yielding methylphosphonate deoxynucleotides).

The present invention additionally provides an isolated nucleic acid that selectively hybridizes with any nucleic acid disclosed herein, including the entire AAV5 genome and any unique fragment thereof, including the Rep and capsid encoding sequences (e.g. SEQ ID NOS: 1, 7, 8, 9, 10, 11, 13, 15, 16, 17, 18, 19, 20, 21, 22 and 23). Specifically, the nucleic acid can selectively or specifically hybridize to an isolated nucleic acid consisting of the nucleotide sequence set forth in SEQ ID NO:1 (AAV5 genome). The present invention further provides an isolated nucleic acid that selectively or specifically hybridizes with an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:1 (AAV5 genome). By "selectively hybridizes" as used herein is meant a nucleic acid that hybridizes to one of the disclosed nucleic acids under sufficient stringency conditions without significant hybridization to a nucleic acid encoding an unrelated protein, and particularly, without detectably hybridizing to nucleic acids of AAV2. Thus, a nucleic acid that selectively hybridizes with a nucleic acid of the present invention will not selectively hybridize under stringent conditions with a nucleic acid encoding a different protein or the corresponding protein from a different serotype of the virus, and vice versa. A "specifically hybridizing" nucleic acid is one that hybridizes under stringent conditions to only a nucleic acid found in AAV5. Therefore, nucleic acids for use, for example, as primers and probes to detect or amplify the target nucleic acids are contemplated herein. Nucleic acid fragments that selectively hybridize to any given nucleic acid can be used, e.g., as primers and or probes for further hybridization or for amplification

methods (e.g., polymerase chain reaction (PCR), ligase chain reaction (LCR)).

Additionally, for example, a primer or probe can be designed that selectively hybridizes with both AAV5 and a gene of interest carried within the AAV5 vector (i.e., a chimeric nucleic acid).

5.

Stringency of hybridization is controlled by both temperature and salt concentration of either or both of the hybridization and washing steps. Typically, the stringency of hybridization to achieve selective hybridization involves hybridization in high ionic strength solution (6X SSC or 6X SSPE) at a temperature that is about 12-  
10 25°C below the  $T_m$  (the melting temperature at which half of the molecules dissociate from their hybridization partners) followed by washing at a combination of temperature and salt concentration chosen so that the washing temperature is about 5°C to 20°C below the  $T_m$ . The temperature and salt conditions are readily determined empirically in preliminary experiments in which samples of reference DNA immobilized on filters  
15 are hybridized to a labeled nucleic acid of interest and then washed under conditions of different stringencies. Hybridization temperatures are typically higher for DNA-RNA and RNA-RNA hybridizations. The washing temperatures can be used as described above to achieve selective stringency, as is known in the art. (Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory,  
20 Cold Spring Harbor, New York, 1989; Kunkel et al. *Methods Enzymol.* 1987:154:367, 1987). A preferable stringent hybridization condition for a DNA:DNA hybridization can be at about 68°C (in aqueous solution) in 6X SSC or 6X SSPE followed by washing at 68°C. Stringency of hybridization and washing, if desired, can be reduced accordingly as the degree of complementarity desired is decreased, and further,  
25 depending upon the G-C or A-T richness of any area wherein variability is searched for. Likewise, stringency of hybridization and washing, if desired, can be increased accordingly as homology desired is increased, and further, depending upon the G-C or A-T richness of any area wherein high homology is desired, all as known in the art.

30 A nucleic acid that selectively hybridizes to any portion of the AAV5 genome is contemplated herein. Therefore, a nucleic acid that selectively hybridizes to AAV5 can be of longer length than the AAV5 genome, it can be about the same length as the



AAV5 genome or it can be shorter than the AAV5 genome. The length of the nucleic acid is limited on the shorter end of the size range only by its specificity for hybridization to AAV5, *i.e.*, once it is too short, typically less than about 5 to 7 nucleotides in length, it will no longer bind specifically to AAV5, but rather will  
5 hybridize to numerous background nucleic acids. Additionally contemplated by this invention is a nucleic acid that has a portion that specifically hybridizes to AAV5 and a portion that specifically hybridizes to a gene of interest inserted within AAV5.

The present invention further provides an isolated nucleic acid encoding an  
10 adeno-associated virus 5 Rep protein. The AAV5 Rep proteins are encoded by open reading frame (ORF) 1 of the AAV5 genome. Examples of the AAV5 Rep genes are shown in the nucleic acid set forth in SEQ ID NO:1, and include nucleic acids consisting essentially of the nucleotide sequences set forth in SEQ ID NOS:10 (Rep52), 11 (Rep78), 13 (Rep40), and 15 (Rep68), and nucleic acids comprising the nucleotide  
15 sequences set forth in SEQ ID NOS:10, 11, 13, and 15. However, the present invention contemplates that the Rep nucleic acid can include any one, two, three, or four of the four Rep proteins, in any order, in such a nucleic acid. Furthermore, minor modifications are contemplated in the nucleic acid, such as silent mutations in the coding sequences, mutations that make neutral or conservative changes in the encoded  
20 amino acid sequence, and mutations in regulatory regions that do not disrupt the expression of the gene. Examples of other minor modifications are known in the art. Further modifications can be made in the nucleic acid, such as to disrupt or alter expression of one or more of the Rep proteins in order to, for example, determine the effect of such a disruption; such as to mutate one or more of the Rep proteins to  
25 determine the resulting effect, etc. However, in general, a modified nucleic acid encoding a Rep protein will have at least about 85%, about 90%, about 93%, about 95%, about 98% or 100% homology to the Rep nucleic sequences described herein *e.g.*, SEQ ID NOS: 10, 11, 13 and 15, and the Rep polypeptide encoded therein will have overall about 93%, about 95%, about 98%, about 99% or 100% homology with  
30 the amino acid sequence described herein, *e.g.*, SEQ ID NOS:2, 3, 12 and 14. Percent homology is determined by the techniques described herein.

The present invention also provides an isolated nucleic acid that selectively or specifically hybridizes with a nucleic acid consisting essentially of the nucleotide sequence set forth in SEQ ID NOS:10, 11, 13 and 15, and an isolated nucleic acid that selectively hybridizes with a nucleic acid comprising the nucleotide sequence set forth  
5 in SEQ ID NOS:10, 11, 13 and 15. "Selectively hybridizing" and "stringency of hybridization" is defined elsewhere herein.

As described above, the present invention provides the nucleic acid encoding a Rep 40 protein and, in particular an isolated nucleic acid comprising the nucleotide  
10 sequence set forth in SEQ ID NO: 13, an isolated nucleic acid consisting essentially of the nucleotide sequence set forth in SEQ ID NO: 13, and a nucleic acid encoding the adeno-associated virus 5 protein having the amino acid sequence set forth in SEQ ID NO: 12. The present invention also provides the nucleic acid encoding a Rep 52 protein, and in particular an isolated nucleic acid comprising the nucleotide sequence  
15 set forth in SEQ ID NO:10, an isolated nucleic acid consisting essentially of the nucleotide sequence set forth in SEQ ID NO:10, and a nucleic acid encoding the adeno-associated virus 5 Rep protein having the amino acid sequence set forth in SEQ ID NO:2. The present invention further provides the nucleic acid encoding a Rep 68 protein and, in particular an isolated nucleic acid comprising the nucleotide sequence  
20 set forth in SEQ ID NO: 15, an isolated nucleic acid consisting essentially of the nucleotide sequence set forth in SEQ ID NO: 15, and a nucleic acid encoding the adeno-associated virus 5 protein having the amino acid sequence set forth in SEQ ID NO: 14. And, further, the present invention provides the nucleic acid encoding a Rep 78 protein, and in particular an isolated nucleic acid comprising the nucleotide  
25 sequence set forth in SEQ ID NO:11, an isolated nucleic acid consisting essentially of the nucleotide sequence set forth in SEQ ID NO:11, and a nucleic acid encoding the adeno-associated virus 5 Rep protein having the amino acid sequence set forth in SEQ ID NO:3. As described elsewhere herein, these nucleic acids can have minor modifications, including silent nucleotide substitutions, mutations causing conservative  
30 amino acid substitutions in the encoded proteins, and mutations in control regions that do not or minimally affect the encoded amino acid sequence.



The present invention further provides a nucleic acid encoding the entire AAV5 Capsid polypeptide. Furthermore, the present invention provides a nucleic acid encoding each of the three AAV5 coat proteins, VP1, VP2, and VP3. Thus, the present invention provides a nucleic acid encoding AAV5 VP1, a nucleic acid encoding AAV5 VP2, and a nucleic acid encoding AAV5 VP3. Thus, the present invention provides a nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:4 (VP1); a nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:5 (VP2), and a nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:6 (VP3). The present invention also specifically provides a nucleic acid comprising SEQ ID NO:7 (VP1 gene); a nucleic acid comprising SEQ ID NO:8 (VP2 gene); and a nucleic acid comprising SEQ ID NO:9 (VP3 gene). The present invention also specifically provides a nucleic acid consisting essentially of SEQ ID NO:7 (VP1 gene), a nucleic acid consisting essentially of SEQ ID NO:8 (VP2 gene), and a nucleic acid consisting essentially of SEQ ID NO:9 (VP3 gene). Minor modifications in the nucleotide sequences encoding the capsid, or coat, proteins are contemplated, as described above for other AAV5 nucleic acids. However, in general, a modified nucleic acid encoding a capsid protein will have at least about 85%, about 90%, about 93%, about 95%, about 98% or 100% homology to the capsid nucleic sequences described herein e.g., SEQ ID NOS: 7, 8, and 9, and the capsid polypeptide encoded therein will have overall about 93%, about 95%, about 98%, about 99% or 100% homology with the amino acid sequence described herein, e.g., SEQ ID NOS:4, 5, and 6. Nucleic acids that selectively hybridize with the nucleic acids of SEQ ID NOS:7,8 and 9 under the conditions described above are also provided.

The present invention also provides a cell containing one or more of the herein described nucleic acids, such as the AAV5 genome, AAV5 ORF1 and ORF2, each AAV5 Rep protein gene, or each AAV5 capsid protein gene. Such a cell can be any desired cell and can be selected based upon the use intended. For example, cells can include bacterial cells, yeast cells, insect cells, human HeLa cells and simian Cos cells as well as other human and mammalian cells and cell lines. Primary cultures as well as established cultures and cell lines can be used. Nucleic acids of the present invention can be delivered into cells by any selected means, in particular depending upon the

target cells. Many delivery means are well-known in the art. For example, electroporation, calcium phosphate precipitation, microinjection, cationic or anionic liposomes, and liposomes in combination with a nuclear localization signal peptide for delivery to the nucleus can be utilized, as is known in the art. Additionally, if the  
5 nucleic acids are in a viral particle, the cells can simply be transduced with the virion by standard means known in the art for AAV transduction. Small amounts of the recombinant AAV5 virus can be made to infect cells and produce more of itself.

The invention provides purified AAV5 polypeptides. The term "polypeptide"  
10 as used herein refers to a polymer of amino acids and includes full-length proteins and fragments thereof. Thus, "protein," "polypeptide," and "peptide" are often used interchangeably herein. Substitutions can be selected by known parameters to be neutral (*see, e.g.*, Robinson WE Jr, and Mitchell WM., AIDS 4:S151-S162 (1990)). As will be appreciated by those skilled in the art, the invention also includes those  
15 polypeptides having slight variations in amino acid sequences or other properties. Such variations may arise naturally as allelic variations (*e.g.*, due to genetic polymorphism) or may be produced by human intervention (*e.g.*, by mutagenesis of cloned DNA sequences), such as induced point, deletion, insertion and substitution mutants. Minor changes in amino acid sequence are generally preferred, such as conservative amino  
20 acid replacements, small internal deletions or insertions, and additions or deletions at the ends of the molecules. Substitutions may be designed based on, for example, the model of Dayhoff, *et al.* (in *Atlas of Protein Sequence and Structure* 1978, Nat'l Biomed. Res. Found., Washington, D.C.). These modifications can result in changes in the amino acid sequence, provide silent mutations, modify a restriction site, or provide  
25 other specific mutations. The location of any modifications to the polypeptide will often determine its impact on function. Particularly, alterations in regions non-essential to protein function will be tolerated with fewer effects on function. Elsewhere in the application regions of the AAV5 proteins are described to provide guidance as to where substitutions, additions or deletions can be made to minimize the likelihood of  
30 disturbing the function of the variant.

A polypeptide of the present invention can be readily obtained by any of several means. For example, the polypeptide of interest can be synthesized chemically by standard methods. Additionally, the coding regions of the genes can be recombinantly expressed and the resulting polypeptide isolated by standard methods. Furthermore, an antibody specific for the resulting polypeptide can be raised by standard methods (see, 5 *e.g.*, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1988), and the protein can be isolated from a cell expressing the nucleic acid encoding the polypeptide by selective hybridization with the antibody. This protein can be purified to the extent desired by 10 standard methods of protein purification (see, *e.g.*, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989).

Typically, to be unique, a polypeptide fragment of the present invention will be 15 at least about 5 amino acids in length; however, unique fragments can be 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more amino acids in length. A unique polypeptide will typically comprise such a unique fragment; however, a unique polypeptide can also be determined by its overall homology. A unique polypeptide can be 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more amino acids in length. Uniqueness of a 20 polypeptide fragment can readily be determined by standard methods such as searches of computer databases of known peptide or nucleic acid sequences or by hybridization studies to the nucleic acid encoding the protein or to the protein itself, as known in the art. The uniqueness of a polypeptide fragment can also be determined immunologically as well as functionally. Uniqueness can be simply determined in an amino acid-by- 25 amino acid comparison of the polypeptides.

An antigenic or immunoreactive fragment of this invention is typically an amino acid sequence of at least about 5 consecutive amino acids, and it can be derived from the AAV5 polypeptide amino acid sequence. An antigenic AAV5 fragment is any 30 fragment unique to the AAV5 protein, as described herein, against which an AAV5-specific antibody can be raised, by standard methods. Thus, the resulting antibody-antigen reaction should be specific for AAV5.

The present invention provides an isolated AAV5 Rep protein. An AAV5 Rep polypeptide is encoded by ORF1 of AAV5. The present invention also provides each individual AAV5 Rep protein. Thus the present invention provides AAV5 Rep 40 (e.g., SEQ ID NO: 12), or a unique fragment thereof. The present invention provides  
5 AAV5 Rep 52 (e.g., SEQ ID NO: 2), or a unique fragment thereof. The present invention provides AAV5 Rep 68 (e.g., SEQ ID NO: 14), or a unique fragment thereof. The present invention provides an example of AAV5 Rep 78 (e.g., SEQ ID NO: 3), or a unique fragment thereof. By "unique fragment thereof" is meant any smaller polypeptide fragment encoded by an AAV5 rep gene that is of sufficient length to be  
10 found only in the Rep polypeptide. Substitutions and modifications of the amino acid sequence can be made as described above and, further, can include protein processing modifications, such as glycosylation, to the polypeptide.

The present invention further provides an AAV5 Capsid polypeptide or a  
15 unique fragment thereof. AAV5 capsid polypeptide is encoded by ORF 2 of AAV5. The present invention further provides the individual AAV5 capsid proteins, VP1, VP2 and VP3 or unique fragments thereof. Thus, the present invention provides an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:4 (VP1). The present invention additionally provides an isolated polypeptide having the amino acid  
20 sequence set forth in SEQ ID NO:5 (VP2). The present invention also provides an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:6 (VP3). By "unique fragment thereof" is meant any smaller polypeptide fragment encoded by any AAV5 capsid gene that is of sufficient length to be found only in the AAV5 capsid protein. Substitutions and modifications of the amino acid sequence can be made as  
25 described above and, further, can include protein processing modifications, such as glycosylation, to the polypeptide. However, an AAV5 Capsid polypeptide including all three coat proteins will have greater than about 56% overall homology to the polypeptide encoded by the nucleotides set forth in SEQ ID NOS:4,5 or 6. The protein can have about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, 93%,  
30 95%, 97% or even 100% homology to the amino acid sequence encoded by the nucleotides set forth in SEQ ID NOS:4,5 or 6. An AAV5 VP1 polypeptide can have at least about 58%, about 60%, about 70%, about 80%, about 90%, 93%, 95%, 97% or

about 100% homology to the amino acid sequence set forth in SEQ ID NO:4. An AAV5 VP2 polypeptide can have at least about 58%, about 60%, about 70%, about 80%, about 90%, 93%, 95%, 97% or about 100% homology to the amino acid sequence set forth in SEQ ID NO:5. An AAV5 VP3 polypeptide can have at least  
5 about 60%, about 70%, about 80%, about 90%, 93%, 95%, 97% or about 100% homology to the amino acid sequence set forth in SEQ ID NO:6.

The present invention further provides an isolated antibody that specifically binds an AAV5 Rep protein or a unique epitope thereof. Also provided are isolated  
10 antibodies that specifically bind the AAV5 Rep 52 protein, the AAV5 Rep 40 protein, the AAV5 Rep 68 protein and the AAV5 Rep 78 protein having the amino acid sequences set forth in SEQ ID NO:2, SEQ ID NO: 12, SEQ ID NO: 14 and SEQ ID NO: 3, respectively or that specifically binds a unique fragment thereof. Clearly, any given antibody can recognize and bind one of a number of possible epitopes present in  
15 the polypeptide; thus only a unique portion of a polypeptide (having the epitope) may need to be present in an assay to determine if the antibody specifically binds the polypeptide.

The present invention additionally provides an isolated antibody that  
20 specifically binds any of the adeno-associated virus 5 Capsid proteins (VP1, VP2 or VP3), a unique epitope thereof, or the polypeptide comprising all three AAV5 coat proteins. Also provided is an isolated antibody that specifically binds the AAV5 capsid protein having the amino acid sequence set forth in SEQ ID NO:4 (VP1), or that specifically binds a unique fragment thereof. The present invention further provides an  
25 isolated antibody that specifically binds the AAV5 Capsid protein having the amino acid sequence set forth in SEQ ID NO:5 (VP2), or that specifically binds a unique fragment thereof. The invention additionally provides an isolated antibody that specifically binds the AAV5 Capsid protein having the amino acid sequence set forth in  
30 SEQ ID NO:6 (VP3), or that specifically binds a unique fragment thereof. Again, any given antibody can recognize and bind one of a number of possible epitopes present in the polypeptide; thus only a unique portion of a polypeptide (having the epitope) may



need to be present in an assay to determine if the antibody specifically binds the polypeptide.

The antibody can be a component of a composition that comprises an antibody  
5 that specifically binds the AAV5 protein. The composition can further comprise, *e.g.*, serum, serum-free medium, or a pharmaceutically acceptable carrier such as physiological saline, etc..

By "an antibody that specifically binds" an AAV5 polypeptide or protein is  
10 meant an antibody that selectively binds to an epitope on any portion of the AAV5 peptide such that the antibody binds specifically to the corresponding AAV5 polypeptide without significant background. Specific binding by an antibody further means that the antibody can be used to selectively remove the target polypeptide from a sample comprising the polypeptide or and can readily be determined by  
15 radioimmunoassay (RIA), bioassay, or enzyme-linked immunosorbant (ELISA) technology. An ELISA method effective for the detection of the specific antibody-antigen binding can, for example, be as follows: (1) bind the antibody to a substrate; (2) contact the bound antibody with a sample containing the antigen; (3) contact the above with a secondary antibody bound to a detectable moiety (*e.g.*, horseradish  
20 peroxidase enzyme or alkaline phosphatase enzyme); (4) contact the above with the substrate for the enzyme; (5) contact the above with a color reagent; (6) observe the color change.

An antibody can include antibody fragments such as Fab fragments which retain  
25 the binding activity. Antibodies can be made as described in, *e.g.*, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1988). Briefly, purified antigen can be injected into an animal in an amount and in intervals sufficient to elicit an immune response. Antibodies can either be purified directly, or spleen cells can be obtained from the animal. The cells  
30 are then fused with an immortal cell line and screened for antibody secretion. Individual hybridomas are then propagated as individual clones serving as a source for a particular monoclonal antibody.



The present invention additionally provides a method of screening a cell for infectivity by AAV5 comprising contacting the cell with AAV5 and detecting the presence of AAV5 in the cells. AAV5 particles can be detected using any standard physical or biochemical methods. For example, physical methods that can be used for this detection include DNA based methods such as 1) polymerase chain reaction (PCR) for viral DNA or RNA or 2) direct hybridization with labeled probes, and immunological methods such as by 3) antibody directed against the viral structural or non- structural proteins. Catalytic methods of viral detection include, but are not limited to, detection of site and strand specific DNA nicking activity of Rep proteins or replication of an AAV origin- containing substrate. Reporter genes can also be utilized to detect cells that transduct AAV-5. For example,  $\beta$ -gal, green fluorescent protein or luciferase can be inserted into a recombinant AAV-5. The cell can then be contacted with the recombinant AAV-5, either *in vitro* or *in vivo* and a colorimetric assay could detect a color change in the cells that would indicate transduction of AAV-5 in the cell. Additional detection methods are outlined in Fields, *Virology*, Raven Press, New York, New York. 1996.

For screening a cell for infectivity by AAV5, wherein the presence of AAV5 in the cells is determined by nucleic acid hybridization methods, a nucleic acid probe for such detection can comprise, for example, a unique fragment of any of the AAV5 nucleic acids provided herein. The uniqueness of any nucleic acid probe can readily be determined as described herein. Additionally, the presence of AAV5 in cells can be determined by fluorescence, antibodies to gene products, focus forming assays, plaque lifts, Western blots and chromogenic assays. The nucleic acid can be, for example, the nucleic acid whose nucleotide sequence is set forth in SEQ ID NO: 1, 7, 8, 9, 10, 11, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23 or a unique fragment thereof.

The present invention includes a method of determining the suitability of an AAV5 vector for administration to a subject comprising administering to an antibody-containing sample from the subject an antigenic fragment of an isolated AAV5 Rep or Capsid protein, and detecting neutralizing antibody-antigen reaction in the sample, the presence of a neutralizing reaction indicating the AAV5 vector may be unsuitable for

use in the subject. The present method of determining the suitability of an AAV5 vector for administration to a subject can comprise contacting an antibody-containing sample from the subject with a unique antigenic or immunogenic fragment of an AAV5 Rep protein (e.g. Rep 40, Rep 52, Rep 68, Rep 78) and detecting an antibody-antigen  
5 reaction in the sample, the presence of a reaction indicating the AAV5 vector to be unsuitable for use in the subject. The AAV5 Rep proteins are provided herein, and their antigenic fragments are routinely determined. The AAV5 capsid protein can be used to select an antigenic or immunogenic fragment, for example from the amino acid sequence set forth in SEQ ID NO:4 (VP1), the amino acid sequence set forth in SEQ  
10 ID NO: 5 (VP2) or the amino acid sequence set forth in SEQ ID NO:6 (VP3). Alternatively, or additionally, an antigenic or immunogenic fragment of an isolated AAV5 Rep protein can be utilized in this determination method. The AAV5 Rep protein from which an antigenic fragment is selected can have the amino acid sequence encoded by the nucleic acid set forth in SEQ ID NO:1, the amino acid sequence set  
15 forth in SEQ ID NO:2, or the amino acid sequence set forth in SEQ ID NO:3, the amino acid sequence set forth in SEQ ID NO: 12, or the amino acid sequence set forth in SEQ ID NO:14.

The AAV5 polypeptide fragments can be analyzed to determine their  
20 antigenicity, immunogenicity and/or specificity. Briefly, various concentrations of a putative immunogenically specific fragment are prepared and administered to a subject and the immunological response (e.g., the production of antibodies or cell mediated immunity) of an animal to each concentration is determined. The amounts of antigen administered depend on the subject, e.g. a human, rabbit or a guinea pig, the condition  
25 of the subject, the size of the subject, etc. Thereafter an animal so inoculated with the antigen can be exposed to the AAV5 viral particle or AAV5 protein to test the immunoreactivity or the antigenicity of the specific immunogenic fragment. The specificity of a putative antigenic or immunogenic fragment can be ascertained by testing sera, other fluids or lymphocytes from the inoculated animal for cross reactivity  
30 with other closely related viruses, such as AAV1, AAV2, AAV3, AAV4 and AAV5.

The hemagglutination assay can also be used to rapidly identify and detect AAV5 viral particles. Detection of hemagglutination activity correlates with infectivity and can be used to titer the virus. This assay could also be used to identify antibodies in a patient's serum which might interact with the virus. Hemagglutination has been  
5 shown to correlate with infectivity and therefore hemagglutination may be a useful assay for identifying cellular receptors for AAV5.

By the "suitability of an AAV5 vector for administration to a subject" is meant a determination of whether the AAV5 vector will elicit a neutralizing immune response  
10 upon administration to a particular subject. A vector that does not elicit a significant immune response is a potentially suitable vector, whereas a vector that elicits a significant, neutralizing immune response (e.g. at least 90%) is thus likely to be unsuitable for use in that subject. Significance of any detectable immune response is a  
15 standard parameter understood by the skilled artisan in the field. For example, one can incubate the subject's serum with the virus, then determine whether that virus retains its ability to transduce cells in culture. If such virus cannot transduce cells in culture, the vector likely has elicited a significant immune response.

Alternatively, or additionally, one skilled in the art could determine whether or  
20 not AAV5 administration would be suitable for a particular cell type of a subject. For example, the artisan could culture muscle cells *in vitro* and transduce the cells with AAV5 in the presence or absence of the subject's serum. If there is a reduction in transduction efficiency, this could indicate the presence of a neutralizing antibody or other factors that may inhibit transduction. Normally, greater than 90% inhibition  
25 would have to be observed in order to rule out the use of AAV-5 as a vector. However, this limitation could be overcome by treating the subject with an immunosuppressant that could block the factors inhibiting transduction.

As will be recognized by those skilled in the art, numerous types of  
30 immunoassays are available for use in the present invention to detect binding between an antibody and an AAV5 polypeptide of this invention. For instance, direct and indirect binding assays, competitive assays, sandwich assays, and the like, as are

generally described in, e.g., U.S. Pat. Nos. 4,642,285; 4,376,110; 4,016,043; 3,879,262; 3,852,157; 3,850,752; 3,839,153; 3,791,932; and Harlow and Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, N.Y. (1988). For example, enzyme immunoassays such as immunofluorescence assays (IFA), enzyme linked  
5 immunosorbent assays (ELISA) and immunoblotting can be readily adapted to accomplish the detection of the antibody. An ELISA method effective for the detection of the antibody bound to the antigen can, for example, be as follows: (1) bind the antigen to a substrate; (2) contact the bound antigen with a fluid or tissue sample containing the antibody; (3) contact the above with a secondary antibody specific for  
10 the antigen and bound to a detectable moiety (e.g., horseradish peroxidase enzyme or alkaline phosphatase enzyme); (4) contact the above with the substrate for the enzyme; (5) contact the above with a color reagent; (6) observe color change.

The antibody-containing sample of this method can comprise any biological  
15 sample which would contain the antibody or a cell containing the antibody, such as blood, plasma, serum, bone marrow, saliva and urine.

The present invention also provides a method of producing the AAV5 virus by transducing a cell with the nucleic acid encoding the virus.

20 The present method further provides a method of delivering an exogenous (heterologous) nucleic acid to a cell comprising administering to the cell an AAV5 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

25 The AAV ITRs in the vector for the herein described delivery methods can be AAV5 ITRs (SEQ ID NOS: 19 and 20). Furthermore, the AAV ITRs in the vector for the herein described nucleic acid delivery methods can also comprise AAV1, AAV2, AAV3, AAV4, or AAV6 inverted terminal repeats.

30 The present invention also includes a method of delivering a heterologous nucleic acid to a subject comprising administering to a cell from the subject an AAV5

particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, and returning the cell to the subject, thereby delivering the nucleic acid to the subject. The AAV ITRs can be any AAV ITRs, including AAV5 ITRs and AAV2 ITRs. For example, in an *ex vivo* administration, cells are isolated  
5 from a subject by standard means according to the cell type and placed in appropriate culture medium, again according to cell type (*see, e.g.*, ATCC catalog). Viral particles are then contacted with the cells as described above, and the virus is allowed to transduce the cells. Cells can then be transplanted back into the subject's body, again by means standard for the cell type and tissue (*e. g.*, in general, U.S. Patent No.  
10 5,399,346; for neural cells, Dunnett, S.B. and Björklund, A., eds., *Transplantation: Neural Transplantation-A Practical Approach*, Oxford University Press, Oxford (1992)). If desired, prior to transplantation, the cells can be studied for degree of transduction by the virus, by known detection means and as described herein. Cells for *ex vivo* transduction followed by transplantation into a subject can be selected from  
15 those listed above, or can be any other selected cell. Preferably, a selected cell type is examined for its capability to be transfected by AAV5. Preferably, the selected cell will be a cell readily transduced with AAV5 particles; however, depending upon the application, even cells with relatively low transduction efficiencies can be useful, particularly if the cell is from a tissue or organ in which even production of a small  
20 amount of the protein or antisense RNA encoded by the vector will be beneficial to the subject.

The present invention further provides a method of delivering a nucleic acid to a cell in a subject comprising administering to the subject an AAV5 particle containing a  
25 vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to a cell in the subject. Administration can be an *ex vivo* administration directly to a cell removed from a subject, such as any of the cells listed above, followed by replacement of the cell back into the subject, or administration can be *in vivo* administration to a cell in the subject. For *ex vivo*  
30 administration, cells are isolated from a subject by standard means according to the cell type and placed in appropriate culture medium, again according to cell type (*see, e.g.*, ATCC catalog). Viral particles are then contacted with the cells as described above,



and the virus is allowed to transfect the cells. Cells can then be transplanted back into the subject's body, again by means standard for the cell type and tissue (*e. g.*, for neural cells, Dunnett, S.B. and Björklund, A., eds., *Transplantation: Neural Transplantation-A Practical Approach*, Oxford University Press, Oxford (1992)). If  
5 desired, prior to transplantation, the cells can be studied for degree of transfection by the virus, by known detection means and as described herein.

The present invention further provides a method of delivering a nucleic acid to a cell in a subject having neutralizing antibodies to AAV2 comprising administering to  
10 the subject an AAV5 particle containing a vector comprising the nucleic acid, thereby delivering the nucleic acid to a cell in the subject. A subject that has neutralizing antibodies to AAV2 can readily be determined by any of several known means, such as contacting AAV2 protein(s) with an antibody-containing sample, such as blood, from a subject and detecting an antigen-antibody reaction in the sample. Delivery of the  
15 AAV5 particle can be by either *ex vivo* or *in vivo* administration as herein described. Thus, a subject who might have an adverse immunogenic reaction to a vector administered in an AAV2 viral particle can have a desired nucleic acid delivered using an AAV5 particle. This delivery system can be particularly useful for subjects who have received therapy utilizing AAV2 particles in the past and have developed  
20 antibodies to AAV2. An AAV5 regimen can now be substituted to deliver the desired nucleic acid.

In any of the methods of delivering heterologous nucleic acids to a cell or subject described herein, the AAV5-conjugated nucleic acid or AAV5 particle-  
25 conjugated nucleic acids described herein can be used.

*In vivo* administration to a human subject or an animal model can be by any of many standard means for administering viruses, depending upon the target organ, tissue or cell. Virus particles can be administered orally, parenterally (*e.g.*, intravenously), by  
30 intramuscular injection, by direct tissue or organ injection, by intraperitoneal injection, topically, transdermally, via aerosol delivery, via the mucosa or the like. Viral nucleic acids (non-encapsidated) can also be administered, *e.g.*, as a complex with cationic



liposomes, or encapsulated in anionic liposomes. The present compositions can include various amounts of the selected viral particle or non-encapsidated viral nucleic acid in combination with a pharmaceutically acceptable carrier and, in addition, if desired, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc.

5 Parental administration, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Dosages will depend upon the mode of administration, the disease or condition to be treated, and the individual subject's condition, but will be that dosage typical for and used in

10 administration of other AAV vectors, such as AAV2 vectors. Often a single dose can be sufficient; however, the dose can be repeated if desirable.

Administration methods can be used to treat brain disorders such as Parkinson's disease, Alzheimer's disease, and demyelination disease. Other diseases that can be

15 treated by these methods include metabolic disorders such as , musculoskeletal diseases, cardiovascular disease, cancer, and autoimmune disorders.

Administration of this recombinant AAV5 virion to the cell can be accomplished by any means, including simply contacting the particle, optionally

20 contained in a desired liquid such as tissue culture medium, or a buffered saline solution, with the cells. The virion can be allowed to remain in contact with the cells for any desired length of time, and typically the virion is administered and allowed to remain indefinitely. For such *in vitro* methods, the virion can be administered to the cell by standard viral transduction methods, as known in the art and as exemplified

25 herein. Titers of virus to administer can vary, particularly depending upon the cell type, but will be typical of that used for AAV transduction in general which is well known in the art. Additionally the titers used to transduce the particular cells in the present examples can be utilized.

30 The cells that can be transduced by the present recombinant AAV5 virion can include any desired cell, such as the following cells and cells derived from the following tissues, human as well as other mammalian tissues, such as primate, horse,

sheep, goat, pig, dog, rat, and mouse: Adipocytes, Adenocyte, Adrenal cortex, Amnion, Aorta, Ascites, Astrocyte, Bladder, Bone, Bone marrow, Brain, Breast, Bronchus, Cardiac muscle, Cecum, Cervix, Chorion, Colon, Conjunctiva, Connective tissue, Cornea, Dermis, Duodenum, Endometrium, Endothelium, Endothelial cells, Epithelial  
5 tissue, Epithelial cells, Epidermis, Esophagus, Eye, Fascia, Fibroblasts, Foreskin, Gastric, Glial cells, Glioblast, Gonad, Hepatic cells, Histocyte, Ileum, Intestine, small Intestine, Jejunum, Keratinocytes, Kidney, Larynx, Leukocytes, Lipocyte, Liver, Lung, Lymph node, Lymphoblast, Lymphocytes, Macrophages, Mammary alveolar nodule, Mammary gland, Mastocyte, Maxilla, Melanocytes, Mesenchymal, Monocytes, Mouth,  
10 Myelin, Myoblasts Nervous tissue, Neuroblast, Neurons, Neuroglia, Osteoblasts, Osteogenic cells, Ovary, Palate, Pancreas, Papilloma, Peritoneum, Pituicytes, Pharynx, Placenta, Plasma cells, Pleura, Prostate, Rectum, Salivary gland, Skeletal muscle, Skin, Smooth muscle, Somatic, Spleen, Squamous, Stomach, Submandibular gland, Submaxillary gland, Synoviocytes, Testis, Thymus, Thyroid, Trabeculae, Trachea,  
15 Turbinate, Umbilical cord, Ureter, and Uterus.

### STATEMENT OF UTILITY

The present invention provides recombinant vectors based on AAV5. Such  
20 vectors may be useful for transducing erythroid progenitor cells or cells lacking heparin sulfate proteoglycans which is very inefficient with AAV2 based vectors. These vectors may also be useful for transducing cells with a nucleic acid of interest in order to produce cell lines that could be used to screen for agents that interact with the gene product of the nucleic acid of interest. In addition to transduction of other cell types,  
25 transduction of erythroid cells would be useful for the treatment of cancer and genetic diseases which can be corrected by bone marrow transplants using matched donors. Some examples of this type of treatment include, but are not limited to, the introduction of a therapeutic gene such as genes encoding interferons, interleukins, tumor necrosis factors, adenosine deaminase, cellular growth factors such as lymphokines, blood  
30 coagulation factors such as factor VIII and IX, cholesterol metabolism uptake and transport protein such as EpoE and LDL receptor, and antisense sequences to inhibit viral replication of, for example, hepatitis or HIV.

The present invention provides a vector comprising the AAV5 virus as well as AAV5 viral particles. While AAV5 is similar to AAV2, the two viruses are found herein to be physically and genetically distinct. These differences endow AAV5 with some unique advantages which better suit it as a vector for gene therapy.

5

Furthermore, as shown herein, AAV5 capsid protein is distinct from AAV2 capsid protein and exhibits different tissue tropism. AAV2 and AAV5 likely utilize distinct cellular receptors. AAV2 and AAV5 are serologically distinct and thus, in a gene therapy application, AAV5 would allow for transduction of a patient who already possess neutralizing antibodies to AAV2 either as a result of natural immunological defense or from prior exposure to AAV2 vectors.

10

The present invention is more particularly described in the following examples which are intended as illustrative only since numerous modifications and variations therein will be apparent to those skilled in the art.

15

### EXAMPLES

To understand the nature of AAV5 virus and to determine its usefulness as a vector for gene transfer, it was cloned and sequenced.

20

#### *Cell culture and virus propagation*

Cos and HeLa cells were maintained as monolayer cultures in D10 medium (Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 100 µg/ml penicillin, 100 units/ml streptomycin and IX Fungizone as recommended by the manufacturer; (GIBCO, Gaithersburg, MD, USA) . All other cell types were grown under standard conditions which have been previously reported.

25

Virus was produced as previously described for AAV2 using the Beta galactosidase vector plasmid and a helper plasmid containing the AAV5 Rep and Cap genes (9). The helper plasmid was constructed in such a way to minimize any homologous sequence between the helper and vector plasmids. This step was taken to

30

minimize the potential for wild-type (wt) particle formation by homologous recombination.

*DNA Cloning and Sequencing and Analysis*

5 In order to clone the genome of AAV5, infectious cell lysate was expanded in adherent cos cells and then suspension HeLa cells with the resulting viral particles isolated by CsCl isopycnic gradient centrifugation. DNA dot blots of Aliquots of the gradient fractions indicated that the highest concentration of viral genomes were contained in fractions with a refractive index of approx. 1.372. While the initial  
10 description of the virus did not determine the density of the particles, this value is similar to that of AAV2. Analysis of annealed virion derived DNA obtained from these fractions indicated a major species of 4.6 kb in length which upon restriction analysis gave bands similar in size to those previously reported. Additional restriction mapping indicated a unique BssHII site at one end of the viral genome. This site was used to  
15 clone the major fragment of the viral genome. Additional overlapping clones were isolated and the sequence determined. Two distinct open reading frames (ORF) were identified. Computer analysis indicated that the left-hand ORF is approx 60% similar to that of the Rep gene of AAV2. Of the 4 other reported AAV serotypes, all have greater than 90% similarity in this ORF. The right ORF of the viral capsid proteins is  
20 also approximately 60% homologous to the Capsid ORF of AAV2. As with other AAV serotypes reported, the divergence between AAV5 and AAV2 is clustered in multiple blocks. By using the published three dimensional structure of the canine parvovirus and computer aided sequence comparisons, a number of these divergent regions have been shown to be on the exterior of the virus and thus suggest an altered  
25 tissue tropism.

Within the p5 promoter, a number of the core transcriptional elements are conserved such as the tataa box and YY1 site around the transcriptional start site. However the YY1 site at -60 and the upstream E-Box elements are not detectable  
30 suggesting an alternative method of regulation or activation.

The inverted terminal repeats (ITRs) of the virus were cloned as a fragment from the right end of the genome. The resulting fragment was found to contain a number of sequence changes compared to AAV2. However, these changes were found to be complementary and did not affect the ability of this region to fold into a hairpin structure. Within the stem region of the hairpin two sequence elements have been found to be critical for the function of the ITRs as origins of viral replication. A repeat motif of GAGC/T which serves as the recognition site of Rep and a GGTTGAG sequence downstream of the Rep binding site which is the position of Rep's site and strand specific cleavage reaction. This sequence is not conserved between AAV5 and the other cloned AAV's suggesting that the ITRs and Rep proteins of AAV5 cannot complement the other known AAV's.

To test the cross complementarity of AAV2 ITR containing genome and AAV5 ITR containing genomes recombinant particles were packaged either using type 2 Rep and Cap or type 5 Rep and Cap expression plasmids as previously described. As shown in Fig. 2, viral particles were produced only when the respective expression plasmids were used to package the cognate ITRs. This result is distinct from that of other serotypes of AAV which have shown cross complementarity in packaging.

This specificity of AAV5 Rep for AAV5 ITRs was confirmed using a terminal resolution assay which can identify the site within one ITR cleaved by the Rep protein. Incubation of the Type 5 Rep protein with a type 2 ITR did not produce any cleavage products. In contrast, addition of type 2 Rep cleaved the DNA at the expected site. However AAV5 Rep did produce cleavage products when incubated with a type 5 ITR. The site mapped to a region 21 bases from the Rep binding motif that is similar to AAV2 TRS. The site in AAV2 is CGGT TGAG (SEQ ID NO: 22) but in type 5 ITR is CGGT GTGA (SEQ ID NO: 21). The ability of AAV5 Rep to cleave at a different but similarly positioned site may result in integration of AAV5 at a distinct chromosomal locus compared to AAV2.

Recombinant virus produced using AAV5 Rep and Cap was obtained at a greater titer than type 2. For example, in a comparative study, virus was isolated from



$8 \times 10^7$  COS cells by CsCl banding and the distribution of the Beta galactosidase genomes across the gradient were determined by DNA dot blots of aliquots of gradient fractions. DNA dot blot titers indicated that AAV5 particles were produced at a 10-50 fold higher level than AAV2.

5

The sequence divergence in the capsid protein ORF implies that the tissue tropism of AAV2 and AAV5 would differ. To study the transduction efficiency of AAV5 and AAV2, a variety of cell lines were transduced with serial dilution's of the purified virus expressing the gene for nuclear localized Beta galactosidase activity.

10 Approx.  $2 \times 10^4$  cells were exposed to virus in 1 ml of serum containing media for a period of 48-60 hrs. After this time the cells were fixed and stained for Beta-galactosidase activity with 5-Bromo-4-chloro- 3-indolyl-b-D- galactopyranoside (Xgal) (ICN Biochemicals). Biological titers were determined by counting the number of positive cells in the different dilutions using a calibrated microscope ocular then  
15 multiplying by the area of the well. Titters were determined by the average number of cells in a minimum of 10 fields/well. Transduction of cos, HeLa, and 293, and IB3 cells with a similar number of particles showed approximately 10 fold decrease in titer with AAV5 compared with AAV2. In contrast MCF7 cells showed a 50-100 fold difference in transduction efficiency. Furthermore, both vectors transduced NIH 3T3  
20 cells relatively poorly.

A recent publication reported that heparin proteoglycans on the surface of cells are involved in viral transduction. Addition of soluble heparin has been shown to inhibit transduction by blocking viral binding. Since the transduction data suggested a  
25 difference in tissue tropism for AAV5 and AAV2, the sensitivity of AAV5 transduction to heparin was determined. At an MOI of 100, the addition of  $20 \mu\text{g/ml}$  of heparin had no effect on AAV5 transduction. In contrast this amount of heparin inhibited 90% of the AAV2 transduction. Even at an MOI of 1000, no inhibition of AAV5 transduction was detected. These data support the conclusions of the tissue tropism study, i.e. that  
30 AAV2 and AAV5 may utilize a distinct cell surface molecules and therefore the mechanism of uptake may differ as well.



AAV5 is a distinct virus within the dependovirus family based on sequence analysis, tissue tropism, and sensitivity to heparin. While elements of the P5 promoter are retained between AAV2-6 some elements are absent in AAV5 suggesting alternative mechanism of regulation. The ITR and Rep ORF are distinct from those previously identified and fail to complement the packaging of AAV2 based genomes. The ITR of AAV5 contains a different TRS compared to other serotypes of AAV which is responsible for the lack of complementation of the ITRs. This unique TRS should also result in a different integration locus for AAV5 compared to that of AAV2. Furthermore the production of recombinant AAV5 particles using standard packaging systems is approx. 10-50 fold better than AAV2. The majority of the differences in the capsid proteins lies in regions which have been proposed to be on the exterior of the surface of the parvovirus. These changes are most likely responsible for the lack of cross reactive antibodies and altered tissue tropism compared to AAV2.

From the Rep ORF of AAV2, 4 proteins are produced; The p5 promoter (SEQ ID NO: 18) produces rep 68 (a spliced site mutant) and rep78 and the p19 promoter (SEQ ID NO: 16) produces rep 40 (a spliced site mutant) and rep 52. While these regions are not well conserved within the Rep ORF of AAV5 some splice acceptor and donor sites exist in approximately the same region as the AAV2 sites. These sites can be identified using standard computer analysis programs such as signal in the PCGENE program. Therefore the sequences of the Rep proteins can be routinely identified as in other AAV serotypes.

#### *Hemagglutination assay*

Hemagglutination activity was measured essentially as described previously (Chiorini et al 1997 J. Virol. Vol 71 6823-6833) Briefly 2 fold serial dilutions of virus in EDTA-buffered saline were mixed with an equal volume of 0.4% red blood cells in plastic U-bottom 96 well plates. The reaction was complete after a 2-h incubation at 8°C. Addition of purified AAV5 to a hemagglutination assay resulted in hemagglutination activity.

*Transduction of airway epithelial cells*

Primary airway epithelial cells were cultured and plated as previously described (Fasbender et al. J. Clin Invest. 1998 Jul 1; 102 (1): 184-93). Cells were transduced with an equivalent number of rAAV2 or rAAV5 particles containing a nuclear localized  $\beta$ -gal transgene with 50 particles of virus/cell (MOI 50) and continued in culture for 10 days.  $\beta$ -gal activity was determined following the procedure of (Chiorini et al. 1995 HGT Vol: 6 1531-1541) and the relative transduction efficiency compared. As shown in Figure 7, AAV5 transduced these cells 50- fold more efficiently than AAV2. This is the first time apical cells or cells exposed to the air have been shown to be infected by a gene therapy agent.

*Transduction of striated muscle*

Chicken myoblasts were cultured and plated as previously described (Rhodes & Yamada 1995 NAR Vol 23 (12) 2305-13). Cells were allowed to fuse and then transduced with a similar number of particles of rAAV2 or rAAV5 containing a nuclear localized  $\beta$ -gal transgene as previously described above after 5 days in culture. The cells were stained for  $\beta$ -gal activity following the procedure of (Chiorini et al. 1995 HGT Vol: 6 1531-1541) and the relative transduction efficiency compared. As shown in Figure 8, AAV5 transduced these cells approximately 16 fold more efficiently than AAV2.

*Transduction of rat brain explants*

Primary neonatal rat brain explants were prepared as previously described (Scortegagna et al. Neurotoxicology. 1997; 18 (2): 331-9). After 7 days in culture, cells were transduced with a similar number of particles of rAAV5 containing a nuclear localized  $\beta$ -gal transgene as previously described. After 5 days in culture, the cells were stained for  $\beta$ -gal activity following the procedure of (Chiorini et al. 1995 HGT Vol: 6 1531-1541). As shown in Figure 9, transduction was detected in a variety of cell types including astrocytes, neuronal cells and glial cells.

*Transduction of human umbilical vein endothelial cells*

Human umbilical vein endothelial cells were cultured and plated as previously described (Gnantenko et al. J Investig Med. 1997 Feb; 45(2): 87-98). Cells were transduced with rAAV2 or rAAV5 containing a nuclear localized  $\beta$ -gal transgene with 10 particles of virus/ cell (MOI .5) in minimal media then returned to complete media. After 24 hrs in culture the cells were stained for  $\beta$ -gal activity following the procedure of Chiorini et al. (1995 HGT Vol: 6 1531-1541), and the relative transduction efficiency compared. As shown in Figure 10, AAV5 transduced these cell 5-10 fold more efficiently than AAV2.

10

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

15

Although the present process has been described with reference to specific details of certain embodiments thereof, it is not intended that such details should be regarded as limitations upon the scope of the invention except as and to the extent that they are included in the accompanying claims.

20

**References:**

1. Arella, M., S. Garzon, J. Bergeron, and P. Tijssen. Handbook of Parvoviruses. Vol. 1. ed. P. Tijssen. Boca Raton, Florida, CRC Press, 1990.
2. Bachmann, P.A., M.D. Hoggan, E. Kurstak, J.L. Melnick, H.G. Pereira, P. Tattersall, and C. Vago. 1979. Intervirology 11: 248-254.
3. Bantel-Schaal, U. and M. Stohr. 1992. J. Virol. 66: 773-779.
4. Chang, L.S., Y. Shi, and T. Shenk. 1989. J. Virol. 63: 3479-88.
5. Chejanovsky, N. and B.J. Carter. 1989. Virology 173: 120-128.
6. Chejanovsky, N. and B.J. Carter. 1989. Virology 171: 239-247.
7. Chiorini, J.A., S.M. Wiener, R.M. Kotin, R.A. Owens, SRM Kyöstiö, and B. Safer. 1994. J. Virol. 68: 7448-7457.

8. Chiorini, J.A., M.D. Weitzman, R.A. Owens, E. Urcelay, B. Safer, and R.M. Kotin. 1994. *J. Virol.* 68: 797-804.
9. Chiorini, J.A., C.M. Wendtner, E. Urcelay, B. Safer, M. Hallek, and R.M. Kotin. 1995. *Human Gene Therapy* 6: 1531-1541.
10. Chiorini, J.A., L. Yang, B. Safer, and R.M. Kotin. 1995. *J. Virol.* 69: 7334-7338.
11. Dixit, M., M.S. Webb, W.C. Smart, and S. Ohi. 1991. *Gene* 104: 253-7.
12. Fisher, R.E. and H.D. Mayor. 1991. *J Theor Biol* 149: 429-39.
13. Flotte, T.R., S.A. Afione, C. Conrad, S.A. McGrath, R. Solow, H. Oka, P.L. Zeitlin, W.B. Guggino, and B.J. Carter. 1993. *Proc. Natl. Acad. Sci.* 90: 10613-10617.
14. Flotte, T.R., S.A. Afione, R. Solow, M.L. Drumm, D. Markakis, W.B. Guggino, P.L. Zeitlin, and B.J. Carter. 1993. *J Biol Chem* 268: 3781-90.
15. Hermonat, P.L., M.A. Labow, R. Wright, K.I. Berns, and N. Muzyczka. 1984. *J. Virol.* 51: 329-339.
16. Hermonat, P.L. and N. Muzyczka. 1984. *Proc Natl Acad Sci USA* 81: 6466-70.
17. Hunter, L.A. and R.J. Samulski. 1992. *J. Virol.* 66: 317-24.
18. Ito, M. and H.D. Mayor. 1968. *J. Immuno.* 100: 61-68.
19. Janik, J.E., M.M. Huston, K. Cho, and J.A. Rose. 1989. *Virology* 168: 320-9.
20. Kaplitt, M.G., P. Leone, R.J. Samulski, X. Xiao, D.W. Pfaff, K.L. O'Malley, and J.M. During. 1994. *Nature Genetics* 8: 148-154.
21. Kotin, R.M., M. Siniscalco, R.J. Samulski, X. Zhu, L. Hunter, C.A. Laughlin, S. McLaughlin, N. Muzyczka, M. Rocchi, and K.I. Berns. 1990. *Proc. Natl. Acad. Sci. (USA)* 87: 2211-2215.
22. Laughlin, C.A., N. Jones, and B.J. Carter. 1982. *J. Virol.* 41: 868-76.
23. Laughlin, C.A., M.W. Myers, D.L. Risin, B.J. Carter. 1979. *Virology* 94: 162-74.
24. McCarty, D.M., J. Pereira, I. Zolotukhin, X. Zhou, J.H. Ryan, and N. Muzyczka. 1994. *J. Virol.* 68: 4988-4997.
25. Mendelson, E., J.P. Trempe, and B.J. Carter. 1986. *J. Virol.* 60: 823-832.

26. Mizukami, H., N.S. Young, and K.E. Brown. 1996. *Virology* 217: 124-130.
27. Muster, C.J., Y.S. Lee, J.E. Newbold, and J. Leis. 1980. *J. Virol.* 35: 653-61.
28. Muzyczka, N. 1992. *Curr Top Microbiol Immunol* 158: 97-129.
29. Parks, W.P., J.L. Melnick, R. Rongey, and H.D. Mayor. 1967. *J. Virol.* 1: 171-180.
30. Podsakoff, G., K.K. Jr Wong, and S. Chatterjee. 1994. *J. Virol.* 68: 5656-5666.
31. Rose, J.A., M.D. Hoggan, F. Koczot, and A.J. Shatkin. 1968. *J. Virol.* 2: 999-1005.
32. Russell, D.W., A.D. Miller, and I.E. Alexander. 1994. *Proc. Natl. Acad. Sci. USA* 91: 8915-8919.
33. Ryan, J.H., S. Zolotukhin, and N. Muzyczka. 1996. *J. Virol.* 70: 1542-1553.
34. Samulski, R.J., K.I. Berns, M. Tan, and N. Muzyczka. 1982. *Proc Natl Acad Sci USA* 79: 2077-81.
35. Samulski, R.J., L.S. Chang, and T. Shenk. 1989. *J. Virol.* 63: 3822-8.
36. Sanes, J.R., J.L.R. Rubenstein, and J.F. Nicocas. 1986. *EMBO* 5: 3133-3142.
37. Senapathy, P., J.D. Tratschin, and B.J. Carter. 1984. *J Mol Biol* 179: 1-20.
38. Tratschin, J.D., I.L. Miller, and B.J. Carter. 1984. *J. Virol.* 51: 611-619.
39. Trempe, J.P. and B.J. Carter. 1988. *J. Virol.* 62: 68-74.
40. Trempe, J.P., E. Mendelson, and B.J. Carter. 1987. *Virology* 161: 18-28.
41. Walsh, C.E., J.M. Liu, X. Xiao, N.S. Young, A.W. Nienhuis, and R.J. Samulski. 1992. *Proc Natl Acad Sci USA* 89: 7257-61.
42. Winocour, E., M.F. Callaham, and E. Huberman. 1988. *Virology* 167: 393-9.
43. Jaksch, M., K.D. Gerbitz, and C. Kilger. 1995. *Clin. Biochem.* 28:503-509
44. Burcin, M.M., O'Malley, B.W. and S.Y. Tsai. 1998. *Frontiers in Bioscience* 3:1-7.

What is claimed is:

1. A nucleic acid vector comprising a pair of adeno-associated virus 5 (AAV5) inverted terminal repeats and a promoter between the inverted terminal repeats.
2. The vector of claim 1, wherein the promoter is an AAV promoter p5.
3. The vector of claim 1, wherein the p5 promoter is AAV5 p5 promoter.
4. The vector of claim 1, further comprising an exogenous nucleic acid functionally linked to the promoter.
5. The vector of claim 1 encapsidated in an adeno-associated virus particle.
6. The particle of claim 5, wherein the particle is an AAV5 particle.
7. The particle of claim 5, wherein the particle is an AAV1 particle, an AAV2 particle, an AAV3 particle, an AAV4 particle or an AAV6 particle.
8. A recombinant AAV5 virion containing a vector comprising a pair of AAV5 inverted terminal repeats.
9. The virion of claim 8, wherein the vector further comprises an exogenous nucleic acid inserted between the inverted terminal repeats.
10. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:1.
11. An isolated nucleic acid consisting essentially of the nucleotide sequence set forth in SEQ ID NO:1.



12. An isolated nucleic acid that selectively hybridizes with the nucleic acid of claim 11.
13. An isolated nucleic acid encoding an adeno-associated virus 5 Rep protein.
14. The nucleic acid of claim 13, wherein the adeno-associated virus 5 Rep protein has the amino acid sequence set forth in SEQ ID NO:2.
15. The nucleic acid of claim 13, wherein the adeno-associated virus 5 Rep protein has the amino acid sequence set forth in SEQ ID NO:3.
16. The nucleic acid of claim 13, wherein the adeno-associated virus 5 Rep protein has the amino acid sequence set forth in SEQ ID NO:12.
17. The nucleic acid of claim 13, wherein the adeno-associated virus 5 Rep protein has the amino acid sequence set forth in SEQ ID NO:14.
18. An isolated AAV Rep protein.
19. The isolated AAV5 Rep protein of claim 18, having the amino acid sequence set forth in SEQ ID NO:2, or a unique fragment thereof.
20. The isolated AAV5 Rep protein of claim 18, having the amino acid sequence set forth in SEQ ID NO:3, or a unique fragment thereof.
21. An isolated antibody that specifically binds the protein of claim 18.
22. An isolated AAV5 capsid protein.
23. The isolated AAV5 capsid protein of claim 22 having the amino acid sequence set forth in SEQ ID NO:4.

24. An isolated antibody that specifically binds the protein of claim 23.
25. The isolated AAV5 capsid protein of claim 22, having the amino acid sequence set forth in SEQ ID NO:5.
26. An isolated antibody that specifically binds the protein of claim 25.
27. The isolated AAV5 capsid protein of claim 22, having the amino acid sequence set forth in SEQ ID NO:6.
28. An isolated antibody that specifically binds the protein of claim 27.
29. An isolated nucleic acid encoding the protein of claim 22.
30. The nucleic acid of claim 29, having the nucleic acid sequence set forth in SEQ ID NO:7.
31. The nucleic acid of claim 29, having the nucleic acid sequence set forth in SEQ ID NO:8.
32. The nucleic acid of claim 29, having the nucleic acid sequence set forth in SEQ ID NO:9.
33. An isolated nucleic acid that selectively hybridizes with the nucleic acid of claim 29.
34. An AAV5 particle comprising a capsid protein consisting essentially of the amino acid sequence set forth in SEQ ID NO:6.
35. An isolated nucleic acid comprising an AAV5 p5 promoter.

36. A method of screening a cell for infectivity by AAV5, comprising contacting the cell with AAV5 and detecting the presence of AAV5 in the cells.
37. A method of determining the suitability of an AAV5 vector for administration to a subject, comprising contacting an antibody-containing sample from the subject with an antigenic fragment of a protein of claim 22 and detecting an antibody-antigen reaction in the sample, the presence of a neutralizing reaction indicating the AAV5 vector to be unsuitable for use in the subject.
38. A method of determining the presence in a subject of an AAV5-specific antibody comprising, contacting an antibody-containing sample from the subject with an antigenic fragment of the protein of claim 22 and detecting an antibody-antigen reaction in the sample, the presence of a reaction indicating the presence of an AAV5-specific antibody in the subject.
39. A method of delivering a nucleic acid to a cell, comprising administering to the cell an AAV5 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.
40. The method of claim 39, wherein the AAV inverted terminal repeats are AAV5 inverted terminal repeats.
41. A method of delivering a nucleic acid to a subject comprising administering to a cell from the subject an AAV5 particle comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, and returning the cell to the subject, thereby delivering the nucleic acid to the subject.
42. A method of delivering a nucleic acid to a cell in a subject comprising administering to the subject an AAV5 particle comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to a cell in the subject.

43. A method of delivering a nucleic acid to a cell in a subject having antibodies to AAV2 comprising administering to the subject an AAV5 particle comprising the nucleic acid, thereby delivering the nucleic acid to a cell in the subject.

44. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:21.

45. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 23.

1/20




FIG. 1




FIG. 2

AAV2 & 5 PLASMID COBINATIONS

Bgal TRANSDUCING UNITS

SUBSTITUTE SHEET (RULE 26)



3/20

## AAV TYPES 2 &amp; 5 TISSUE TROPISM




FIG. 3

4/20

==23-SEP-1999=====NALIGN=====PC/GENE==

\*\*\*\*\*  
 \* ALIGNMENT OF TWO NUCLEOTIDE SEQUENCES. \*  
 \*\*\*\*\*

The two sequences to be aligned are:

AAV2CG.

Total number of bases: 4679.

AAV5CG.

Total number of bases: 4652.

Open gap cost : 10

Unit gap cost : 12

The character to show that two aligned residues are identical is ':'

```

AAV2CG  - TTGGCCACTCCCTCTCTGCCGCTCGCTCGCTCACTGA-----GCCCGGGCGA -48
          : : : : : : : : : : : : : : : : : : : : : : : : : : : :
AAV5CG  - TGGCACTCTCCCCCTGTCCGTTCCGCTCGCTCGCTGGCTCGTTGGGGGGGTGG -55

AAV2CG  - C-----CAAAGGTC-GCCCGACGCCCGGGCTTTGCCCGG-GCGGCCTCA----- -90
          : : : : : : : : : : : : : : : : : : : : : : : : : : : :
AAV5CG  - CAGCTCAAAGAGCTGCCAGACGACGGCCCTCTGCCCGTCCGCCCCCAAACGAGC -110

AAV2CG  - --GTGAGCGAGCGAGCGCG-CAGAGAGG-GAGTGGCCAACTCCATCACTAGGGGT -141
          : : : : : : : : : : : : : : : : : : : : : : : : : : : :
AAV5CG  - CAGCGAGCGAGCGAACGCGACAGGGGGGAGAGTCCCACTCTCAAGCAAGGGGG -165

AAV2CG  - TCCTGGAGGG-GTGGAGTCGTGACG-TGAATTACGTCATAGGGTTAGGGAGGTCC -194
          : : : : : : : : : : : : : : : : : : : : : : : : : : : :
AAV5CG  - TTTTGTAAAGCAGTGATGTCATAATGATGTAATGCTTATTGTCACGCGATAGTTAA -220

AAV2CG  - TGTATTAGAGGTCACGTGA-GTGTTTTGCGACATTTTGGCACC-----ATGT -242
          : : : : : : : : : : : : : : : : : : : : : : : : : : : :
AAV5CG  - TG-ATTAACAGTCATGTGATGTGTTTTATCCAATAGGAAGAAAGCGCGCGTATGA -274

AAV2CG  - GGTACGCT-----GGGTATTTAAGCCCGAGTGAGCACGCAGGGTCTCCAT -288
          : : : : : : : : : : : : : : : : : : : : : : : : : : : :
AAV5CG  - GTTCTCGCGAGACTTCCGGGGTATAAAAGACCGAGTGAACGAGCCCGC-CGCCAT -328

AAV2CG  - T-TTGAAGCGGGAG-GTTTGAACCGCA-GCCGCCATGCCGGGGTTTTACGAGAT -340
          : : : : : : : : : : : : : : : : : : : : : : : : : : : :
AAV5CG  - TCTTTGCTCTGGACTGCTAGAGGACCCTCGCTGCCATGGCTACCTTCTATGAAGT -383
  
```

FIG.4A

SUBSTITUTE SHEET (RULE 26)

5/20

AAV2CG	- TGTGATTAAGGTCCCCAGCGACCTTGACGGGCATCTGCCCGGCATTTC TGACAGC -395 :
AAV5CG	- CATTGTTCCGCTCCCATTGACGTGGAGGAACATCTGCCTGGAATTTCTGACAGC -438
AAV2CG	- TTTGTGAAGTGGGTGGCCGAGAAGGAATGGGAGTTGCCGCCAGATTCTGACATGG -450 :
AAV5CG	- TTTGTGGACTGGGTAAGTGGTCAAATTTGGGAGCTGCCTCCAGAGTCAGATTTAA -493
AAV2CG	- ATCTGAATCTGATTGAGCAGGCACCCCTGACCGTGCCCGAGAAGCTGCAGCGCGA -505 :
AAV5CG	- ATTTGACTCTGTTGAACAGCCTCAGTTGACGGTGGCTGATAGAATTCGCCCGCT -548
AAV2CG	- CTTTCTGACGGAATGGCGCCGTGTGAGTAAGGCCCGGAGGCCCTTTTCTTTGTG -560 :
AAV5CG	- GTTCCTGTACGAGTGAACAAAATTTCCAAG—CAGGAGTCCAAATTC TTGTG -600
AAV2CG	- CAATTTGAGAAGGGAGAGAGCTACTTCCACATGCACGTGCTCGTGAAACCACCG -615 :
AAV5CG	- CAGTTTGAAAAGGGATCTGAATATTTTCATCTGCACACGCTTGTGGAGACCTCCG -655
AAV2CG	- GCGTGAAATCCATGTTTTGGGACGTTTCCTGAGTCAGATTCGCGAAAACTGAT -670 :
AAV5CG	- GCATCTCTTCCATGGTCTCGGCCGTACGTGAGTCAGATTCGCGCCCAGCTGGT -710
AAV2CG	- TCAGAGAATTTACCGCGGGATCGAGCCGACTTTGCCAAACTGGTTCGCGGTACA -725 :
AAV5CG	- GAAAGTGGTCTTCCAGGAATTGAACCCAGATCAACGACTGGGTCGCCATCACC -765
AAV2CG	- AAGACCAGAAATGGCGCCGAGGCGGGAACAAGGTGGTGGATGAGTGCTACATCC -780 :
AAV5CG	- AAGGTAAAGAAGGGC—GGAGCC—AATAAGGTGGTGGATTCTGGGTATATTC -814
AAV2CG	- CCAATTACTTGCTCCCCAAAACCCAGCCTGAGCTCCAGTGGGCGTGGACTAATAT -835 :
AAV5CG	- CCGCCTACCTGCTGCCGAAGGTCCAACCGGAGCTTCAGTGGGCGTGGACAAACCT -869
AAV2CG	- GGAACAGTATTTAAGCGCCTGTTTGAATCTCACGGACCGTAAACGGTTGGTGGCG -890 :
AAV5CG	- GGACGAGTATAAATTGCCCGCCCTGAATCTGGAGGAGCGCAAACGGCTCGTCGGC -924
AAV2CG	- CAGCATCTGACGCACGTGTCGCAGACGCAGGAGCAGAACAAGAGAATCAGAATC -945 :
AAV5CG	- CAGTTTCTGGCAGAATCCTCGCAG-CGCTCG—CAGGAGGCGGCTTCGCAGCGTG -976

FIG. 4B

**SUBSTITUTE SHEET (RULE 26)**

6/20

AAV2CG - CCAATTCTGATGCCCGGTGATCAGATCAAAAACCTTCAGCCAGGTACATGGAGCT -1000  
:: : :: : : : : : : : : : : : : : : : :  
AAV5CG - AGTTCTCGGCTGACCCCGTCAATCAAAAGCAAGACTTCCCAGAAATACATGGCGCT -1031

AAV2CG - GGTCCGGTGGCTCGTGACAAGGGGATTACCTCGGAGAAGCAGTGGATCCAGGAG -1055  
::  
AAV5CG - CGTCAACTGGCTCGTGAGCACGGCATCACTTCCGAGAAGCAGTGGATCCAGGAA -1086

AAV2CG - GACCAGGCCTCATACATCTCCTTCAATGCCGCCTCCAAC TCGCGGTCCCAAATCA -1110  
:  
AAV5CG - AATCAGGAGAGCTACCTCTCCTTCAACTCCACCGGCAACTCTCGGAGCCAGATCA -1141

AAV2CG - AGGCTGCCTTGGACAATGCCGGAAAGATTATGAGCCTGACTAAAACCGCCCCCGA -1165  
:  
AAV5CG - AGGCCGCGCTCGACAACCGGACCAAAATTATGAGTCTGACAAAAAGCGCGGTGGA -1196

AAV2CG - CTACCTGGTGGGCCAGCAGCCCGTG-GAGGACATTTCCAGCAATCGGATTTATAA -1219  
:  
AAV5CG - CTACCTCGTGGGG-AGCTCCGTTCCCGAGGACATTTCAAAAAACAGAATCTGGCA -1250

AAV2CG - AATTTTGGAACTAAACGGGTACGATCCCCAATATGCCGCTTCCGTCTTTCTGGGA -1274  
:  
AAV5CG - AATTTTGGAGATGAATGGCTACGACCCGGCCTACGCGGGATCCATCCTCTACGGC -1305

AAV2CG - TGGGCCACGAAAAAGTTCCGCAAGAGGAACACCATCTGGCTGTTTGGCCCTGCAA -1329  
:  
AAV5CG - TGGTGTACGCGCTCCTTCAACAAGAGGAACACCGTCTGGCTCTACGGACCCGCCA -1360

AAV2CG - CTACCGGAAGACCAACATCGCGGAGGCCATAGCCCACACTGTGCCCTTCTACGG -1384  
:  
AAV5CG - CGACCGGAAGACCAACATCGCGGAGGCCATCGCCCACACTGTGCCCTTTTACGG -1415

AAV2CG - GTCCGTAAACTGGACCAATGAGAACTTTCCCTTCAACGACTGTGTGACAAGATG -1439  
:  
AAV5CG - CTCGTGA ACTGGACCAATGAAACTTTCCCTTTAATGACTGTGTGGACAAAATG -1470

AAV2CG - GTGATCTGGTGGGAGGAGGGGAAGATGACCGCCAAGGTGCTGGAGTCGGCCAAAG -1494  
:  
AAV5CG - CTCATTTGGTGGGAGGAGGGGAAGATGACCAACAAGGTGGTTGAATCCGCCAAGG -1525

AAV2CG - CCATTCTCGGAGGAAGCAAGGTGCCGCTGGACCAGAAATGCAAGTCCTCGGCCCA -1549  
:  
AAV5CG - CCATCCTGGGGGGCTCAAAGGTGCCGGTGCATCAGAAATGTAAATCCTCTGTICA -1580

FIG. 4C

7/20

AAV2CG - GATAGACCCGACTCCCGTGATCGTCACCTCCAACACCAACATGTGCGCCGTGATT -1604  
:: ::  
AAV5CG - AATTGATTCTACCCCTGTCATTGTAACCTCCAATACAAACATGTGTGTGGTGGTG -1635  
  
AAV2CG - GACGGGAAGTCAACGACCTTCGAACACCAGCAGCCGTTGCAAGACCGGATGTTCA -1659  
:  
AAV5CG - GATGGGAATTCCACGACCTTTGAACACCAGCAGCCGCTGGAGGACCGCATGTTCA -1690  
  
AAV2CG - AATTGAACTCACCCGCCGTCTGGATCATGACTTTGGGAAGGTCACCAAGCAGGA -1714  
:  
AAV5CG - AATTGAACTGACTAAGCGGCTCCCGCCAGATTTTGGCAAGATTACTAAGCAGGA -1745  
  
AAV2CG - AGTCAAAGACTTTTTCCGGTGGGCAAAGGATCACGTGGTTGAGGTGGAGCATGAA -1769  
:  
AAV5CG - AGTCAAGGACTTTTTTGCTTGGGCAAAGGTCAATCAGGTGCCGGTGACTCAGGAG -1800  
  
AAV2CG - TTCTACGTCAAAAAGGG—TGGAGCCAAGAAAAGACCCGCCCCCAGTGACGCAGA -1822  
:  
AAV5CG - TTTAAAGTTCCCAGGGAATTGGCGGGAAGTAAAGGGGCG——GAGAAATCTC -1849  
  
AAV2CG - TATAAGTGAGCCCAAACGGGTGCGCGAGTCAGTTGCCGAGCCATCGACGTCAGAC -1877  
:  
AAV5CG - TAAAC—GCCCACT—GGGTGA—CGTCACCAATACT—AGCTATAAAAGTCTGGA -1898  
  
AAV2CG - GCCGAAGCTTCGATCAACTACGCAGACAGGTACCAAAACAAAT—GTTCTCGTCAC -1931  
:  
AAV5CG - G—AAGC—GGGCCAGGCTCTCATTT—GTTCCCGAGACGCCTCGCAGTTCAGAC -1947  
  
AAV2CG - GTGGGCATGAATCT—GATGCTGTTTCCCTGCAGACAATGCGAGAGAATGAATCAG -1985  
:  
AAV5CG - GTGACTGTTGATCCCGCTCCTCTGCGACCGCTCA—ATTGGAATTCAAGGTAT—G -1999  
  
AAV2CG - AATTCAAATATCTGCTTCACTCACGGACAGAAAGACTGTTTAGAGTGCTTTCCCG -2040  
:  
AAV5CG - ATTGCAAATG—TGA—A—TCATGCTCAATTTGACA——ACATTTCTAACAAA -2046  
  
AAV2CG - TGTCA—GAATCTCAACCCGTTTCTGTGCTCAAAAAGGC—GTATCAGAACTGTG -2092  
:  
AAV5CG - TGTGATGAATGTGAATATTTGAATCGGGGCAAAAATGGATGTATCTGTCACAATG -2101  
  
AAV2CG - CTACATTCA—TCATAT——CATGGGAAAGGTGCCAGACGCTTGCACTGCCTGCC -2142  
:  
AAV5CG - TAACTCACTGTCAAATTTGTCATGGGATTCCCCCTGGGAAAAGGAAAAGTGT— -2154  
  
AAV2CG - ATCTGGTCAATGTGGATTTGGATGACTGCATCTTTGAACAATAAATGATTTAAAT -2197  
:  
AAV5CG - —TCAGATTT—TGGGATTTTGACGATGCCAATAAAGAACAGTAAATAAAGCGAGT -2207

FIG.4D

SUBSTITUTE SHEET (RULE 26)

8/20

AAV2CG - CAGGTATGGCTGCCGATGTTATCTTCCAGATTGGCTCGAGGACACTCTCTCTGA -2252  
:: :: :: : : : : : : : : : : : : : :  
AAV5CG - AGTCATGTCTTTTGTTGATCACCTCCAGATTGGTTGGAAGAAGTTGG—TGA -2258

AAV2CG - AGGAATAAGACAGTGGTGGAAAGCTCAAACCTGGCCCACCACCACCAAGCCCCGA -2307  
:: : : : : : : : : : : : : : : : :  
AAV5CG - AGGTCTTCGCGAGTTTTTGGGCCTTGAAGCGGGCCACCGAAACCAAAACCCAAT -2313

AAV2CG - GAGCGGCATAAGGACGACAGCAGGGTCTTGTGCTTCCTGGGTACAAGTACCTCG -2362  
:: : : : : : : : : : : : : : : : :  
AAV5CG - CAGCAGCATCAAGATCAAGCCCGTGGTCTTGTGCTGCCTGGTTATAACTATCTCG -2368

AAV2CG - GACCCTTCAACGGACTCGACAAGGGAGAGCCGGTCAACGAGGCAGACGCCGCGGC -2417  
:::: : : : : : : : : : : : : : : : :  
AAV5CG - GACCCGGAACGGTCTCGATCGAGGAGAGCCTGTCAACAGGGCAGACGAGGTCCG -2423

AAV2CG - CCTCGAGCAGACAAAGCCTACGACCGGCAGCTCGACAGCGGAGACAACCCGTAC -2472  
: : : : : : : : : : : : : : : : :  
AAV5CG - GCGAGAGCAGACATCTCGTACAACGAGCAGCTTGAGGCGGGAGACAACCCCTAC -2478

AAV2CG - CTCAAGTACAACCACGCCGACGCGGAGTTTCAGGAGCGCCTTAAGAAGATACGT -2527  
: : : : : : : : : : : : : : : : :  
AAV5CG - CTCAAGTACAACCACGCCGACGCGGAGTTTCAGGAGAAGCTCGCCGACGACACAT -2533

AAV2CG - CTTTTGGGGGCAACCTCGGACGAGCAGTCTTCCAGGCGAAAAGAGGGTTCTTGA -2582  
: : : : : : : : : : : : : : : : :  
AAV5CG - CCTTCGGGGGAAACCTCGGAAAGGCAGTCTTTCAGGCCAAGAAAAGGGTTCTCGA -2588

AAV2CG - ACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTCCGGGAAAAAAGAGGCCG -2637  
: : : : : : : : : : : : : : : : :  
AAV5CG - ACCTTTTGGCCTGGTTGAAGAGGGTGCTAAGACGGCCCCTACCGGAAAGCGGATA -2643

AAV2CG - GTAGAGCACTCTCCTGTGGAGCCAGACTCCTCCTCGGGAACCGGAAAGCGGGCC -2692  
: : : : : : : : : : : : : : : : :  
AAV5CG - GACGACCACTTTCCAAAA-AGAAAGAAGGCTC——GGA-CCGAAGAGGACT-CC -2691

AAV2CG - AGCAGCCTGCAAGAAAAAGATTGAATTTTGGTCAGACTGGAGACGCAG-ACTCAG -2746  
: : : : : : : : : : : : : : : : :  
AAV5CG - A-AGCCTTCCACC—————TCGTCAGAC-GCCGAAGCTGGACCCAG -2729

AAV2CG - TACCTGACCCCCAGCCTCTCGGACAGCCACCAGCAGCCCCCTCTGGTCTGGGAAC -2801  
: : : : : : : : : : : : : : : : :  
AAV5CG - —CGGATCCC-AGCAGCTGCAAATCCCAGCCCAACCAGCCTCAAGTTGGGAGC -2780

FIG. 4E

SUBSTITUTE SHEET (RULE 26)



9/20

AAV2CG	- TAATACGATGGCTACAGGCAGTGGCGCACCAATGGCAGACAATAACGAGGGCGCC -2856 :
AAV5CG	- TGATACAATGTCTGCCGGAGGTGGCGGCCCATTTGGCGACAATAACCAAGGTGCC -2835
AAV2CG	- GACGGAGTGGGTAATTTCCTCGGGAATTGGCATTGCGATTCCACATGGATGGGCG -2911 :
AAV5CG	- GATGGAGTGGGCAATGCCTCGGAGATTGGCATTGCGATTCCACGTGGATGGGCG -2890
AAV2CG	- ACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCACCTACAACAACCA -2966 :
AAV5CG	- ACAGAGTCGTCACCAAGTCCACCCGAACCTGGGTGCTGCCAGCTACAACAACCA -2945
AAV2CG	- CCTCTACAAACAAATTTCCAGCCAATCAGGAGCCTCGA—ACGACAATCACTAC -3018 :
AAV5CG	- CCAGTACCGAGAGATCAAAAGCGGCTCCGTGACGGAAGCAACGCCAACGCCTAC -3000
AAV2CG	- TTTGGCTACAGCACCCCTTGGGGGTATTTGACTTCAACAGATTCCACTGCCACT -3073 :
AAV5CG	- TTTGGATACAGCACCCCTTGGGGGTACTTTGACTTTAACCGCTTCCACAGCCACT -3055
AAV2CG	- TTTCACCACGTGACTGGCAAAGACTCATCAACAACAACTGGGGATTCCGACCCAA -3128 :
AAV5CG	- GGAGCCCCCGAGACTGGCAAAGACTCATCAACAACAACTGGGGCTTCAGACCCCG -3110
AAV2CG	- GAGACTCAACTTCAAGCTCTTTAACATTCAAGTCAAAGAGGTCACGCAGAATGAC -3183 :
AAV5CG	- GTCCCTCAGAGTCAAAATCTTCAACATTCAAGTCAAAGAGGTCACGGTGACAGGAC -3165
AAV2CG	- GGTACGACGACGATTGCCAATAACCTTACCAGCACGGTTCAGGTGTTTACTGACT -3238 :
AAV5CG	- TCCACCACCACCATCGCCAACAACCTCACCTCCACCGTCCAAGTGTTTACGGACG -3220
AAV2CG	- CGGAGTACCAGCTCCCGTACGTCCTCGGCTCGGCGCATCAAGGATGCCTCCCGCC -3293 :
AAV5CG	- ACGACTACCAGCTGCCCTACGTCGTCGGCAACGGGACCGAGGGATGCCTGCCGGC -3275
AAV2CG	- GTTCCCAGCAGACGTCTTCATGGTGCCACAGTATGGATACCTCACCTGAACAAC -3348 :
AAV5CG	- CTTCCCTCCGCAGGTCTTTACGCTGCCGCAGTACGGTTACGCGACGCTGAACCGC -3330
AAV2CG	- GGGAGT-CAGGCAGTAGGAC—GCTCTTCA—TTTTACTGCCTGGAGTACTTTC -3397 :
AAV5CG	- GACAACACAGAAAATCCCACCGAGAGGAGCAGCTTCTTCTGCCTAGAGTACTTTC -3385

FIG. 4F

SUBSTITUTE SHEET (RULE 26)

AAV2CG - CTTCTCAGATGCTGCCGTACCGGAAACAACCTTTACCTTCAGCTACACTTTTGAGGA -3452  
:  
AAV5CG - CCAGCAAGATGCTGAGAACGGGCAACAACCTTTGAGTTTACCTACAACCTTTGAGGA -3440

AAV2CG - CGTTCCTTTCCACAGCAGCTACGCTCACAGCCAGAGTCTGGACCGTCTCATGAAT -3507  
:  
AAV5CG - GGTGCCCTTCCACTCCAGCTTCGCTCCCAGTCAGAACCTGTTCAAGCTGGCCAAC -3495

AAV2CG - CCTCTCATCGACCAGTACCTGTATTACTT—GAGCAGAACAAACACTC—— -3553  
:  
AAV5CG - CCGCTGGTGGACCAGTACTTGTACCGCTTCGTGAGCACAATAACACTGGCGGAG -3550

AAV2CG - —CAAGTGAACCACCAC—GCAGTCA-AGGCTTCAGTT—TTCTCAGGCCGGAG -3601  
:  
AAV5CG - TCCAGTTCAACAAGAACCTGGCCGGGAGATACGCCAACACCTACAAAACTGGTT -3605

AAV2CG - CGAGTGACATTCGGGACCAGTCTAGGAACTGGCTTCCTGGACCCTGTTACCGCCA -3656  
:  
AAV5CG - CCCGGGGCCCCATGGGCCGAACCCAGGG-CTGGAA-CCTGGGCTCCGGGGTCAACC -3658

AAV2CG - GCAGCGAGTATCAAAGACATCTGCGGATAACAACAACAGTGAATACTCGTGGACT -3711  
:  
AAV5CG - GC-GCCAGTGTGAGCGCCTTC-GCCACGACCAATAGGA-TGGAG-CTCGAGGGCG -3709

AAV2CG - GGAGCTACCAAGTACCACCTCAATGGCAGAGACTCTCTGGTGAATCCGGGCCCCG -3766  
:  
AAV5CG - CGAGTTACCAGGTGCCCCCGCA—GCCGA-ACGGCATGACCAACAACCTCCAGG -3760

AAV2CG - CCATGGCAAGCCACAAGGACGATGAAGAAAAGTTTTTCTCAGAGCGGGTTCT -3821  
:  
AAV5CG - GCA—GCAA—CACCTATGCCCTGGAGAACACTATGATCTTCAA—CAG—C- -3804

AAV2CG - CATCTTTGGGAAGCAAGGCTCAGAGAAAACAAATGTGGACATTGAAAAGGTCATG -3876  
:  
AAV5CG - CAGCCG-GCGAACCCGGGCACCACCGCCACGTACCTCGAGGGCAACATGCTCATC -3858

AAV2CG - ATTACAGACGAAGAGGAAATCAGGACAACCAATCCCGTGGC-TACGGAGCAGTAT -3930  
:  
AAV5CG - AC—CAG-CGAGAGCGAGACGCAGCCGGTGAACCGCGTGGCGTACAACGTCGGCG -3910

AAV2CG - GGTTCGTATCTACCAACCTCCAGAGAGGCAACAGACAAGCAGCTACCGCAGATG -3985  
:  
AAV5CG - GGCAGA-TGGCCACCAACAACCAGAGCTCCACCACTGCCCCCGCGACCGGCACGT -3964

FIG.4G  
SUBSTITUTE SHEET (RULE 26)

AAV2CG	- TCAACACACAAGGCGTTCTTCCAGGCATGGTCTGGCAGGACAGAGATGTGTACCT -4040 ::: : : : : :::: : : : : : :
AAV5CG	- ACAACCTCCAGGAAATCGTGCCCGGCAGCGTGTGGATGGAGAGGGACGTGTACCT -4019
AAV2CG	- TCAGGGGCCCATCTGGGCAAAGATTCCACACACGGACGGACATTTTCACCCCTCT -4095 : : : : : : : : : : : : : : : : : :
AAV5CG	- CCAAGGACCCATCTGGGCCAAGATCCCAGAGACGGGGGCGCACTTTTCACCCCTCT -4074
AAV2CG	- CCCCTCATGGGTGGATTCCGACTTAAACACCCTCCTCCACAGATTCTCATCAAGA -4150 : : : : : : : : : : : : : : : : : :
AAV5CG	- CCGGCCATGGGCGGATTCCGACTCAAACACCCACCGCCCATGATGCTCATCAAGA -4129
AAV2CG	- ACACCCCGGTACCTGCGAATCCTTCGACCACCTTCAGTG-CGGCAAAGTTTGCTT -4204 : : : : : : : : : : : : : : : : : :
AAV5CG	- ACACGCCTGTGCCCCGAAATA-TC-ACCAGCTTCTCGGACGTGCCCCGTCAGCAG -4181
AAV2CG	- CCTTCATCACACAGTACTCCACGGGACAGGTCAGCGTGGAGATCGAGTGGGAGCT -4259 : : : : : : : : : : : : : : : : : :
AAV5CG	- C-TTCATCACCCAGTACAGCACCGGGCAGGTCACCGTGGAGATGGAGTGGGAGCT -4235
AAV2CG	- GCAGAAGGAAAACAGCAAACGCTGGAATCCCGAAATTCAGTACACTTCCA ACTAC -4314 : : : : : : : : : : : : : : : : : :
AAV5CG	- CAAGAAGGAAA ACTCCAAGAGGTGGAACCCAGAGATCCAGTACACAAACA ACTAC -4290
AAV2CG	- AACAACTCTGTTAATGTGGACTTTACTGTGGACACTAATGGCGTGTATTCAGAGC -4369 : : : : : : : : : : : : : : : : : :
AAV5CG	- AACGACCCCCAGTTTGTGGACTTTGCCCCGGACAGCACCGGGGA-ATACAGAAC -4343

FIG. 4H

AAV2CG - CTC—GCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAAT—TGCTTGT- -4418  
:  
:: : :: : : : : : : : : : : :  
AAV5CG - CACCAGACCTATCGGAACCCGATACTTACCCGACCCCCTTTAACCCATTTCATGTC -4398

AAV2CG - —TAA—TCAATAAACCGTTTTAATTGTTTTAGTTGAACTTTGG-TCTCTGCCGT -4467  
:  
: : : : : : : : : : : : : : : :  
AAV5CG - GCATACCCTCAATAAACCGTGTA-TTCGTGTCAGTAAAATACTGCCTCTTGTTGGT -4452

AAV2CG - ATTTCTTTCT-TATCTAGTTTCCATGGCTACGTAGATAAGTAGCATGGCGGGTTA -4521  
:  
: : : : : : : : : : : : : : : :  
AAV5CG - CATTC AATGAATAACAGCTTACAACATCTACAAAACCTCCTTGCTTGA-GAGTGT -4506

AAV2CG - ATCATTA ACTACAAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTC-TCTGCCG -4575  
:  
: : : : : : : : : : : : : : : :  
AAV5CG - GGGACT—CTCCCC——CCTGTCCG GTTCGC-TCGCTCGCTGGCTCGTTTGGGG -4554

AAV2CG - GCTCGCTCGCTCACTGAG—GCCGGGGGACCAAAGGTGCCCCGACGCCCCGGGCTT -4628  
:  
: : : : : : : : : : : : : : : :  
AAV5CG - GGGTGGCAGCTCAAAGAGCTGCCAGACGACGGCCCTCTGGCCGTGCCCC—— -4604

AAV2CG - TGCCCCGGGCGGCCTCAGTGAGCGAGCGAGCGGCAGAGAGGGAGTGCCAA -4679  
:  
: : : : : : : : : : : : : : : :  
AAV5CG - —CCCAAACGAGC-CAGCGAGCGAGCGAACGCGACAGGGGGGAGAGTGCCA -4652

Identity : 3013 (64.77%)  
Number of gaps inserted in AAV2CG: 43  
Number of gaps inserted in AAV5CG: 63

==23-SEP-1999==NAL IGN==PC/GENE==

FIG. 41

13/20

==23-SEP-1999=====PC/GENE==

\*\*\*\*\*  
 \* ALIGNMENT OF TWO PROTEIN SEQUENCES. \*  
 \*\*\*\*\*

The two sequences to be aligned are:

AAV2VP1.  
 DE VP1  
 OS AAV2  
 Total number of residues: 735.

AAV5VP1.  
 DE AAV5VP1  
 OS AAV5VP1  
 Total number of residues: 724.

Comparison matrix : Structure-genetic matrix.  
 Open gap cost : 8  
 Unit gap cost : 5

The character to show that two aligned residues are identical is ':'  
 The character to show that two aligned residues are similar is '.'  
 Amino acids said to be 'similar' are: A,S,T; D,E; N,Q; R,K; I,L,M,V; F,Y,W

```

AAV2VP1  - MAADGYLPDWLEDTLSEGIQWWKLKPGPPPKPAERHKDDSRGLVLPGYKYLGP -55
          :.      :..... :.:: : : : : : : : : : : : : : : : : :
AAV5VP1  - MSFVDHPPDWLEE-VGEGLREFLGLEAGPPKPKPNQQHQDQARGLVLPGYNYLGP -54

AAV2VP1  - FNGLDKGEPVNEADAAALEHDKAYDRQLDSGDNPYLKYNHADAEFQERLKEDTSF -110
          :.....: : : : : : : : : : : : : : : : : : : : : :
AAV5VP1  - GNGLDRGEPVNRADDEVAREHDI SYNEQLEAGDNPYLKYNHADAEFQEKLADDTSF -109

AAV2VP1  - GGNLGRAVFQAKKRVLEPLGLVEEPVKTAPGKKRPVEHSPVEPDSSSGTGKAGQQ -165
          :.....: : : : : : : : : : : : : : : : : : : : :
AAV5VP1  - GGNLGKAVFQAKKRVLEPFGLVEEGAKTAPTGKRIDDHFPKR-KKARTEEDSKP -162

AAV2VP1  - PARKRLNFGQTGDADSVDPQPLGQPPAAPSGLGNTMATGSGAPMADNNEGADG -220
          : : : : : : : : : : : : : : : : : : : : :
AAV5VP1  - STS-----SDAEAGPSGSQQQLQIPAQPASSLGADTMSAGGGGPLGDNNQGADG -210

AAV2VP1  - VGNSSGNWHCDSTWMGDRVITTTSTRTWALPTYNNHLYKQISSQSG-ASNDNHYFG -274
          :.....: : : : : : : : : : : : : : : : : : : :
AAV5VP1  - VGNASGDWHCDSTWMGDRVVTKSTRTWVLP SYN NHQYREIKSGSVDGSNANAYFG -265
  
```

FIG.5A

SUBSTITUTE SHEET (RULE 26)

AAV2VP1 - YSTPWGYFDFNRFHCHFSPRDWQRLINNNWGF RPKRLNF KLFNIQVKEVTQNDGT -329  
 AAV5VP1 - YSTPWGYFDFNRFHSHWSPRDWQRLINNYWGF RPRSLRVKIFNIQVKEVTVQDST -320  
 AAV2VP1 - TTIANNL TSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMVPQYGYLTLNNGS -384  
 AAV5VP1 - TTIANNL TSTVQVFTDDDYQLPYVVGNGTEGCLPAFPQVFTLPQYGYATLNRDN -375  
 AAV2VP1 - Q—AVGRSSFYCLEYFPSQMLRTGNNFTFSYTFEDVPFHSSYAHSQSLDRLMNPL -437  
 AAV5VP1 - TENPTERSSFFCLEYFPSKMLRTGNNFEFTYNFEEVPFHSSFAPSQNLFKLANPL -430  
 AAV2VP1 - IDQYLYLSRTNTPSGTTTQSRLQFSQAGASDIRDQSRNWLPGPCYRQQRVSKTS -492  
 AAV5VP1 - VDQYLYRFVSTNNTGG——VQFNKNLAGRYANTYKNWFPGPMGRTQGWNLGS -479  
 AAV2VP1 - ADMNNSEYSWTGATKYHLNGRDSL VNPGPAMASHKDDEEKFFPQSGVLIFGKQGS -547  
 AAV5VP1 - GVNRAVSFAFATTNRMELEGASYQVPPQPNGMTNNLQGSNTYALENTMIFNSQPA -534  
 AAV2VP1 - EKTNVDI——EKVMITDEEEIRTTNPVATEQYGSVSTNLQRGNRQAATADVNTQG -599  
 AAV5VP1 - NPGTTATYLEGNMLITSESETQPVNRVAYNVGGQMATNNQSSTTAPATGTYNLQE -589  
 AAV2VP1 - VLPGMVWQDRDVYLQGP IWAKI PHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVP -654  
 AAV5VP1 - IVPGSVMMERDVYLQGP IWAKI PETGAHFHPSPAMGGFGLKHPPPMMLIKNTPVP -644  
 AAV2VP1 - ANPSTTFSAAKFASFITQYSTGQVSVEIEWELQKENS KRWNPEIQYTSNYNKS VN -709  
 AAV5VP1 - GNI—TSFSDVPVSSFITQYSTGQVTVEMEWELKKENS KRWNPEIQYTNNYNDPQF -698  
 AAV2VP1 - VDFTVDTNGVYSEPRPIGTRYLTRNL -735  
 AAV5VP1 - VDFAPDSTGEYRTTRPIGTRYLTRPL -724

Identity : 421 ( 58.2%)  
Similarity: 63 ( 8.7%)  
Number of gaps inserted in AAV2VP1: 3  
Number of gaps inserted in AAV5VP1: 5

==23-SEP-1999==PC/GENE==

FIG. 5B

**SUBSTITUTE SHEET (RULE 26)**



15/20

==23-SEP-1999=====PALIGN=====PC/GENE==

\*\*\*\*\*  
 \* ALIGNMENT OF TWO PROTEIN SEQUENCES. \*  
 \*\*\*\*\*

The two sequences to be aligned are:

REP78.

DE REP78

OS AAV

Total number of residues: 621.

AAV5REP.

DE REP

OS AAV5

Total number of residues: 610.

Comparison matrix : Structure-genetic matrix.

Open gap cost : 8

Unit gap cost : 5

The character to show that two aligned residues are identical is ':'

The character to show that two aligned residues are similar is '.'

Amino acids said to be 'similar' are: A,S,T; D,E; N,Q; R,K; I,L,M,V; F,Y,W

```

REP78      - MPGFYEVIVIKVPSDLGHLPGISDSFVNWVAEKELPPDSMDLNLIEQAPLTV -55
              : .....: : .....: : .....: : .....: : .....:
AAV5REP    - MATFYEVIVRVFDFVEEHLPGISDSFVDWVTGQIWELPPESDLNLTLVEQPQLTV -55

REP78      - AEKLQRDFLTEWRRVSKAPEALFFVQFEKGESYFHHVLTETGKSMVLGRFLS -110
              :... : : : : : : : : .....: .....: .....: .....:
AAV5REP    - ADRIIRVFLYEWNKFSKQ-ESKFFVQFEKGSEYFHLHTLVETSGISSMVLGRYVS -109

REP78      - QIREKLIQRIYRGIEPTLPNWF AVTKTRNGAGGKNKVDECYIPNYLLPKTQPEL -165
              : : : : : : : : : : : : : : : : : : : : : :
AAV5REP    - QIRAQLVKVVFQGI EPQINDWVAITKVKKG--GANKVVDSGYIPAYLLPKVQPEL -162

REP78      - QWAWTNMEQYLSACLNLTERKRLVAQHLTHVSQTQEQNKENQNPNSDAPVIRSKT -220
              : .....: : : : : : : : : : : : : : : :
AAV5REP    - QWAWTNLDEYKLAALNLEERKRLVAQFLA-ESSQRSQEAASQREFSADPVIKSKT -216

REP78      - SARYMELVGWLVDKGITSEKQWIQEDQASYISFNAASNSRSQIKAALDNAGKIMS -275
              : : : : : : : : : : : : : : : : : : : : : :
AAV5REP    - SQKYMALVNWLVHGITSEKQWIQENQESYLSFNSTGNSRSQIKAALDNATKIMS -271
  
```

FIG.6A

SUBSTITUTE SHEET (RULE 26)

REP78	- LTKTAPDYLVGQOPVEDISSNRITYKILELNGYDPQYAASVFLGWATKKFGKRNTI -330 :: :: : : : : : : : : : : : :
AAV5REP	- LTSAVDYL VGSSVPEDISKNIWQIFEMNGYDPAYAGSILYGWCQRSFNKRNTV -326
REP78	- WLFGPATTGKTNIAEAIAHTVPFYGCVNWTNENFPFNDVCVKMVIWWEEGKM TAK -385 : : : : : : : : : : : : : : : : : :
AAV5REP	- WLYGPATTGKTNIAEAIAHTVPFYGCVNWTNENFPFNDVCVKML I WWEEGKM TNK -381
REP78	- VVESAKAILGGSKVRVDQCKSSAQIDPTPVIVTSNTNMCAVIDGNSTTFEHQQP -440 : : : : : : : : : : : : : : : : : :
AAV5REP	- VVESAKAILGGSKVRVDQCKSSVQIDSTPVIVTSNTNM CVVV DGNSTTFEHQQP -436
REP78	- LQDRMFKFELTRRLDHDFGKVTKQE VKDFFRWAKDHVEHEFEFYVKKGGAKKRP -495 : : : : : : : : : : : : : : : : :
AAV5REP	- LEDRMFKFEL TKRLLPPDFGKI TKQE VKDFFAWAKVNQPVT HE FK V——PRELA -487
REP78	- APSDADISEPKRVRESVAQPSTS DA EASI NYADRYQNKC SRHVGMNL ML FPCRQC -550 : : : : : : : : : : : : : : : : :
AAV5REP	- GTKGAEKS-LKRPLGDVTNTSYKSLEKRARLSFVPETPRSSDVTVDPA—PLRPL -539
REP78	- ERMNQNSNICFTHGQKDCLEC FPVS ES QPVS VVK KAYQLCYIH H IM GK VPDA CT -605 : : : : : : : : : : : : : : : : :
AAV5REP	- NWNSRYDCKCDYHAQFDNI-SNK CDECE YLN RGKN GCICHNVTHCQIC HGIPWE -593
REP78	- ACDLVNV-DLODCIFEQ -621 : : : : : : : : : : : : : : : : :
AAV5REP	- KENLSDF GDF DDANKEQ -610

```
Identity   : 363 (59.51%)
Similarity: 55 (9.02%)
Number of gaps inserted in REP78: 1
Number of gaps inserted in AAV5REP: 7
```

==23-SEP-1999==PALIGN==PC/GENE==

FIG. 6B

17/20

Apical transduction of human airway epithelia with rAAV2 and rAAV5




FIG. 7

18/20




FIG. 8

19/20

rAAV5 Primary Rat Brain Explant



FIG.9

20/20

HUVEC

rAAV2

rAAV5




FIG.10



## SEQUENCE LISTING

&lt;110&gt; Chiorini, John

&lt;120&gt; AAV5 VECTOR AND USES THEREOF

&lt;130&gt; 14014.0323/P

&lt;150&gt; 60/087,029

&lt;151&gt; 1998-05-28

&lt;160&gt; 23

&lt;170&gt; FastSEQ for Windows Version 3.0

&lt;210&gt; 1

&lt;211&gt; 4652

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:/Note =  
synthetic construct

&lt;400&gt; 1

tggcactctc	ccccctgtcg	cgttcgctcg	ctcgctggct	cgtttggggg	ggtggcagct	60
caaagagctg	ccagacgacg	gccctctggc	cgtcgcccc	ccaaacgagc	cagcgagcga	120
gcgaacgcga	caggggggag	agtgccacac	tctcaagcaa	gggggttttg	taagcagtga	180
tgtcataatg	atgtaatgct	tattgtcacg	cgatagttaa	tgattaacag	tcatgtgatg	240
tgttttatcc	aataggaaga	aagcgcgcgt	atgagttctc	gcgagacttc	cgggggtataa	300
aagaccgagt	gaacgagccc	gccgccattc	tttgcctctg	actgctagag	gaccctcgct	360
gccatggcta	ccttctatga	agtcattggt	cgcgctccat	ttgacgtgga	ggaacatctg	420
cctggaattt	ctgacagctt	tgtggactgg	gtaactggtc	aaatttgga	gctgcctcca	480
gagtcagatt	taaatttgac	tctggttgaa	cagcctcagt	tgacggtggc	tgatagaatt	540
cgcgcgtgt	tcctgtacga	gtggaacaaa	ttttccaagc	aggagtccaa	attctttgtg	600
cagtttgaaa	agggatctga	atattttcat	ctgcacacgc	ttgtggagac	ctccggcatc	660
tcttccatgg	tcctcggccg	ctacgtgagt	cagattcgcg	cccagctggg	gaaagtggtc	720
ttccagggaa	ttgaacccca	gatcaacgac	tggtgcgcca	tcaccaaggt	aaagaagggc	780
ggagccaata	aggtggtgga	ttctgggtat	attcccgcct	acctgctgcc	gaagggtccaa	840
ccggagcttc	agtgggcgtg	gacaaacctg	gacgagtata	aattggccgc	cctgaatctg	900
gaggagcgca	aacggctcgt	cgcgcagttt	ctggcagaat	cctcgcagcg	ctcgcaggag	960
gcggcttcgc	agcgtgagtt	ctcggctgac	ccggtcatca	aaagcaagac	ttcccagaaa	1020
tacatggcgc	tcgtcaactg	gctcgtggag	cacggcatca	cttccgagaa	gcagtggatc	1080
caggaaaatc	aggagagcta	cctctccttc	aactccaccg	gcaactctcg	gagccagatc	1140
aaggccgcgc	tcgacaacgc	gaccaaatt	atgagtctga	caaaaagcgc	ggtggactac	1200
ctcgtgggga	gctccgttcc	cgaggacatt	tcaaaaaaca	gaatctggca	aatttttgag	1260
atgaatggct	acgaccgggc	ctacgcggga	tccatcctct	acggctgggt	tcagcgctcc	1320
ttcaacaaga	ggaacaccgt	ctggctctac	ggacccgcca	cgaccggcaa	gaccaacatc	1380
gcggaggcca	tcgcccacac	tgtgcccttt	tacggctgcg	tgaactggac	caatgaaaac	1440
tttcccttta	atgactgtgt	ggacaaaatg	ctcatttggt	gggaggaggg	aaagatgacc	1500
aacaagggtg	ttgaatccgc	caaggccatc	ctggggggct	caaagggtgc	ggtcgatcag	1560
aaatgtaa	cctctgttca	aattgattct	accctgtca	ttgtaacttc	caatacaaac	1620
atgtgtgtg	tgggtgatgg	gaattccacg	acctttgaac	accagcagcc	gctggaggac	1680
cgcattgtca	aattttgaact	gactaagcgg	ctcccgccag	attttgga	gattactaag	1740
caggaagtca	aggacttttt	tgcttgggca	aagggtcaatc	aggtgccggg	gactcacgag	1800
tttaaagttc	ccagggaatt	ggcgggaact	aaaggggcgg	agaaatctct	aaaacgcccc	1860

ctgggtgacg	tcaccaatac	tagctataaa	agtctggaga	agcggggccag	gctctcattt	1920
gttcccgaga	cgccctgcag	ttcagacgtg	actgttgatc	ccgctcctct	gcgaccgctc	1980
aattggaatt	caaggatatga	ttgcaaattgt	gactatcatg	ctcaattttga	caacattttct	2040
aacaaatgtg	atgaatgtga	atattttgaat	cggggcaaaa	atggatgtat	ctgtcacaaat	2100
gtaactcact	gtcaaatttg	tcatgggatt	ccccctggg	aaaaggaaaa	cttgtcagat	2160
tttggggatt	ttgacgatgc	caataaagaa	cagtaaataa	agcgagtagt	catgtctttt	2220
gttgatcacc	ctccagattg	gttggaaagaa	gttgggtgaag	gtcttcgcga	gtttttgggc	2280
cttgaagcgg	gcccaccgaa	acaaaaaccc	aatcagcagc	atcaagatca	agcccgtggt	2340
cttgtgctgc	ctggttataa	ctatctcgga	cccgaaacg	gtctcgatcg	aggagagcct	2400
gtcaacaggg	cagacgaggt	cgcgcgagag	cacgacatct	cgtacaacga	gcagcttgag	2460
gcgggagaca	acccttacct	caagtacaac	cacgcggacg	ccgagtttca	ggagaagctc	2520
gccgacgaca	catccttcgg	gggaaacctc	ggaaaggcag	tctttcaggc	caagaaaagg	2580
gttctcgaac	cttttgccct	ggttgaagag	ggtgctaaga	cggccccctac	cggaaagcgg	2640
atagacgacc	actttccaaa	aagaaagaag	gctcggaccg	aagaggactc	caagccttcc	2700
acctcgtcag	acgccgaagc	tggacccagc	ggatcccagc	agctgcaaat	cccagcccaa	2760
ccagcctcaa	gtttggggagc	tgatacaatg	tctgcgggag	gtggcggccc	attgggagac	2820
aataaccaag	gtgccgatgg	agtgggcaat	gcctcgggag	attggcattg	cgattccacg	2880
tggatggggg	acagagtcgt	caccaagtcc	accgaacct	gggtgctgcc	cagctacaac	2940
aaccaccagt	accgagagat	caaaagcggc	tccgtcgacg	gaagcaacgc	caacgcctac	3000
tttgatata	gcaccccttg	gggttacttt	gactttaacc	gcttccacag	ccactggagc	3060
ccccgagact	ggcaaagact	catcaacaac	tactggggct	tcagaccccg	gtccctcaga	3120
gtcaaaatct	tcaacattca	agtcaaagag	gtcacggtgc	aggactccac	caccaccatc	3180
gccaacaacc	tcacctccac	cgtccaagtg	tttacggacg	acgactacca	gctgccctac	3240
gtcgtcggca	acgggaccga	gggatgcctg	ccggccttcc	ctccgcaggt	ctttacgctg	3300
ccgcagtacg	gttacgcgac	gctgaaccgc	gacaacacag	aaaatcccac	cgagaggagc	3360
agcttcttct	gcctagagta	ctttcccagc	aagatgctga	gaacgggcaa	caactttgag	3420
tttacctaca	actttgagga	ggtgcccttc	cactccagct	tcgctcccag	tcagaacctg	3480
ttcaagctgg	ccaacccgct	ggtggaccag	tacttggtacc	gcttcgtgag	cacaaataac	3540
actggcggag	tccagttcaa	caagaacctg	gccgggagat	acgccaacac	ctacaaaaac	3600
tggttcccgg	ggcccatggg	ccgaacccag	ggctggaacc	tgggctccgg	ggtcaaccgc	3660
gccagtgtca	gcgccttcgc	cacgaccaat	aggatggagc	tcgagggcgc	gagttaccag	3720
gtgcccccg	agccgaacgg	catgaccaac	aacctccagg	gcagcaacac	ctatgccctg	3780
gagaacacta	tgatcttcaa	cagccagccg	gcgaacccgg	gcaccaccgc	cacgtacctc	3840
gagggcaaca	tgctcatcac	cagcgagagc	gagacgcagc	cgggtgaaccg	cgtggcgtag	3900
aacgtcggcg	ggcagatggc	caccaacaac	cagagctcca	ccactgcccc	cgcgaccggc	3960
acgtacaacc	tccaggaaat	cgtgcccggc	agcgtgtgga	tggagaggga	cgtgtacctc	4020
caaggaccca	tctgggccaa	gatcccagag	acgggggcgc	actttcaccc	ctctccggcc	4080
atgggaggat	tcggactcaa	acacccaccg	cccatgatgc	tcatcaagaa	cacgcctgtg	4140
cccgaaata	tcaccagctt	ctcggacgtg	cccgtcagca	gcttcatcac	ccagtacagc	4200
accgggcagg	tcaccgtgga	gatggagtgg	gagctcaaga	aggaaaactc	caagagggtg	4260
aaccagaga	tccagtacac	aaacaactac	aacgaccccc	agtttggtga	ctttgccccg	4320
gacagcaccg	gggaatacag	aaccaccaga	cctatcgga	cccgatacct	taccgaccc	4380
ctttaaccca	ttcatgtcgc	ataccctcaa	taaaccgtgt	attcgtgtca	gtaaaatact	4440
gcctcttgtg	gtcattcaat	gaataacagc	ttacaacatc	tacaaaacct	ccttgcttga	4500
gagtgtggca	ctctcccccc	tgctcgcttc	gctcgctcgc	tggctcgttt	ggggggggtg	4560
cagctcaaag	agctgccaga	cgacggccct	ctggccgctc	cccccccaaa	cgagccagcg	4620
agcgagcgaa	cgcgacaggg	gggagagtgc	ca			4652

&lt;210&gt; 2

&lt;211&gt; 390

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:/Note =  
synthetic construct

&lt;400&gt; 2

```

Met Ala Leu Val Asn Trp Leu Val Glu His Gly Ile Thr Ser Glu Lys
 1           5           10           15
Gln Trp Ile Gln Glu Asn Gln Glu Ser Tyr Leu Ser Phe Asn Ser Thr
           20           25           30
Gly Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Thr Lys
           35           40           45
Ile Met Ser Leu Thr Lys Ser Ala Val Asp Tyr Leu Val Gly Ser Ser
           50           55           60
Val Pro Glu Asp Ile Ser Lys Asn Arg Ile Trp Gln Ile Phe Glu Met
65           70           75           80
Asn Gly Tyr Asp Pro Ala Tyr Ala Gly Ser Ile Leu Tyr Gly Trp Cys
           85           90           95
Gln Arg Ser Phe Asn Lys Arg Asn Thr Val Trp Leu Tyr Gly Pro Ala
           100          105          110
Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Thr Val Pro
           115          120          125
Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp
           130          135          140
Cys Val Asp Lys Met Leu Ile Trp Trp Glu Glu Gly Lys Met Thr Asn
145          150          155          160
Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg
           165          170          175
Val Asp Gln Lys Cys Lys Ser Ser Val Gln Ile Asp Ser Thr Pro Val
           180          185          190
Ile Val Thr Ser Asn Thr Asn Met Cys Val Val Val Asp Gly Asn Ser
           195          200          205
Thr Thr Phe Glu His Gln Gln Pro Leu Glu Asp Arg Met Phe Lys Phe
           210          215          220
Glu Leu Thr Lys Arg Leu Pro Pro Asp Phe Gly Lys Ile Thr Lys Gln
225          230          235          240
Glu Val Lys Asp Phe Phe Ala Trp Ala Lys Val Asn Gln Val Pro Val
           245          250          255
Thr His Glu Phe Lys Val Pro Arg Glu Leu Ala Gly Thr Lys Gly Ala
           260          265          270
Glu Lys Ser Leu Lys Arg Pro Leu Gly Asp Val Thr Asn Thr Ser Tyr
           275          280          285
Lys Ser Leu Glu Lys Arg Ala Arg Leu Ser Phe Val Pro Glu Thr Pro
           290          295          300
Arg Ser Ser Asp Val Thr Val Asp Pro Ala Pro Leu Arg Pro Leu Asn
305          310          315          320
Trp Asn Ser Arg Tyr Asp Cys Lys Cys Asp Tyr His Ala Gln Phe Asp
           325          330          335
Asn Ile Ser Asn Lys Cys Asp Glu Cys Glu Tyr Leu Asn Arg Gly Lys
           340          345          350
Asn Gly Cys Ile Cys His Asn Val Thr His Cys Gln Ile Cys His Gly
           355          360          365
Ile Pro Pro Trp Glu Lys Glu Asn Leu Ser Asp Phe Gly Asp Phe Asp
           370          375          380
Asp Ala Asn Lys Glu Gln
385          390

```

&lt;210&gt; 3

&lt;211&gt; 610

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:/Note =

## synthetic construct

&lt;400&gt; 3

```

Met Ala Thr Phe Tyr Glu Val Ile Val Arg Val Pro Phe Asp Val Glu
 1          5          10          15
Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Asp Trp Val Thr Gly
          20          25          30
Gln Ile Trp Glu Leu Pro Pro Glu Ser Asp Leu Asn Leu Thr Leu Val
          35          40          45
Glu Gln Pro Gln Leu Thr Val Ala Asp Arg Ile Arg Arg Val Phe Leu
 50          55          60
Tyr Glu Trp Asn Lys Phe Ser Lys Gln Glu Ser Lys Phe Phe Val Gln
65          70          75          80
Phe Glu Lys Gly Ser Glu Tyr Phe His Leu His Thr Leu Val Glu Thr
          85          90          95
Ser Gly Ile Ser Ser Met Val Leu Gly Arg Tyr Val Ser Gln Ile Arg
          100          105          110
Ala Gln Leu Val Lys Val Val Phe Gln Gly Ile Glu Pro Gln Ile Asn
          115          120          125
Asp Trp Val Ala Ile Thr Lys Val Lys Lys Gly Gly Ala Asn Lys Val
130          135          140
Val Asp Ser Gly Tyr Ile Pro Ala Tyr Leu Leu Pro Lys Val Gln Pro
145          150          155          160
Glu Leu Gln Trp Ala Trp Thr Asn Leu Asp Glu Tyr Lys Leu Ala Ala
          165          170          175
Leu Asn Leu Glu Glu Arg Lys Arg Leu Val Ala Gln Phe Leu Ala Glu
          180          185          190
Ser Ser Gln Arg Ser Gln Glu Ala Ala Ser Gln Arg Glu Phe Ser Ala
          195          200          205
Asp Pro Val Ile Lys Ser Lys Thr Ser Gln Lys Tyr Met Ala Leu Val
210          215          220
Asn Trp Leu Val Glu His Gly Ile Thr Ser Glu Lys Gln Trp Ile Gln
225          230          235          240
Glu Asn Gln Glu Ser Tyr Leu Ser Phe Asn Ser Thr Gly Asn Ser Arg
          245          250          255
Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Thr Lys Ile Met Ser Leu
          260          265          270
Thr Lys Ser Ala Val Asp Tyr Leu Val Gly Ser Ser Val Pro Glu Asp
          275          280          285
Ile Ser Lys Asn Arg Ile Trp Gln Ile Phe Glu Met Asn Gly Tyr Asp
290          295          300
Pro Ala Tyr Ala Gly Ser Ile Leu Tyr Gly Trp Cys Gln Arg Ser Phe
305          310          315          320
Asn Lys Arg Asn Thr Val Trp Leu Tyr Gly Pro Ala Thr Thr Gly Lys
          325          330          335
Thr Asn Ile Ala Glu Ala Ile Ala His Thr Val Pro Phe Tyr Gly Cys
          340          345          350
Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp Cys Val Asp Lys
          355          360          365
Met Leu Ile Trp Trp Glu Glu Gly Lys Met Thr Asn Lys Val Val Glu
370          375          380
Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg Val Asp Gln Lys
385          390          395          400
Cys Lys Ser Ser Val Gln Ile Asp Ser Thr Pro Val Ile Val Thr Ser
          405          410          415
Asn Thr Asn Met Cys Val Val Val Asp Gly Asn Ser Thr Thr Phe Glu
          420          425          430

```

His Gln Gln Pro Leu Glu Asp Arg Met Phe Lys Phe Glu Leu Thr Lys  
                   435                                  440                                  445  
 Arg Leu Pro Pro Asp Phe Gly Lys Ile Thr Lys Gln Glu Val Lys Asp  
                   450                                  455                                  460  
 Phe Phe Ala Trp Ala Lys Val Asn Gln Val Pro Val Thr His Glu Phe  
 465                                  470                                  475                                  480  
 Lys Val Pro Arg Glu Leu Ala Gly Thr Lys Gly Ala Glu Lys Ser Leu  
                                   485                                  490                                  495  
 Lys Arg Pro Leu Gly Asp Val Thr Asn Thr Ser Tyr Lys Ser Leu Glu  
                                   500                                  505                                  510  
 Lys Arg Ala Arg Leu Ser Phe Val Pro Glu Thr Pro Arg Ser Ser Asp  
                                   515                                  520                                  525  
 Val Thr Val Asp Pro Ala Pro Leu Arg Pro Leu Asn Trp Asn Ser Arg  
                                   530                                  535                                  540  
 Tyr Asp Cys Lys Cys Asp Tyr His Ala Gln Phe Asp Asn Ile Ser Asn  
 545                                  550                                  555                                  560  
 Lys Cys Asp Glu Cys Glu Tyr Leu Asn Arg Gly Lys Asn Gly Cys Ile  
                                   565                                  570                                  575  
 Cys His Asn Val Thr His Cys Gln Ile Cys His Gly Ile Pro Pro Trp  
                                   580                                  585                                  590  
 Glu Lys Glu Asn Leu Ser Asp Phe Gly Asp Phe Asp Asp Ala Asn Lys  
                                   595                                  600                                  605  
 Glu Gln  
                   610

&lt;210&gt; 4

&lt;211&gt; 724

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:/Note =  
 synthetic construct

&lt;400&gt; 4

Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu  
 1                                  5                                  10                                  15  
 Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys  
                                   20                                  25                                  30  
 Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly  
                                   35                                  40                                  45  
 Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val  
                                   50                                  55                                  60  
 Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu  
 65                                  70                                  75                                  80  
 Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp  
                                   85                                  90                                  95  
 Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn  
                                   100                                  105                                  110  
 Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Phe  
                                   115                                  120                                  125  
 Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg Ile  
                                   130                                  135                                  140  
 Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp Ser  
 145                                  150                                  155                                  160  
 Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser Gln  
                                   165                                  170                                  175



Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp Thr  
 180 185 190  
 Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly Ala  
 195 200 205  
 Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr Trp  
 210 215 220  
 Met Gly Asp Arg Val Val Thr Lys Ser Thr Arg Thr Trp Val Leu Pro  
 225 230 235 240  
 Ser Tyr Asn Asn His Gln Tyr Arg Glu Ile Lys Ser Gly Ser Val Asp  
 245 250 255  
 Gly Ser Asn Ala Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr  
 260 265 270  
 Phe Asp Phe Asn Arg Phe His Ser His Trp Ser Pro Arg Asp Trp Gln  
 275 280 285  
 Arg Leu Ile Asn Asn Tyr Trp Gly Phe Arg Pro Arg Ser Leu Arg Val  
 290 295 300  
 Lys Ile Phe Asn Ile Gln Val Lys Glu Val Thr Val Gln Asp Ser Thr  
 305 310 315 320  
 Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp  
 325 330 335  
 Asp Asp Tyr Gln Leu Pro Tyr Val Val Gly Asn Gly Thr Glu Gly Cys  
 340 345 350  
 Leu Pro Ala Phe Pro Pro Gln Val Phe Thr Leu Pro Gln Tyr Gly Tyr  
 355 360 365  
 Ala Thr Leu Asn Arg Asp Asn Thr Glu Asn Pro Thr Glu Arg Ser Ser  
 370 375 380  
 Phe Phe Cys Leu Glu Tyr Phe Pro Ser Lys Met Leu Arg Thr Gly Asn  
 385 390 395 400  
 Asn Phe Glu Phe Thr Tyr Asn Phe Glu Glu Val Pro Phe His Ser Ser  
 405 410 415  
 Phe Ala Pro Ser Gln Asn Leu Phe Lys Leu Ala Asn Pro Leu Val Asp  
 420 425 430  
 Gln Tyr Leu Tyr Arg Phe Val Ser Thr Asn Asn Thr Gly Gly Val Gln  
 435 440 445  
 Phe Asn Lys Asn Leu Ala Gly Arg Tyr Ala Asn Thr Tyr Lys Asn Trp  
 450 455 460  
 Phe Pro Gly Pro Met Gly Arg Thr Gln Gly Trp Asn Leu Gly Ser Gly  
 465 470 475 480  
 Val Asn Arg Ala Ser Val Ser Ala Phe Ala Thr Thr Asn Arg Met Glu  
 485 490 495  
 Leu Glu Gly Ala Ser Tyr Gln Val Pro Pro Gln Pro Asn Gly Met Thr  
 500 505 510  
 Asn Asn Leu Gln Gly Ser Asn Thr Tyr Ala Leu Glu Asn Thr Met Ile  
 515 520 525  
 Phe Asn Ser Gln Pro Ala Asn Pro Gly Thr Thr Ala Thr Tyr Leu Glu  
 530 535 540  
 Gly Asn Met Leu Ile Thr Ser Glu Ser Glu Thr Gln Pro Val Asn Arg  
 545 550 555 560  
 Val Ala Tyr Asn Val Gly Gly Gln Met Ala Thr Asn Asn Gln Ser Ser  
 565 570 575  
 Thr Thr Ala Pro Ala Thr Gly Thr Tyr Asn Leu Gln Glu Ile Val Pro  
 580 585 590  
 Gly Ser Val Trp Met Glu Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp  
 595 600 605  
 Ala Lys Ile Pro Glu Thr Gly Ala His Phe His Pro Ser Pro Ala Met  
 610 615 620  
 Gly Gly Phe Gly Leu Lys His Pro Pro Pro Met Met Leu Ile Lys Asn  
 625 630 635 640



Thr Pro Val Pro Gly Asn Ile Thr Ser Phe Ser Asp Val Pro Val Ser  
                                 645                                650                                655  
 Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Thr Val Glu Met Glu  
                                 660                                665                                670  
 Trp Glu Leu Lys Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln  
                                 675                                680                                685  
 Tyr Thr Asn Asn Tyr Asn Asp Pro Gln Phe Val Asp Phe Ala Pro Asp  
                                 690                                695                                700  
 Ser Thr Gly Glu Tyr Arg Thr Thr Arg Pro Ile Gly Thr Arg Tyr Leu  
                                 705                                710                                715                                720  
 Thr Arg Pro Leu

<210> 5  
 <211> 588  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:/Note =  
           synthetic construct

<400> 5  
 Thr Ala Pro Thr Gly Lys Arg Ile Asp Asp His Phe Pro Lys Arg Lys  
   1                                5                                10                                15  
 Lys Ala Arg Thr Glu Glu Asp Ser Lys Pro Ser Thr Ser Ser Asp Ala  
                                 20                                25                                30  
 Glu Ala Gly Pro Ser Gly Ser Gln Gln Leu Gln Ile Pro Ala Gln Pro  
                                 35                                40                                45  
 Ala Ser Ser Leu Gly Ala Asp Thr Met Ser Ala Gly Gly Gly Gly Pro  
                                 50                                55                                60  
 Leu Gly Asp Asn Asn Gln Gly Ala Asp Gly Val Gly Asn Ala Ser Gly  
   65                                70                                75                                80  
 Asp Trp His Cys Asp Ser Thr Trp Met Gly Asp Arg Val Val Thr Lys  
                                 85                                90                                95  
 Ser Thr Arg Thr Trp Val Leu Pro Ser Tyr Asn Asn His Gln Tyr Arg  
                                 100                                105                                110  
 Glu Ile Lys Ser Gly Ser Val Asp Gly Ser Asn Ala Asn Ala Tyr Phe  
                                 115                                120                                125  
 Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Ser  
                                 130                                135                                140  
 His Trp Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Tyr Trp Gly  
   145                                150                                155                                160  
 Phe Arg Pro Arg Ser Leu Arg Val Lys Ile Phe Asn Ile Gln Val Lys  
                                 165                                170                                175  
 Glu Val Thr Val Gln Asp Ser Thr Thr Thr Ile Ala Asn Asn Leu Thr  
                                 180                                185                                190  
 Ser Thr Val Gln Val Phe Thr Asp Asp Asp Tyr Gln Leu Pro Tyr Val  
                                 195                                200                                205  
 Val Gly Asn Gly Thr Glu Gly Cys Leu Pro Ala Phe Pro Pro Gln Val  
                                 210                                215                                220  
 Phe Thr Leu Pro Gln Tyr Gly Tyr Ala Thr Leu Asn Arg Asp Asn Thr  
   225                                230                                235                                240  
 Glu Asn Pro Thr Glu Arg Ser Ser Phe Phe Cys Leu Glu Tyr Phe Pro  
                                 245                                250                                255  
 Ser Lys Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Thr Tyr Asn Phe  
                                 260                                265                                270

Glu Glu Val Pro Phe His Ser Ser Phe Ala Pro Ser Gln Asn Leu Phe  
 275 280 285  
 Lys Leu Ala Asn Pro Leu Val Asp Gln Tyr Leu Tyr Arg Phe Val Ser  
 290 295 300  
 Thr Asn Asn Thr Gly Gly Val Gln Phe Asn Lys Asn Leu Ala Gly Arg  
 305 310 315 320  
 Tyr Ala Asn Thr Tyr Lys Asn Trp Phe Pro Gly Pro Met Gly Arg Thr  
 325 330 335  
 Gln Gly Trp Asn Leu Gly Ser Gly Val Asn Arg Ala Ser Val Ser Ala  
 340 345 350  
 Phe Ala Thr Thr Asn Arg Met Glu Leu Glu Gly Ala Ser Tyr Gln Val  
 355 360 365  
 Pro Pro Gln Pro Asn Gly Met Thr Asn Asn Leu Gln Gly Ser Asn Thr  
 370 375 380  
 Tyr Ala Leu Glu Asn Thr Met Ile Phe Asn Ser Gln Pro Ala Asn Pro  
 385 390 395 400  
 Gly Thr Thr Ala Thr Tyr Leu Glu Gly Asn Met Leu Ile Thr Ser Glu  
 405 410 415  
 Ser Glu Thr Gln Pro Val Asn Arg Val Ala Tyr Asn Val Gly Gly Gln  
 420 425 430  
 Met Ala Thr Asn Asn Gln Ser Ser Thr Thr Ala Pro Ala Thr Gly Thr  
 435 440 445  
 Tyr Asn Leu Gln Glu Ile Val Pro Gly Ser Val Trp Met Glu Arg Asp  
 450 455 460  
 Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro Glu Thr Gly Ala  
 465 470 475 480  
 His Phe His Pro Ser Pro Ala Met Gly Gly Phe Gly Leu Lys His Pro  
 485 490 495  
 Pro Pro Met Met Leu Ile Lys Asn Thr Pro Val Pro Gly Asn Ile Thr  
 500 505 510  
 Ser Phe Ser Asp Val Pro Val Ser Ser Phe Ile Thr Gln Tyr Ser Thr  
 515 520 525  
 Gly Gln Val Thr Val Glu Met Glu Trp Glu Leu Lys Lys Glu Asn Ser  
 530 535 540  
 Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Asn Asn Tyr Asn Asp Pro  
 545 550 555 560  
 Gln Phe Val Asp Phe Ala Pro Asp Ser Thr Gly Glu Tyr Arg Thr Thr  
 565 570 575  
 Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu  
 580 585

&lt;210&gt; 6

&lt;211&gt; 532

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:/Note =  
 synthetic construct

&lt;400&gt; 6

Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly Ala  
 1 5 10 15  
 Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr Trp  
 20 25 30  
 Met Gly Asp Arg Val Val Thr Lys Ser Thr Arg Thr Trp Val Leu Pro  
 35 40 45

Ser	Tyr	Asn	Asn	His	Gln	Tyr	Arg	Glu	Ile	Lys	Ser	Gly	Ser	Val	Asp
50						55				60					
Gly	Ser	Asn	Ala	Asn	Ala	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr
65					70					75					80
Phe	Asp	Phe	Asn	Arg	Phe	His	Ser	His	Trp	Ser	Pro	Arg	Asp	Trp	Gln
			85						90					95	
Arg	Leu	Ile	Asn	Asn	Tyr	Trp	Gly	Phe	Arg	Pro	Arg	Ser	Leu	Arg	Val
			100					105					110		
Lys	Ile	Phe	Asn	Ile	Gln	Val	Lys	Glu	Val	Thr	Val	Gln	Asp	Ser	Thr
		115						120				125			
Thr	Thr	Ile	Ala	Asn	Asn	Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Thr	Asp
		130				135					140				
Asp	Asp	Tyr	Gln	Leu	Pro	Tyr	Val	Val	Gly	Asn	Gly	Thr	Glu	Gly	Cys
145					150					155					160
Leu	Pro	Ala	Phe	Pro	Pro	Gln	Val	Phe	Thr	Leu	Pro	Gln	Tyr	Gly	Tyr
			165						170					175	
Ala	Thr	Leu	Asn	Arg	Asp	Asn	Thr	Glu	Asn	Pro	Thr	Glu	Arg	Ser	Ser
			180					185					190		
Phe	Phe	Cys	Leu	Glu	Tyr	Phe	Pro	Ser	Lys	Met	Leu	Arg	Thr	Gly	Asn
		195					200					205			
Asn	Phe	Glu	Phe	Thr	Tyr	Asn	Phe	Glu	Glu	Val	Pro	Phe	His	Ser	Ser
		210				215					220				
Phe	Ala	Pro	Ser	Gln	Asn	Leu	Phe	Lys	Leu	Ala	Asn	Pro	Leu	Val	Asp
225					230					235					240
Gln	Tyr	Leu	Tyr	Arg	Phe	Val	Ser	Thr	Asn	Asn	Thr	Gly	Gly	Val	Gln
			245						250					255	
Phe	Asn	Lys	Asn	Leu	Ala	Gly	Arg	Tyr	Ala	Asn	Thr	Tyr	Lys	Asn	Trp
		260						265					270		
Phe	Pro	Gly	Pro	Met	Gly	Arg	Thr	Gln	Gly	Trp	Asn	Leu	Gly	Ser	Gly
		275					280					285			
Val	Asn	Arg	Ala	Ser	Val	Ser	Ala	Phe	Ala	Thr	Thr	Asn	Arg	Met	Glu
		290				295					300				
Leu	Glu	Gly	Ala	Ser	Tyr	Gln	Val	Pro	Pro	Gln	Pro	Asn	Gly	Met	Thr
305					310					315					320
Asn	Asn	Leu	Gln	Gly	Ser	Asn	Thr	Tyr	Ala	Leu	Glu	Asn	Thr	Met	Ile
			325						330					335	
Phe	Asn	Ser	Gln	Pro	Ala	Asn	Pro	Gly	Thr	Thr	Ala	Thr	Tyr	Leu	Glu
		340						345					350		
Gly	Asn	Met	Leu	Ile	Thr	Ser	Glu	Ser	Glu	Thr	Gln	Pro	Val	Asn	Arg
		355					360					365			
Val	Ala	Tyr	Asn	Val	Gly	Gly	Gln	Met	Ala	Thr	Asn	Asn	Gln	Ser	Ser
		370				375					380				
Thr	Thr	Ala	Pro	Ala	Thr	Gly	Thr	Tyr	Asn	Leu	Gln	Glu	Ile	Val	Pro
385					390					395					400
Gly	Ser	Val	Trp	Met	Glu	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp
			405						410					415	
Ala	Lys	Ile	Pro	Glu	Thr	Gly	Ala	His	Phe	His	Pro	Ser	Pro	Ala	Met
			420					425					430		
Gly	Gly	Phe	Gly	Leu	Lys	His	Pro	Pro	Pro	Met	Met	Leu	Ile	Lys	Asn
		435					440					445			
Thr	Pro	Val	Pro	Gly	Asn	Ile	Thr	Ser	Phe	Ser	Asp	Val	Pro	Val	Ser
		450				455					460				
Ser	Phe	Ile	Thr	Gln	Tyr	Ser	Thr	Gly	Gln	Val	Thr	Val	Glu	Met	Glu
465					470					475					480
Trp	Glu	Leu	Lys	Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Ile	Gln
			485						490					495	
Tyr	Thr	Asn	Asn	Tyr	Asn	Asp	Pro	Gln	Phe	Val	Asp	Phe	Ala	Pro	Asp
			500					505					510		

Ser Thr Gly Glu Tyr Arg Thr Thr Arg Pro Ile Gly Thr Arg Tyr Leu  
 515 520 525  
 Thr Arg Pro Leu  
 530

<210> 7  
 <211> 2307  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:/Note =  
 synthetic construct

<400> 7  
 aggtcttcat ttgttcccga gacgcctcgc agttcagacg tgactgttga tcccgtcct 60  
 ctgcgaccgc tcaattggaa ttcaagtaaa taaagcgagt agtcatgtct tttgttgatc 120  
 accctccaga ttggttggaa gaagttggtg aaggtcttcg cgagtttttg ggccttgaag 180  
 cgggcccacc gaaacaaaaa cccaatcagc agcatcaaga tcaagcccgt ggtcttgtgc 240  
 tgcttggtta taactatctc ggacccggaa acggtctcga tcgaggagag cctgtcaaca 300  
 gggcagacga ggtcgcgcga gagcacgaca tctcgtacaa cgagcagctt gaggcgggag 360  
 acaacccta cctcaagtac aaccacgcgg acgccgagtt tcaggagaag ctccgccgacg 420  
 acacatcctt cgggggaaac ctccgaaagg cagtctttca ggccaagaaa agggttctcg 480  
 aaccttttgg cctggttgaa gaggggtgcta agacggcccc taccggaaag cggatagacg 540  
 accactttcc aaaaagaaaag aaggctcggg ccgaagagga ctccaagcct tccacctcgt 600  
 cagacgccga agctggaccc agcggatccc agcagctgca aatcccagcc caaccagcct 660  
 caagtttggg agctgataca atgtctgcgg gaggtggcgg ccatttgggc gacaataacc 720  
 aaggtgccga tggagtgggc aatgcctcgg gagattggca ttgcgattcc acgtggatgg 780  
 gggacagagt cgtcaccaag tccaccgaa cctgggtgct gccagctac aacaaccacc 840  
 agtaccgaga gatcaaaagc ggctccgtcg acggaagcaa cgccaacgcc tactttggat 900  
 acagcacccc ctgggggtac tttgacttta accgcttcca cagccactgg agcccccgag 960  
 actggcaaag actcatcaac aactactggg gcttcagacc ccggtccctc agagtcaaaa 1020  
 tcttcaacat tcaagtcaaa gaggtcacgg tgcaggactc caccaccacc atcgccaaca 1080  
 acctcacctc caccgtccaa gtgtttacgg acgacgacta ccagctgccc tacgtcgtcg 1140  
 gcaacgggac cgagggatgc ctgccggcct tccctccgca ggtctttacg ctgccgcagt 1200  
 acggttacgc gacgctgaac cgcgacaaca cagaaaatcc caccgagagg agcagcttct 1260  
 tctgcctaga gtactttccc agcaagatgc tgagaacggg caacaacttt gagtttacct 1320  
 acaactttga ggaggtgccc ttccactcca gcttcgctcc cagtcagaac ctgttcaagc 1380  
 tggccaaccc gctggtggac cagtacttgt accgcttcgt gagcacaat aacactggcg 1440  
 gagtccagtt caacaagaac ctggccggga gatacgccaa cacctacaaa aactggttcc 1500  
 cggggcccat gggccgaacc cagggctgga acctgggctc cggggtcaac cgcgccagtg 1560  
 tcagcgcctt cgccacgacc aataggatgg agctcgaggg cgcgagttac caggtgcccc 1620  
 cgcagccgaa cggcatgacc aacaacctcc agggcagcaa cacctatgcc ctggagaaca 1680  
 ctatgatctt caacagccag ccggcgaacc cgggcaccac cgccacgtac ctcgagggca 1740  
 acatgctcat caccagcgag agcgagacgc agccggtgaa ccgcgtggcg tacaacgtcg 1800  
 gcgggcagat ggccaccaac aaccagagct ccaccactgc ccccgcgacc ggcacgtaca 1860  
 acctccagga aatcgtgccc ggcagcgtgt ggatggagag ggacgtgtac ctccaaggac 1920  
 ccatctgggc caagatccca gagacggggg cgcactttca cccctctccg gccatgggag 1980  
 gattcggact caaacaccca ccgcccatga tgctcatcaa gaacacgcct gtgcccggaa 2040  
 atatcaccag cttctcggac gtgcccgtca gcagcttcat caccagtac agcaccgggc 2100  
 aggtcaccgt ggagatggag tgggagctca agaaggaaaa ctccaagagg tggaaaccag 2160  
 agatccagta cacaacaac tacaacgacc ccagtttgt ggactttgcc ccggacagca 2220  
 ccggggaata cagaaccacc agacctatcg gaacccgata ccttaccgga cccctttaac 2280  
 ccattcatgt cgcataccct caataaa 2307

<210> 8  
 <211> 2264  
 <212> DNA

## &lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:/Note =  
synthetic construct

&lt;400&gt; 8

aggctctcat	ttgttcccga	gacgcctcgc	agttcagacg	tgactgttga	tcccgcctcct	60
ctgcgaccgc	tcaattggaa	ttcaagattg	gttgggaagaa	gttgggtgaag	gtcttcgcga	120
gtttttgggc	cttgaagcgg	gcccaccgaa	acaaaaaccc	aatcagcagc	atcaagatca	180
agcccgtggt	cttgtgctgc	ctgggtataa	ctatctcgga	cccggaacg	gtctcgatcg	240
aggagagcct	gtcaacaggg	cagacgaggt	cgcgcgagag	cacgacatct	cgtacaacga	300
gcagcttgag	gcgggagaca	acccctacct	caagtacaac	cacgcggacg	ccgagtttca	360
ggagaagctc	gccgacgaca	catccttcgg	gggaaacctc	ggaaaggcag	tctttcaggc	420
caagaaaagg	gttctcgaac	cttttggcct	ggttgaagag	ggtgctaaga	cggcccctac	480
cggaaagcgg	atagacgacc	actttccaaa	aagaaagaag	gctcggaccg	aagaggactc	540
caagccttcc	acctcgtcag	acgccgaagc	tggaccacgc	ggatcccagc	agctgcaa at	600
cccagcccaa	ccagcctcaa	gtttgggagc	tgatacaatg	tctgcgggag	gtggcgggccc	660
attgggcgac	aataaccaag	gtgccgatgg	agtgggcaat	gcctcgggag	attggcattg	720
cgattccacg	tggatggggg	acagagtcgt	caccaagtec	acccgaacct	gggtgctgcc	780
cagctacaac	aaccaccagt	accgagagat	caaaagcggc	tccgtcgacg	gaagcaacgc	840
caacgcctac	tttggataca	gcacccccctg	ggggtacttt	gactttaacc	gcttccacag	900
ccactggagc	ccccgagact	ggcaaagact	catcaacaac	tactggggct	tcagaccccg	960
gtccctcaga	gtcaaaatct	tcaacattca	agtcaaagag	gtcacgggtgc	aggactccac	1020
caccaccatc	gccaaacaacc	tcacctccac	cgtccaagtg	tttacggacg	acgactacca	1080
gctgccctac	gtcgtcggca	acgggaccga	gggatgcctg	ccggccttcc	ctccgcaggt	1140
ctttacgctg	ccgcagtagc	gttacgcgac	gctgaaccgc	gacaacacag	aaaatcccac	1200
cgagaggagc	agcttcttct	gcctagagta	ctttcccagc	aagatgctga	gaacggggcaa	1260
caactttgag	tttacctaca	actttgagga	ggtgcccttc	cactccagct	tcgctcccag	1320
tcagaacctg	ttcaagctgg	ccaacccgct	ggtggaccag	tacttgtacc	gcttcgtgag	1380
cacaaataac	actggcggag	tccagttcaa	caagaacctg	gccgggagat	acgccaacac	1440
ctacaaaaac	tgggtcccgg	ggcccatggg	ccgaacccag	ggctggaacc	tgggctccgg	1500
ggtcaaccgc	gccagtgtca	gcgccttcgc	cacgaccaat	aggatggagc	tcgagggcgc	1560
gagttaccag	gtgccccgcg	agccgaacgg	catgaccaac	aacctccagg	gcagcaacac	1620
ctatgccctg	gagaacacta	tgatcttcaa	cagccagccg	gcgaacccgg	gcaccaccgc	1680
cacgtacctc	gagggcaaca	tgctcatcac	cagcgagagc	gagacgcagc	cgggtgaaccg	1740
cgtggcgtac	aacgtcggcg	ggcagatggc	caccaacaac	cagagctcca	ccactgcccc	1800
cgcgaccggc	acgtacaacc	tccaggaaat	cgtgcccggc	agcgtgtgga	tggagaggga	1860
cgtgtacctc	caaggaccca	tctggggcaa	gatcccagag	acggggggcg	actttcaccc	1920
ctctccggcc	atggggcggat	tcggactcaa	acacccaccg	cccatgatgc	tcatacaaga	1980
cacgcctgtg	cccggaaata	tcaccagctt	ctcggacgtg	cccgtcagca	gcttcatcac	2040
ccagtacagc	accgggcagg	tcaccgtgga	gatggagtgg	gagctcaaga	aggaaaactc	2100
caagaggtgg	aaccagaga	tccagtacac	aaacaactac	aacgaccccc	agtttgtgga	2160
ctttgccccg	gacagcaccg	gggaatacag	aaccaccaga	cctatcgga	cccgatacct	2220
tacccgaccc	ctttaaccca	ttcatgtcgc	ataccctcaa	taaa		2264

&lt;210&gt; 9

&lt;211&gt; 2264

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:/Note =  
synthetic construct

&lt;400&gt; 9

aggctctcat	ttgttcccga	gacgcctcgc	agttcagacg	tgactgttga	tcccgcctcct	60
ctgcgaccgc	tcaattggaa	ttcaagattg	gttgggaagaa	gttgggtgaag	gtcttcgcga	120



gtttttgggc	cttgaagcgg	gcccaccgaa	accaaaaccc	aatcagcagc	atcaagatca	180
agcccggtgt	cttgtgctgc	ctgggtataa	ctatctcgga	cccggaaacg	gtctcgatcg	240
aggagagcct	gtcaacaggg	cagacgaggt	cgcgcgagag	cacgacatct	cgtacaacga	300
gcagcttgag	gcgggagaca	acccctacct	caagtacaac	cacgcggacg	ccgagtttca	360
ggagaagctc	gccgacgaca	catccttcgg	gggaaacctc	ggaaaggcag	tctttcaggc	420
caagaaaagg	gttctcgaac	cttttgacct	ggttgaagag	gggtgctaaga	cggccccctac	480
cggaaagcgg	atagacgacc	actttccaaa	aagaaagaag	gctcggaccg	aagaggactc	540
caagccttcc	acctcgtcag	acgccgaagc	tggaccacgc	ggatcccagc	agctgcaaat	600
cccagcccaa	ccagcctcaa	gtttgggagc	tgatacaatg	tctgcgggag	gtggcgggccc	660
attgggagac	aataaccaag	gtgccgatgg	agtgggcaat	gcctcgggag	attggcattg	720
cgattccacg	tggatggggg	acagagtcgt	caccaagtcg	acccgaacct	gggtgctgcc	780
cagctacaac	aaccaccagt	accgagagat	caaaagcggc	tccgtcgacg	gaagcaacgc	840
caacgcctac	tttgatatac	gcacccctcg	gggtgacttt	gactttaacc	gcttccacag	900
ccactggagc	ccccgagact	ggcaaagact	catcaacaac	tactgggggt	tcagaccccg	960
gtccctcaga	gtcaaaaatct	tcaacattca	agtcaaagag	gtcacggtgc	aggactccac	1020
caccaccatc	gccaaacaac	tcacctccac	cgtccaagtg	tttacggacg	acgactacca	1080
gctgccctac	gtcgctcgga	acgggaccga	gggatgcctg	ccggccttcc	ctccgcaggt	1140
ctttacgctg	ccgcagtagc	gttacgcgac	gctgaaccgc	gacaacacag	aaaatcccac	1200
cgagaggagc	agcttcttct	gcctagagta	ctttcccagc	aagatgctga	gaacgggcaa	1260
caactttgag	tttacctaca	actttgagga	gggtgccctc	cactccagct	tcgctcccag	1320
tcagaacctg	ttcaagctgg	ccaacccgct	gggtggaccag	tacttggtacc	gcttcgtgag	1380
cacaaataac	actggcggag	tccagttcaa	caagaacctg	gccgggagat	acgccaacac	1440
ctacaaaaac	tggttcccgg	ggcccatggg	ccgaacccag	ggctggaacc	tgggctccgg	1500
ggtcaaccgc	gccagtgtca	gcgccttcgc	cacgaccaat	aggatggagc	tcgagggcgc	1560
gagttaccag	gtgccccgcg	agccgaacgg	catgaccaac	aacctccagg	gcagcaacac	1620
ctatgccttg	gagaacacta	tgatcttcaa	cagccagccg	gcgaacccgg	gcaccaccgc	1680
cacgtacctc	gagggcaaca	tgctcatcac	cagcgagagc	gagacgcagc	cggtgaaccg	1740
cgtggcgtag	aacgtcggcg	ggcagatggc	caccaacaac	cagagctcca	ccactgcccc	1800
cgcgaccggc	acgtacaacc	tccaggaaat	cgtgcccggc	agcgtgtgga	tggagaggga	1860
cgtgtacctc	caaggaccca	tctggggcaa	gatcccagag	acgggggcgc	actttcaccc	1920
ctctccggcc	atgggcggat	tcggactcaa	acaccaccgc	cccatgatgc	tcatacaaga	1980
cacgcctgtg	cccggaaata	tcaccagctt	ctcggacgtg	cccgtcagca	gcttcataac	2040
ccagtacagc	accgggcagg	tcaccgtgga	gatggagtgg	gagctcaaga	aggaaaactc	2100
caagaggtgg	aaccagagag	tccagtacac	aaacaactac	aacgaccccc	agtttggtga	2160
ctttgccccg	gacagcaccg	gggaatacag	aaccaccaga	cctatcgga	cccataacct	2220
taccggaccc	ctttaaccac	ttcatgtcgc	ataccctcaa	taaa		2264

&lt;210&gt; 10

&lt;211&gt; 1292

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:/Note =  
synthetic construct

&lt;400&gt; 10

agcgcaaacg	gctcgtcgcg	cagtttcttg	cagaatcctc	gcagcgctcg	caggaggcgg	60
cttcgcagcg	tgagttctcg	gctgaccggg	tcatacaaaag	caagacttcc	cagaaatata	120
tggcgctcgt	caactggctc	gtggagcagc	gcataccttc	cgagaagcag	tggatccagg	180
aaaatcagga	gagctacctc	tccttcaact	ccaccggcaa	ctctcggagc	cagatcaagg	240
ccgcgctcga	caacgcgacc	aaaattatga	gtctgacaaa	aagcgcggtg	gactacctcg	300
tggggagctc	cgttcccagag	gacatttcaa	aaaacagaat	ctggcaaatt	tttgagatga	360
atggctacga	cccggcctac	gcgggatcca	tcctctacgg	ctgggtgtag	cgctccttca	420
acaagaggaa	caccgtcttg	ctctacggac	ccgccacgac	cggcaagacc	aacatcgagg	480
aggccatcgc	ccacactgtg	cccttttacg	gctgcgtgaa	ctggaccaat	gaaaactttc	540
cctttaatga	ctgtgtggac	aaaatgctca	tttggtggga	ggagggaaag	atgaccaaca	600
aggtgggtga	atccgccaag	gccatcctgg	ggggctcaaa	gggtcggggtc	gatacagaat	660



gtaaatcctc	tgttcaaatt	gattctaccc	ctgtcattgt	aacttccaat	acaaacatgt	720
gtgtggtggt	ggatgggaat	tccacgacct	ttgaacacca	gcagccgctg	gaggaccgca	780
tgttcaaatt	tgaactgact	aagcggctcc	cgccagattt	tggcaagatt	actaagcagg	840
aagtcaagga	ctttttttgct	tgggcaaagg	tcaatcaggt	gccggtgact	cacgagttta	900
aagttcccag	ggaattggcg	ggaactaaag	gggcggagaa	atctctaaaa	cgcccactgg	960
gtgacgtcac	caatactagc	tataaaagtc	tggagaagcg	ggccaggctc	tcatttggtc	1020
ccgagacgcc	tcgcagttca	gacgtgactg	ttgatcccgc	tcctctgcga	ccgctcaatt	1080
ggaattcaag	gtatgattgc	aaatgtgact	atcatgctca	atttgacaac	atttctaaca	1140
aatgtgatga	atgtgaatat	ttgaatcggg	gcaaaaatgg	atgtatctgt	cacaatgtaa	1200
ctcactgtca	aattttgtcat	gggattcccc	cctgggaaaa	ggaaaacttg	tcagattttg	1260
gggattttga	cgatgccaat	aaagaacagt	aa			1292

&lt;210&gt; 11

&lt;211&gt; 1870

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:/Note =  
synthetic construct

&lt;400&gt; 11

attctttgct	ctggactgct	agaggaccct	cgctgccatg	gctaccttct	atgaagtcac	60
tgttcgcgtc	ccatttgacg	tggaggaaca	tctgcctgga	atttctgaca	gctttgtgga	120
ctgggtaact	ggtcaaattt	gggagctgcc	tccagagtca	gatttaaatt	tgactctggt	180
tgaacagcct	cagttgacgg	tggctgatag	aattcgcgcg	gtgttcctgt	acgagtgga	240
caaattttcc	aagcaggagt	ccaaattctt	tgtgcagttt	gaaaagggat	ctgaatat	300
tcactctcac	acgcttgtgg	agacctccgg	catctcttcc	atggctctcg	gccgctacgt	360
gagtcagatt	cgcgccacgc	tggtgaaagt	ggtcttccag	ggaattgaac	cccagatcaa	420
cgactgggtc	gccatcacca	aggtaaagaa	gggcggagcc	aataaggtgg	tggattctgg	480
gtatattccc	gcctacctgc	tgccgaaggt	ccaaccggag	cttcagtggg	cgtggacaaa	540
cctggacgag	tataaattgg	ccgccctgaa	tctggaggag	cgcaaaccgg	tcgtcgcgca	600
gtttctggca	gaatcctcgc	agcgtctcga	ggaggcggct	tcgcagcgtg	agttctcggc	660
tgacccggtc	atcaaaagca	agacttccca	gaaatacatg	gcgctcgtca	actggctcgt	720
ggagcacggc	atcacttccg	agaagcagtg	gatccaggaa	aatcaggaga	gctacctctc	780
cttcaactcc	accggcaact	ctcggagcca	gatcaaggcc	gcgctcgaca	acgcgaccaa	840
aattatgagt	ctgacaaaaa	gcgcgggtgga	ctacctcgtg	gggagctccg	ttcccagagga	900
catttcaaaa	aacagaatct	ggcaaatttt	tgagatgaat	ggctacgacc	cggcctacgc	960
gggatccatc	ctctacggct	ggtgtcagcg	ctccttcaac	aagaggaaca	ccgtctggct	1020
ctacggaccc	gccacgaccg	gcaagaccaa	catcgcggag	gccatcgccc	acactgtgcc	1080
cttttacggc	tgcgtgaact	ggaccaatga	aaactttccc	tttaattgact	gtgtggacaa	1140
aatgctcatt	tgggtgggag	agggaaagat	gaccaacaag	gtgggtgaat	ccgccaaggc	1200
catcctgggg	ggctcaaagg	tgcgggtcga	tcagaaatgt	aaatcctctg	ttcaaattga	1260
ttctaccctt	gtcattgtaa	cttccaatac	aaacatgtgt	gtgggtgggtg	atgggaattc	1320
cacgaccttt	gaacaccagc	agccgctgga	ggaccgcatg	ttcaaatttg	aactgactaa	1380
gcggctcccc	ccagattttg	gcaagattac	taagcaggaa	gtcaaggact	tttttgcttg	1440
ggcaaaggtc	aatcagggtg	cggtgactca	cgagttaaaa	gttcccaggg	aattggcggg	1500
aactaaaggg	gcggagaaat	ctctaaaacg	cccactgggt	gacgtcacca	atactagcta	1560
taaaagtctg	gagaagcggg	ccaggctctc	at ttgttccc	gagacgcctc	gcagttcaga	1620
cgtgactgtt	gatccccgctc	ctctgcgacc	gctcaattgg	aattcaagg	atgattgcaa	1680
atgtgactat	catgctcaat	ttgacaacat	ttctaacaaa	tgtgatgaat	gtgaatat	1740
gaatcggggc	aaaaatggat	gtatctgtca	caatgttaact	cactgtcaaa	tttgtcatgg	1800
gattcccccc	tgggaaaagg	aaaacttgctc	agattttggg	gatttttgacg	atgccaat	1860
agaacagtaa						1870

&lt;210&gt; 12

&lt;211&gt; 330

&lt;212&gt; PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/Note =  
synthetic construct

<400> 12

Met	Ala	Leu	Val	Asn	Trp	Leu	Val	Glu	His	Gly	Ile	Thr	Ser	Glu	Lys
1				5					10					15	
Gln	Trp	Ile	Gln	Glu	Asn	Gln	Glu	Ser	Tyr	Leu	Ser	Phe	Asn	Ser	Thr
			20					25					30		
Gly	Asn	Ser	Arg	Ser	Gln	Ile	Lys	Ala	Ala	Leu	Asp	Asn	Ala	Thr	Lys
		35					40					45			
Ile	Met	Ser	Leu	Thr	Lys	Ser	Ala	Val	Asp	Tyr	Leu	Val	Gly	Ser	Ser
	50					55					60				
Val	Pro	Glu	Asp	Ile	Ser	Lys	Asn	Arg	Ile	Trp	Gln	Ile	Phe	Glu	Met
65					70					75				80	
Asn	Gly	Tyr	Asp	Pro	Ala	Tyr	Ala	Gly	Ser	Ile	Leu	Tyr	Gly	Trp	Cys
			85						90					95	
Gln	Arg	Ser	Phe	Asn	Lys	Arg	Asn	Thr	Val	Trp	Leu	Tyr	Gly	Pro	Ala
			100					105					110		
Thr	Thr	Gly	Lys	Thr	Asn	Ile	Ala	Glu	Ala	Ile	Ala	His	Thr	Val	Pro
		115					120					125			
Phe	Tyr	Gly	Cys	Val	Asn	Trp	Thr	Asn	Glu	Asn	Phe	Pro	Phe	Asn	Asp
	130					135					140				
Cys	Val	Asp	Lys	Met	Leu	Ile	Trp	Trp	Glu	Glu	Gly	Lys	Met	Thr	Asn
145					150					155				160	
Lys	Val	Val	Glu	Ser	Ala	Lys	Ala	Ile	Leu	Gly	Gly	Ser	Lys	Val	Arg
			165						170					175	
Val	Asp	Gln	Lys	Cys	Lys	Ser	Ser	Val	Gln	Ile	Asp	Ser	Thr	Pro	Val
			180					185					190		
Ile	Val	Thr	Ser	Asn	Thr	Asn	Met	Cys	Val	Val	Val	Asp	Gly	Asn	Ser
		195					200					205			
Thr	Thr	Phe	Glu	His	Gln	Gln	Pro	Leu	Glu	Asp	Arg	Met	Phe	Lys	Phe
	210					215					220				
Glu	Leu	Thr	Lys	Arg	Leu	Pro	Pro	Asp	Phe	Gly	Lys	Ile	Thr	Lys	Gln
225					230					235				240	
Glu	Val	Lys	Asp	Phe	Phe	Ala	Trp	Ala	Lys	Val	Asn	Gln	Val	Pro	Val
			245						250					255	
Thr	His	Glu	Phe	Lys	Val	Pro	Arg	Glu	Leu	Ala	Gly	Thr	Lys	Gly	Ala
			260					265					270		
Glu	Lys	Ser	Leu	Lys	Arg	Pro	Leu	Gly	Asp	Val	Thr	Asn	Thr	Ser	Tyr
		275					280					285			
Lys	Ser	Leu	Glu	Lys	Arg	Ala	Arg	Leu	Ser	Phe	Val	Pro	Glu	Thr	Pro
	290					295					300				
Arg	Ser	Ser	Asp	Val	Thr	Val	Asp	Pro	Ala	Pro	Leu	Arg	Pro	Leu	Asn
305					310					315				320	
Trp	Asn	Ser	Arg	Leu	Val	Gly	Arg	Ser	Trp						
			325						330						

<210> 13

<211> 1115

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/Note =  
synthetic construct.

&lt;400&gt; 13

```

aggagcgcaa acggctcgtc gcgcagtttc tggcagaatc ctgcgagcgc tcgcaggagg      60
cggcttcgca gcgtgagttc tcggctgacc cggatcatcaa aagcaagact tcccagaaat      120
acatggcgct cgtcaactgg ctctgtggagc acggcatcac ttccgagaag cagtggatcc      180
aggaaaatca ggagagctac ctctccttca actccaccgg caactctcgg agccagatca      240
aggccgcgct cgacaacgcg accaaaatta tgagtctgac aaaaagcgcg gtggactacc      300
tcgtggggag ctccgttccc gaggacattt caaaaaacag aatctggcaa atttttgaga      360
tgaatggcta cgacccggcc tacgcgggat ccattcctta cggctgggtg cagcgctcct      420
tcaacaagag gaacaccgtc tggctctacg gacccgccac gaccggcaag accaacatcg      480
cggaggccat cgcccacact gtgccctttt acggctgcgt gaactggacc aatgaaaact      540
ttccctttta tgactgtgtg gacaaaatgc tcatttggtg ggaggaggga aagatgacca      600
acaaggtggt tgaatccgcc aaggccatcc tgggggggctc aaaggtgcgg gtcgatcaga      660
aatgtaaatc ctctgttcaa attgattcta cccctgtcat tgtaacttcc aatacaaaca      720
tgtgtgtggt ggtggatggg aattccacga cctttgaaca ccagcagccg ctggaggacc      780
gcatgttcaa atttgaactg actaagcggc tcccgccaga ttttggcaag attactaagc      840
aggaagtcaa ggactttttt gcttgggcaa aggtcaatca ggtgccggtg actcacgagt      900
ttaaagttcc caggggaattg gcgggaacta aagggggcga gaaatctcta aaacgcccac      960
tgggtgacgt caccaatact agctataaaa gtctggagaa gcgggccagg ctctcatttg     1020
ttcccgagac gcctcgcagt tcagacgtga ctgttgatcc cgctcctctg cgaccgctca     1080
attggaattc aagattgggtt ggaagaagtt ggtga                                  1115

```

&lt;210&gt; 14

&lt;211&gt; 550

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:/Note =  
synthetic construct

&lt;400&gt; 14

```

Met Ala Thr Phe Tyr Glu Val Ile Val Arg Val Pro Phe Asp Val Glu
 1              5              10              15
Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Asp Trp Val Thr Gly
              20              25              30
Gln Ile Trp Glu Leu Pro Pro Glu Ser Asp Leu Asn Leu Thr Leu Val
              35              40              45
Glu Gln Pro Gln Leu Thr Val Ala Asp Arg Ile Arg Arg Val Phe Leu
              50              55              60
Tyr Glu Trp Asn Lys Phe Ser Lys Gln Glu Ser Lys Phe Phe Val Gln
65              70              75              80
Phe Glu Lys Gly Ser Glu Tyr Phe His Leu His Thr Leu Val Glu Thr
              85              90              95
Ser Gly Ile Ser Ser Met Val Leu Gly Arg Tyr Val Ser Gln Ile Arg
              100             105             110
Ala Gln Leu Val Lys Val Val Phe Gln Gly Ile Glu Pro Gln Ile Asn
              115             120             125
Asp Trp Val Ala Ile Thr Lys Val Lys Lys Gly Gly Ala Asn Lys Val
              130             135             140
Val Asp Ser Gly Tyr Ile Pro Ala Tyr Leu Leu Pro Lys Val Gln Pro
145             150             155             160
Glu Leu Gln Trp Ala Trp Thr Asn Leu Asp Glu Tyr Lys Leu Ala Ala
              165             170             175
Leu Asn Leu Glu Glu Arg Lys Arg Leu Val Ala Gln Phe Leu Ala Glu
              180             185             190
Ser Ser Gln Arg Ser Gln Glu Ala Ala Ser Gln Arg Glu Phe Ser Ala
              195             200             205

```

16

Asp Pro Val Ile Lys Ser Lys Thr Ser Gln Lys Tyr Met Ala Leu Val  
 210 215 220  
 Asn Trp Leu Val Glu His Gly Ile Thr Ser Glu Lys Gln Trp Ile Gln  
 225 230 235 240  
 Glu Asn Gln Glu Ser Tyr Leu Ser Phe Asn Ser Thr Gly Asn Ser Arg  
 245 250 255  
 Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Thr Lys Ile Met Ser Leu  
 260 265 270  
 Thr Lys Ser Ala Val Asp Tyr Leu Val Gly Ser Ser Val Pro Glu Asp  
 275 280 285  
 Ile Ser Lys Asn Arg Ile Trp Gln Ile Phe Glu Met Asn Gly Tyr Asp  
 290 295 300  
 Pro Ala Tyr Ala Gly Ser Ile Leu Tyr Gly Trp Cys Gln Arg Ser Phe  
 305 310 315 320  
 Asn Lys Arg Asn Thr Val Trp Leu Tyr Gly Pro Ala Thr Thr Gly Lys  
 325 330 335  
 Thr Asn Ile Ala Glu Ala Ile Ala His Thr Val Pro Phe Tyr Gly Cys  
 340 345 350  
 Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp Cys Val Asp Lys  
 355 360 365  
 Met Leu Ile Trp Trp Glu Glu Gly Lys Met Thr Asn Lys Val Val Glu  
 370 375 380  
 Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg Val Asp Gln Lys  
 385 390 395 400  
 Cys Lys Ser Ser Val Gln Ile Asp Ser Thr Pro Val Ile Val Thr Ser  
 405 410 415  
 Asn Thr Asn Met Cys Val Val Val Asp Gly Asn Ser Thr Thr Phe Glu  
 420 425 430  
 His Gln Gln Pro Leu Glu Asp Arg Met Phe Lys Phe Glu Leu Thr Lys  
 435 440 445  
 Arg Leu Pro Pro Asp Phe Gly Lys Ile Thr Lys Gln Glu Val Lys Asp  
 450 455 460  
 Phe Phe Ala Trp Ala Lys Val Asn Gln Val Pro Val Thr His Glu Phe  
 465 470 475 480  
 Lys Val Pro Arg Glu Leu Ala Gly Thr Lys Gly Ala Glu Lys Ser Leu  
 485 490 495  
 Lys Arg Pro Leu Gly Asp Val Thr Asn Thr Ser Tyr Lys Ser Leu Glu  
 500 505 510  
 Lys Arg Ala Arg Leu Ser Phe Val Pro Glu Thr Pro Arg Ser Ser Asp  
 515 520 525  
 Val Thr Val Asp Pro Ala Pro Leu Arg Pro Leu Asn Trp Asn Ser Arg  
 530 535 540  
 Leu Val Gly Arg Ser Trp  
 545 550

&lt;210&gt; 15

&lt;211&gt; 1690

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:/Note =  
 synthetic construct

&lt;400&gt; 15

attctttgct ctggactgct agaggaccct cgctgccatg gctaccttct atgaagtcac 60  
 tgttcgcgtc ccatttgacg tggaggaaca tctgcctgga atttctgaca gctttgtgga 120  
 ctgggtaact ggtcaaattt gggagctgcc tccagagtca gatttaaatt tgactctggt 180

17

tgaacagcct	cagttgacgg	tggctgatag	aattcgccgc	gtgttcctgt	acgagtggaa	240
caaattttcc	aagcaggagt	ccaaattctt	tgtgcagttt	gaaaagggat	ctgaatat	300
tcatctgcac	acgcttgtgg	agacctccgg	catctcttcc	atggtcctcg	gccgctacgt	360
gagtcagatt	cgcgcccagc	tgggtgaaagt	ggctcttccag	ggaattgaac	cccagatcaa	420
cgactgggtc	gccatcacca	aggtaaagaa	gggcggagcc	aataagggtg	tggattctgg	480
gtatatcc	gcctacctgc	tgccgaaggt	ccaaccggag	cttcagtggg	cgtggacaaa	540
cctggacgag	tataaattgg	ccgccctgaa	tctggaggag	cgcaaaccgg	tcgtcgcgca	600
gtttctggca	gaatcctcgc	agcgctcgca	ggaggcggct	tcgcagcgtg	agttctcggc	660
tgaccgggtc	atcaaaaagca	agacttccca	gaaatacatg	gcgctcgtca	actggctcgt	720
ggagcacggc	atcacttccg	agaagcagtg	gatccaggaa	aatcaggaga	gctacctctc	780
cttcaactcc	accggcaact	ctcggagcca	gatcaaggcc	gcgctcgaca	acgcgaccaa	840
aattatgagt	ctgacaaaaa	gcgcgggtgga	ctacctcgtg	gggagctccg	ttcccaggga	900
cattttcaaaa	aacagaatct	ggcaaatttt	tgagatgaat	ggctacgacc	cggcctacgc	960
gggatccatc	ctctacggct	ggtgtcagcg	ctccttcaac	aagaggaaca	ccgtctggct	1020
ctacggaccc	gccacgaccg	gcaagaccaa	catcgcggag	gccatcgccc	acactgtgcc	1080
cttttacggc	tgcgtgaact	ggaccaatga	aaactttccc	tttaatgact	gtgtggacaa	1140
aatgctcatt	tgggtgggagg	agggaaagat	gaccaacaag	gtggttgaat	ccgccaaggc	1200
catcctgggg	ggctcaaagg	tgcgggtcga	tcagaaatgt	aaatcctctg	ttcaaattga	1260
ttctaccctt	gtcattgtaa	cttccaatac	aaacatgtgt	gtggtgggtg	atgggaattc	1320
cacgaccttt	gaacaccagc	agccgctgga	ggaccgcatg	ttcaaatttg	aactgactaa	1380
gcggctcccg	ccagattttg	gcaagattac	taagcaggaa	gtcaaggact	tttttgcttg	1440
ggcaaagggtc	aatcagggtgc	cggtgactca	cgagtttaaa	gttcccaggg	aattggcggg	1500
aactaaaggg	gcggagaaat	ctctaaaacg	cccactgggt	gacgtcacca	atactagcta	1560
taaaagtctg	gagaagcggg	ccaggctctc	atgtgttccc	gagacgcctc	gcagttcaga	1620
cgtgactgtt	gatcccgctc	ctctgcgacc	gctcaattgg	aattcaagat	tggttggaag	1680
aagttggtga						1690

&lt;210&gt; 16

&lt;211&gt; 145

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:/Note =  
synthetic construct

&lt;400&gt; 16

ccatcaccaa	ggtaaagaag	ggcggagcca	ataagggtgg	ggattctggg	tatattcccg	60
cctacctgct	gccgaagggtc	caaccggagc	ttcagtgggc	gtggacaaac	ctggacgagt	120
ataaattggc	cgccctgaat	ctgga				145

&lt;210&gt; 17

&lt;211&gt; 174

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:/Note =  
synthetic construct

&lt;400&gt; 17

taagcaggaa	gtcaaggact	tttttgcttg	ggcaaagggtc	aatcagggtgc	cggtgactca	60
cgagttttaa	gttcccaggg	aattggcggg	aactaaaggg	gcggagaaat	ctctaaaacg	120
cccactgggt	gacgtcacca	atactagcta	taaaagtctg	gagaagcggg	ccag	174

&lt;210&gt; 18

&lt;211&gt; 187

&lt;212&gt; DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/Note =  
synthetic construct

<400> 18

cactctcaag caaggggggtt ttgtaagcag tgatgtcata atgatgtaat gcttattgtc	60
acgcgatagt taatgattaa cagtcatgtg atgtgtttta tccaatagga agaaagcgcg	120
cgtatgagtt ctgcgcgagac ttccggggta taaaagaccg agtgaacgag cccgccgcca	180
ttctttg	187

<210> 19

<211> 168

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/Note =  
synthetic construct

<400> 19

aaacctcctt gcttgagagt gtggcactct ccccccctgtc gcgttcgctc gctcgctggc	60
tcgtttgggg ggggtggcagc tcaaagagct gccagacgac ggccctctgg ccgtcgcccc	120
cccaaacgag ccagcgagcg agcgaacgag acagggggga gagtgcc	168

<210> 20

<211> 168

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/Note =  
synthetic construct

<400> 20

aaacctcctt gcttgagagt gtggcactct ccccccctgtc gcgttcgctc gctcgctggc	60
tcgtttgggg gggcgacggc cagagggccg tcgtctgccg gctctttgag ctgccacccc	120
cccaaacgag ccagcgagcg agcgaacgag acagggggga gagtgcc	168

<210> 21

<211> 8

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/Note =  
synthetic construct

<400> 21

cggtgtga

8

<210> 22

<211> 8

<212> DNA

<213> Artificial Sequence

<220>



<223> Description of Artificial Sequence:/Note =  
synthetic construct

<400> 22  
cggttgag

8

<210> 23  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:/Note =  
synthetic construct

<400> 23  
caaaacctcc ttgcttgaga g

21

# INTERNATIONAL SEARCH REPORT

Inter. .nal Application No

PCT/US 99/11958

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N7/01 C12N15/34 C12N15/35 C07K16/08 C07K14/015  
C12N15/85

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	B. GEORG-FRIES ET AL.: "Analysis of proteins, helper dependence and seroepidemiology of a new human parvovirus" VIROLOGY, vol. 134, 1984, pages 64-71, XP002027460	1-45
X	the whole document	34, 35
Y	R.J. SAMULSKI ET AL.: "Helper-free stocks of recombinant AAV: normal integration does not require viral gene expression" JOURNAL OF VIROLOGY, vol. 63, no. 9, 1989, pages 3822-3828, XP000283071 the whole document	1-45

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 December 1999

Date of mailing of the international search report

28/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Marie, A

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/11958

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Y. MAEDA ET AL.: "Gene transfer into vascular cells using AAV vectors" CARDIOVASCULAR RESEARCH, vol. 35, 1997, pages 514-522, XP002125030 the whole document ---	1-45
Y	WO 93 24641 A (THE UNITED STATES OF AMERICA ET AL.) 9 December 1993 (1993-12-09) the whole document ---	1-45
Y	WO 96 15777 A (THE GOVERNMENT OF THE USA ) 30 May 1996 (1996-05-30) the whole document ---	1-45
X	D.S. IM ET AL.: "Partial purification of AAV Rep 78, Rep52 and Rep40 and their biochemical characterization" JOURNAL OF VIROLOGY, vol. 66, no. 2, 1992, pages 1119-1128, XP002125031 the whole document ---	18
Y	the whole document ---	19,20
X	S.R.M. KYOSTIO ET AL.: "Analysis of AAV wild-type and mutant rep proteins for their ability to negatively regulate AAV p5 and p19 mRNA levels" JOURNAL OF VIROLOGY, vol. 68, no. 5, 1994, pages 2947-2957, XP002125032 the whole document ---	18
Y	the whole document ---	19,20
Y	DE 44 36 664 A (MAX PLANCK GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.) 4 July 1996 (1996-07-04) the whole document ---	18
X	K. PRASAD ET AL.: "Characterization of the Rep78/AAV complex" VIROLOGY, vol. 229, 1997, pages 183-192, XP002125033 the whole document ---	21
Y	WO 95 11997 A (DEUTSCHES KREBSFORSCHUNGSZENTRUM) 4 May 1995 (1995-05-04) the whole document ---	18
X	WO 96 00587 A (UNIVERSITY OF PITTSBURGH) 11 January 1996 (1996-01-11) the whole document ---	22
Y	the whole document ---	23-34
	-/--	

# INTERNATIONAL SEARCH REPORT

Intern .al Application No

PCT/US 99/11958

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	M.J. DURING ET AL.: "AAV vectors for gene therapy of neurodegenerative disorders" CLINICAL NEUROSCIENCE, vol. 3, no. 5, 1995, pages 292-300, XP002125034	22
Y	the whole document	23-34
Y	WO 98 11244 A (THE GOVERNEMENT OF THE USA) 19 March 1998 (1998-03-19) the whole document	1-45
P,X	WO 98 41240 A (THE CHILDREN'S HOSPITAL OF PHILADELPHIA) 24 September 1998 (1998-09-24) the whole document	1-45
P,X	WO 98 45462 A (ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A.) 15 October 1998 (1998-10-15) the whole document	1-45
P,X	J.A. CHIORINI ET AL.: "Cloning and characterization of AAV5" JOURNAL OF VIROLOGY, vol. 73, no. 2, 1999, pages 1309-1319, XP002125035 the whole document	1-45
X	Database EMBL, Entry GGACTAA, Accession number M61166, 27/3/91 XP002125220 the whole document	44

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/11958

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9324641 A	09-12-1993	US 5587308 A AU 673367 B AU 4598193 A CA 2136441 A EP 0644944 A US 5866696 A	24-12-1996 07-11-1996 30-12-1993 09-12-1993 29-03-1995 02-02-1999
WO 9615777 A	30-05-1996	CA 2205874 A EP 0786989 A JP 10509046 T	30-05-1996 06-08-1997 08-09-1998
DE 4436664 A	04-07-1996	CA 2202664 A WO 9612010 A EP 0785991 A JP 10507352 T	25-04-1996 25-04-1996 30-07-1997 21-07-1998
WO 9511997 A	04-05-1995	CA 2175256 A EP 0725837 A JP 9504173 T	04-05-1995 14-08-1996 28-04-1997
WO 9600587 A	11-01-1996	AU 705564 B AU 2913895 A CA 2193802 A EP 0766569 A JP 10502526 T US 5863541 A	27-05-1999 25-01-1996 11-01-1996 09-04-1997 10-03-1998 26-01-1999
WO 9811244 A	19-03-1998	AU 4645697 A EP 0932694 A	02-04-1998 04-08-1999
WO 9841240 A	24-09-1998	AU 6458698 A	12-10-1998
WO 9845462 A	15-10-1998	IT RM970200 A AU 7077898 A	08-10-1998 30-10-1998

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**